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South African children currently receive vaccines against Diphtheria, Tetanus, Pertussis 
(administered as DTP), Hepatitis B (HBV) and Haemophilus influenzae type b (Hib) at 6, 
10 and 14 weeks. The use of combination vaccines provides a means of avoiding the 
logistical problems and costs associated with multiple injections of these different 
vaccines. A local vaccine manufacturer is in the process of developing a combined 
tetravalent DTP-HBV as well as a liquid pentavalent DTP-HBV-Hib vaccine. The Hib 
vaccine is a glycoconjugate in which Haemophilus influenzae type b capsular 
polysaccharide (polyribosylribitolphosphate or PRP) is conjugated to a carrier protein. 
The conjugate is immunogenic in infants who have a higher risk of infection while the 
polysaccharide vaccine is not. The compatibility of the Hib antigenic component in the 
presence of the other antigens and adjuvant presents a challenge. Aluminium containing 
adjuvants have been the most widely used adjuvants in human vaccines. Aluminium 
hydroxide has been found to catalyse the hydrolysis of PRP when added to Hib 
conjugate vaccines. Although this can be circumvented by the use of aluminium 
phosphate, there is a need for new adjuvants that elicit broader immune responses. This 
thesis presents a study of the size, structure and composition of a locally developed 
experimental adjuvant called Pheroid™ by use of NMR spectroscopy and Coulter 
Counter. NMR analysis of Pheroid™ formulations provided a structural fingerprint for the 
formulations and indicated the relative proportions of the major components present, 
whereas their particle size distribution was profiled using a Coulter Counter. The 
average size distribution was similar in the formulations tested including those that had 
been activated using nitrous oxide. 
The primary focus of this thesis was the application of appropriate physicochemical 
procedures for evaluation of the locally manufactured Hib vaccine alone and when in 
combination with DTP-HBV-Hib. Investigating the stability and integrity of Hib conjugate 
vaccines requires determination of the total saccharide and unbound or free saccharide 
which is expressed as the percentage of free saccharide present. In the absence of a 
suitable Hib conjugate, model compounds such as human serum albumin (HSA) , 
meningococcal group A polysaccharide (PsA) and the derived conjugate (Mn A-IT) were 
used to investigate three methods of free saccharide separation: solid phase extraction 
(SPE), acid precipitation using deoxycholate (DOC/HCI) and ultrafiltration (UF). At 
physiological pH, the binding capacity was low and so the SPE method was not 











saccharide values than the UF method; this was attributed to entrapment and co-
precipitation of free saccharide by DOC/HCI. In contrast, washing steps in the UF 
method ensured good free saccharide recovery. A colorimetric assay for phosphorus 
and high performance anion exchange chromatography with pulsed amperometric 
detection (HPAEC-PAD) were investigated for saccharide quantification in Mn A-TT 
vaccines. The HPAEC-PAD method for the monomer (mannosamine-6-phosphate from 
acid hydrolysis) permitted higher specificity and sensitivity for the free saccharide 
analysis compared to the phosphate assay. The DOC/HCI and UF methods were 
compared by their application to Mn A-TT samples subjected to an accelerated stability 
study. 
The free saccharide assay methods developed for Mn A-TT were applied to the analysis 
of Hib-TT vaccines. Quantification of Hib was performed using the phosphate and ribose 
colorimetric assays and HPAEC-PAD analysis of the ribitol component (released by acid 
hydrolysis). The HPAEC-PAD method proved to be sensitive and specific and with the 
use of an internal standard (sorbitol), potentially applicable to the analysis of Hib in both 
monovalent and combination vaccines. This was tested on a Hib pentavalent vaccine 
containing sucrose formulated with Pheroid™ or aluminium-containing adjuvant and 
subjected to a thermal stability study. Poor free saccharide extraction by phosphate in 
the Pheroid™- and aluminium hydroxide-adjuvanted vaccines as well as interference 
from the sucrose excipient complicated the analysiS. In the control pentavalent vaccine 
and aluminium phosphate-adjuvanted vaccine, the finding that the free saccharide assay 
could detect increasing amounts of free saccharide generated showed the potential of 
this method for these formulations. The free saccharide assay was applied to aluminium 
phosphate-adjuvanted Hib pentavalent liquid vaccines formulated without sucrose. 
Similar free saccharide values were obtained for Hib in the pentavalent formulation as 
determined for the monovalent Hib-TT vaccines. These results confirmed that without 
interference from sucrose, the free saccharide assay can be used to measure low levels 
of free saccharide in Hib combination vaccines containing aluminium phosphate 
adjuvant. The present study established that the application of the DOC/HCI method to 
Hib vaccines can be greatly improved by using a high ionic strength buffer. The use of a 
50 kDa UF membrane gave free saccharide values comparable to the 100 kDa 
membrane, yielded good free saccharide spike recovery and <5 % protein was detected 
in the filtrate. Preliminary experiments showed fucose to be a better internal standard 
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1.1 Introduction to currently available (paediatric) combination vaccines 
Immunisation remains the most effective weapon against infectious diseases1 . The 
smallpox vaccine which led to eradication of smallpox worldwide is one of the most 
acclaimed victories of medical science2• Paralytic poliomyelitis has disappeared from 
the Americas, Europe, Australia and many countries on other continents, and represents 
the next target for worldwide eradication3. The introduction of conjugate vaccines 
against Haemophilus influenzae type b (Hib)", Streptococcus pneumoniaes and 
Neisseria meningitidis6 has Significantly reduced the number of cases due to these 
pathogens. 
The rapid development of new technologies has helped to overcome technological 
barriers that used to limit vaccine developmene. Gene-based vaccines for example are 
a new approach to immunisation and immunotherapy, in which , rather than a live or 
inactivated organism (or subunit thereof) , one or more genes that encode proteins of the 
pathogen are delivered. The goal of this approach is to generate immunity against 
diseases for which traditional vaccines and treatments have not worked and to improve 
vaccines8. Protein-based approaches have been applied to produce vaccines against 
B. perlussis9 , S. pneumoniae10 , non-typeable H. Influenzae'\ and some viruses such as 
hepatitis B (HBV)12, hepatitis C (HCV)13, human immunodeficiency virus (HIV}u and 
human papilloma virus (HPV}15. 
Progress in vaccine development has resulted in an increase in the number of vaccine 
preventable diseases1s. 17. There are currently 20 vaccines recommended for routine 
immunisation by the World Health Organisation (WHO)18. It will thus be difficult to add 
any new vaccines to an already overcrowded immunisation calendar for young children1• 
A solution to this problem is the combination of antigens that induce immunity against 
several diseases, into a multivalent vaccine '· 2. 16-19. A combination vaccine may 
therefore consist of two or more live organisms, inactivated organisms or purified 
antigens combined by a manufacturer or mixed immediately before administration20• 
Combining vaccines in this way spares patients the discomfort of multiple injections and 












and needles and a reduced requirement for cold storage of vaccines21 . 22, Furthermore, 
when vaccines are given separately, there is greater capacity for missed doses, so 
combined vaccines can also increase compliance and therefore the overall effectiveness 
of vaccination programmes21 , 
Combined vaccines that have been used for many decades include DTP (triple vaccine 
against diphtheria, tetanus and pertussis) , trivalent oral (OPV) and injectable (IPV) polio, 
MMR (measles, mumps and rubella), trivalent influenzae, polyvalent pneumococcal and 
meningococcal vaccines"·. In recent years, vaccine manufacturers have used DTP as 
the corner stone on which to build more polyvalent vaccines. Concerns over safety has 
prompted a shift from use of the classical whole cell pertussis vaccine to acellular 
vaccines composed of purified antigens from B. pertussis believed to be involved in 
immunity23. More recently combination vaccines have been developed which contain six 
valencies (diphtheria, tetanus, acellular pertussis, IPV, Haemophilus inffuenzae type b 
(Hib) and hepatitis 824. 25) or seven valencies (Prevnar is a pneumococcal conjugate 
vaccine containing the seven vaccine-serotypes of Streptococcus pneumoniae - 4, 68, 
9V, 14, 18C, 19F and 23F)26 Developing such a combined vaccine poses a number of 
challenges that will be discussed in the following section. 
1.2 Development of combination vaccines 
The development of combination vaccines involves considerable research and expense 
to ensure efficacy and safety. Each combination vaccine must be evaluated in 
preclinical and clinical trials to ensure antigen compatibility, immunogenicity and 
acceptable reactogenicit),21. Various scientific, regulatory, public health and 
manufacturer issues are involved in determining which vaccines are combined and 
evaluated28. It is important to take all these issues into account as early as possible in 
the development programme because they are interrelated and such planning will 
maximise the probability of developing the final vaccine product in the shortest period of 
time 's. 
Vaccines are complex mixtures that contain not only viral or bacterial antigens but also 
other components such as preservatives, adjuvants, buffers, salts and stabilisers such 
as gelatine and alditols29• The incompatibility of any of these components would 












of inactivated vaccines may adversely affect one or more components of the active 
components. This occurred when whole-cell pertussis vaccine and inactivated poliovirus 
vaccine were combined, resulting in a combination with decreased pertussis potency2C'. 
For multi~disease combinations, excipients from one vaccine component may adversely 
affect the stability of other components. For instance, an antigen not adsorbed to 
aluminium adjuvant may be mixed with an aluminium-adsorbed antigen and itself 
become adsorbed or conversely, thereby changing its immunological properties. An 
exchange of antigens from one type of aluminium adjuvant to another may also occur16. 
As an example of the interaction of a preservative with a vaccine antigen, Sawyer and 
co-workers reported that thiomersal , used to preserve the DTwP vaccine, is detrimental 
to the IPV component in a OTwP-IPV combination vaccine30, Thus. not only should the 
combination be characterised and its components assessed through a series of 
phYSicochemical, biochemical and biological assays, but the formulation should also be 
optimised for its component antigens and their excipients 16, 20, 
In multi-disease combinations, vaccines may be manufactured at different sites by 
different companies under different protocols, so it may be necessary to review the 
conformity of procedures and documentation for assuring regulatory acceptability16. 
Preclinical animal trials must be conducted to determine the consequences of 
combination on potency and immunogenicity2°. It is also necessary to demonstrate 
consistency at the level of both manufacturing and clinical trials2, 2O, 
Prior to licensure, clinical studies are conducted to demonstrate the safety, 
immunogenicity and efficacy of a new vaccine with evaluation of simultaneous 
administration with other licensed vaccines29. For multi-disease combinations, this 
implies that the combination is at least as well tolerated as its component vaccines given 
separately17, 21, 23 . 31.36. For example DTP-Hib (combined) vs. DTP + Hib (separate). 
Administration of the new vaccine simultaneously with other vaccines given to the same 
age-group is evaluated to assure that there is no interference with such vaccinest6. The 
effectiveness of a biological product is defined as the clinically significant prevention of 
disease in a significant proportion of the target population, with proof of effectiveness 












For some antigens, studies of vaccine efficacy and immunogenicity have identified 
correlations between levels of antibody and protection from disease (calted a serologic 
correlate)21. 38. Correlates of protection have been established by identifying an antibody 
level above which the majority of a population is protected from disease37• If a 
combination vaccine produces serologic results for a particular antigen that are 
significantly lower than those seen in the monovalent vaccine but are nonetheless 
greater than the level known to provide clinical protection throughout the period of risk, 
then the diminished immunogenicity would not alter the acceptability of the combination 
vaccine38• 
The regulatory process consists of a logical progression from preclinical testing through 
phase I, II and III studies, to post-licensure or phase IV studies37. During phase I, the 
initial safety and immunologic activity of a combination is evaluated in a small number of 
subjects which may not comprise the final target population. The sample size in phase II 
is increased to include several hundred individuals. In the case of new combination 
vaccines, phase II includes assessment of the immunogenicity of all antigens contained 
in the combination. It may also provide initial evaluation of the immune response to 
other vaccines administered in the same schedule as the combination38 . These studies 
will be able to determine any common adverse events in the combination compared to 
monovalent vaccines2• In addition, phase II studies evaluate whether the immune 
response to any antigen in the combination vaccine is decreased before proceeding with 
large--scale pivotal safety and efficacy studies. Data collected to this point will be used to 
determine whether progression to larger phase III studies is justified. It will also form the 
basis for formulating safety and immunogenicity endpoints for pivotal studies. In phase 
III the sample size is generally larger - hundreds to several thousand subjects in multiple 
centres· from different ethnic and geographic backgrounds. It enables acquisition of 
additional information on safety and effectiveness which if found to be satisfactory will 
lead to the vaccine being licensed3a. Even after licensure clinical studies continue as 
manufacturers are usually asked to commit to completing specific post marketing or 
phase IV studies in large numbers of vaccine recipients29 . These studies will provide 













Commercial companies usually coordinate and finance the developmental work and 
extensive clinical testing that is required before a combined vaccine can be approved for 
routine use' , The decision to develop any particular combined vaccine will therefore be 
influenced not only by its medical desirability and technical feasibility but also by the 
potential financial returns that the required investments in time and resources may bring 
to the companyl . Despite the fact that an increasing number of diseases can be 
prevented by vaccination39, the potential for disease control offered by vaccines is not 
being fully realised in the world " .0, In the developing world, inadequacies in vaccine 
delivery, communication and transportation infrastructures are generally the most 
relevant problems41. Added to this is the fact that vaccine efficacy can vary markedly in 
different host populations perhaps due to nutritional inadequacies or prior contact with 
antigens contained within the vaccine42. In the developed world, there has been 
heightened parental concern about combination vaccines following reports by Wakefield 
and co-workers which suggested that MMR immunisation was associated with autism, 
inflammatory bowel disease and diabetes43 . Their interpretation was based on the 
reports by parents or general practitioners of 12 children that symptoms were observed 
soon after MMR immunisation. Still , the article showed only a temporal association and 
no evidence of causation«. Since then, several agencies have established the safety of 
licensed MMR vaccines4s.<4B and over 500 million children worldwide have received MMR 
vaccine since its licensure in 1971 49• 
There is no doubt that developing a new combination vaccine presents unique 
challenges to both manufacturers and regulatory authorities, however, success is 
attainable if both parties cooperate. 
1.3 Role of adjuvants in vaccines 
live attenuated vaccines such as those against measles, mumps and tuberculosis are 
very effective because they multiply in the body thereby inducing a large immune 
response. However, the disadvantage of these live attenuated vaccines is their potential 
to mutate back to the virulent form at any time. Such mutation would result in induction 
of the disease rather than in protection against it. For this reason , attenuated vaccines 
are not recommended for use in immunocompromised individuals. Many new vaccines 
or vaccine candidates are purified, subunit and synthetic vaccines which are poorly 












elicited by live vaccines50-52, Thus, there is a need for immunomodulatory adjuvants that 
will render these vaccines sufficiently immunogenic. 
Nearly 80 years ago the French scientist Ramon discovered helper substances, known 
as adjuvants, which when added to a vaccine, significantly increased the level of 
protection afforded by the vaccine5! . In the years that followed, many adjuvant 
formulations have been developed among them mineral salts, emulsions, saponins, 
liposomes, micropartictes, small molecules, nucleic acids and bacterial products5J..S7. 
Immunological adjuvants can be defined as compounds that bias the immune system 
toward Th1 or Th2 immunity and significantly enhance the immune response against an 
antigen5a• 
The ideal adjuvant should fulfill all of the following requirements: 
• Is non-toxic or has a negligible toxicity at the dose range for effective 
adjuvanticity 
• Stimulates a strong humoral and/or T cell immune response 
• Provides good immunological memory or long-term immunity 
• Does not induce autoimmunity 
• Is non-mutagenic, carcinogenic or teratogenic 
• Is non-pyrogenic 
• Is stable under broad ranges of storage time, temperature and pH58 . 
As such. it will produce a protective immune response even with weak antigens such as 
polysaccharide-protein conjugates with lower doses of antigen and with fewer injections 
and will be effective in infants and young children , ideally at birth, and elicit high affinity 
antibodies. In reality. the above requirements are rarely met and thus, the availability of 
suitable adjuvants is limited. Currently, although aluminium-containing adjuvants are the 
most widely used adjuvants they do not meet all the above criteria and hence the 
motivation for finding better adjuvants5T. 58. 
MF59 is a squalene-based oil-in-water emulsion that was licensed for a flu vaccine 
formulation (Fluad) a decade ago. More recently, AS03, another oil-in water emulsion, 












combination of two adjuvants, monophosphoryl lipid A (MPL) and aluminium hydroxide, 
namely AS04, was approved for use in HBV (Fendrix) and HPV (Cervarix) vaccines55 , 
Adjuvants can be divided into three classes based on their properties. The first group of 
adjuvants, referred to as vehicles, consist of a two-phased system that can transport 
antigens from injection sites to lymphoid tissues and includes mineral oil emulsions (e.g. 
incomplete Freund's adjuvant) , biodegradable oil emulsions (e.g. emulsions containing 
peanut oil or squalene), non-ionic block copolymer surfactants, liposomes and 
biodegradable polymer microspheresSS ' 59. Carriers are the second type of adjuvants. A 
carrier is a molecule which when bound to a second antigen, greatly intensifies the 
immune response to the latter6. Included in this category are bacterial toxoids, outer 
membrane proteins, fatty acids and live vectorsS8· 59. Immunomodulators are the third 
type of adjuvants. Immunomodulation is the ability of an adjuvant to modify the cytokine 
network and includes aluminium salts, saponin, muramyl di- and tripeptides, 
monophophoryl lipid A, Bordetella pertussis and cytokines, to mention a fevr9• Their 
mode of action is discussed in further detail in the following section. 
1.4 Mode of adjuvant action 
One mechanism by which adjuvants exert their effects is depot formation , where 
antigens and adjuvants are sequestered at the injection site and released over time to 
stimulated antigen-presenting cells (APCs), such as macrophages and dendritic cells 
(DCS)S8. Short term depots are produced by aluminium salts and water-in-oil emulsions, 
where antigen is trapped at the injection site and therefore cannot be lost by liver 
clearance60. More recently, long term depots have been achieved using synthetic 
polymers such as polylactide-co-glycolide (PLG) to produce microspheres which 
degrade to yield a pulsed delivery6I.62. 
Targeting is the mechanism by which an adjuvant-antigen complex is delivered to 
antigen-presenting cells for processing - particulate adjuvants bind to antigens forming 
aggregates that are engulfed by APCs via endocytosis to form endosomes53. 58. Studies 
have demonstrated that particles of 1-10 j.lm can be delivered orally to optimise uptake 
of Peyer's patches61 . More effective targeting is achieved using adjuvants with residues 
that are recognised by receptors on antigen-presenting cells. For example, the 












binds compounds containing mannose (e.g. mannans), N-acetylglucosamine or fucose 
residues (e.g. some saponins) and sulfated oligosaccharides. Binding of these adjuvant-
antigen complexes to pattern-recognition receptor initiates efficient receptor-mediated 
endocytosis and antigen processing58 . 
1.4.1 Innate immunity 
The immune system is divided into innate and adaptive components. The main 
distinction between the two lies in the mechanisms and receptors used for immune 
recognition (Fig 1). The adaptive component is organised into T cells and B cells. Each 
clonal receptor in both T and B cells is structurally unique and not encoded in the germ 
line. Binding of an antigen to its receptor triggers activation and proliferation of the cell. 
This process of clonal selection and expansion is essential for the generation of an 
effective immune response63• However, it takes 3-5 days for a sufficient number of 
clones to be produced and to differentiate into effector cells. In contrast, the effector 
mechanisms of innate immunity, which include antimicrobial peptides, phagocytes and 
the alternative complement pathway, are activated immediately after infection and 
rapidly control the replication of the infecting pathogen63. 
The strategy of the innate immune response is to focus on a few highly conserved 
structures present in large groups of microorganisms. These structures are known as 
Pathogen-Associated Molecular Patterns (PAMPs), and the receptors that recognise 
them are called Pattern Recognition Receptors (PRRs). For example, bacterial 
polysaccharide, peptidoglycans, lipoteichoic acid and bacterial DNA are bound by 
germline-encoded pattern recognition receptors 58. 63. Structurally, pattern recognition 
receptors belong to several families of proteins. Leucine-rich repeat domains, calcium-
dependent lectin domains and scavenger-receptor protein domains, for example, are 
often involved in pattern recognition83. These pattern recognition receptors can be (a) 
secreted molecules found in blood and lymph that are associated with complement and 
opsonisation, (b) surface receptors on phagocytic cells that are associated with 
endocytosis, or (c) toll-like receptors (TLRs), a family of receptors found on 
macrophages, dendritic cells and epithelial cells that have been conserved from insects 
to mammals64 . Toll-like receptors are transmembrane proteins with an extracellular 
domain containing leucine-rich repeats that recognise conserved motifs on pathogens, 












receptor"" 65, TolI~like receptors induce signall ing pathways, leading to activation of the 
nuclear factor-KB (NF-KB) in antigen presenting cells, which results in the expression of 
various cytokine genes, production of co-stimulatory ligands 87-1 (COSO) and 87-2 
(COB6), and activation of adaptive imunity63. 65, It is the initial response of the innate 
immune system, stimulated by pathogen-associated molecular patterns, that triggers 
and controls the adaptive immune system response58, The binding of pathogen-
associated molecular patterns, such as lipopolysaccharide or bacterial CpG-DNA, 
initiating the activation of adaptive immunity, is indicative of their adjuvant effect acting 
via specific toll-li ke receptors. Indeed several natural or synthetic adjuvants, including 
monophosphoryllipid A and lipoarabinomannan, that are bacterial cell·wall components, 
or the yeast polysaccharide glycan, are structurally closely related to different pathogen-
associated molecular pattemsS8· 66. The receptors involved in the interplay of the innate 
and adaptive immune systems are shown in Fig 1.1. 
'".,- C\l1ollnn 
'" 
Rg 1.1: Recognition of the pathogen-associated molecular pettern (PAMP) by pettern-recognition 
receptors, such as the toll·like receptors, generetes signals that activat6 the adaptive immune 
syst&m. ProlfJins dfJrived from the microorganisms ara process6d in the Iysosomes to g6neral6 
entig&nic p6ptides, which form a complex with mEtor-histocompatibility-complex (MHC) class /I 
moIecul6S on fh6 surface of antigen prss6nting cells. Th6se pap/ides are recognized by T-cell 
receptors. In the case of the signs/ing class of pattern-recognition receptas, the recognition of 
pathogen-associated molecular patterns by tOlI·llke receptors leads to the activation of signaling 
pathways that induce the expression of cytCkines, chemCkines, and costimuletory molecules. 
Therefore, pattern-recognition receptors have a role in the generation of bah the peptide-MHC-












1.4.2 Adaptive immunity 
Processing and presentation of protein antigens by antigen-presenting cells to T or 8 
cells is dependent on whether the antigen is intracellular (endogenous) or extracellular 
(exogenous)67, Endogenous antigens (e.g. viral antigens produced or delivered into the 
cell cytosol) are degraded into small peptides which are transported into the 
endoplasmic reticulum (ER) and loaded onto the Major Histocompatibility Complex 
(MHC) class I, to form MHC-I-peptide complexes. These complexes are exported via 
the Goigi apparatus to the antigen-presenting cell surface for presentation and binding to 
COB+ T cells , containing both T cell receptors (TCRs) and COB molecules that recognise 
both the MHC-I-peptide complexes and COB receptors on the antigen-presenting cell , 
respectivelr8. Exogenous antigens (e.g. bacteria) are taken up by antigen-presenting 
cells via endocytosis and degraded in the Iysosomes into small peptides, bound by MHC 
class II molecules that are embedded in the lysosome membrane to form MHC-II-
peptide complexes and delivered by exocytosis to the cell membrane for presentation to 
CD4+ T cells. Certain adjuvants such as amphipathic non-ionic block copolymers, bind 
to exogenous antigens, preserving their three-dimensional conformation (required for the 
production of neutralising antibodies) during the internalisation by antigen presenting 
cellsS3• 68• Depending on their size and the balance of hydrophilic (polyethylene) to 
lipophilic (polyoxypropylene) chains, block polymers can deliver exogenous antigens to 
the class I (cytoplasm) or class II (phagosomes) pathways for processing; they are 
effective antigen delivery systems that can be used with other adjuvantsS2. sa. 
1.4.3 T-cell activation 
CD4+ and CDB+ T cells recognise antigens that are present on antigen-presenting cells 
as complexes with MHC class liar I, respectively. The process mediated by the T cell 
receptors leads to T cell activation and the production of effector cells that are capable of 
secreting cytokines67. Two signals are necessary for T cell activation, one is derived 
from the interaction of the T cell receptors with the antigen-MHC complex and the other 
is the co-stimulatory signal delivered by the 87-1 or 87-2 ligand, present on the antigen-
presenting cells, to the C02B receptor on T cells. Several studies indicate that 87-1 
signals preferentially promote development of Th1 cells and 87-2 signals, Th2 cells66-73. 
This co-stimulatory signal provides an avenue for immune stimulation by adjuvants that 
can substitute for the 87-1 or 87-2 ligands7 •. Activated T cells produce two major types 












respectively. CD4 cells interact with antigen-presenting cells carrying MHC-II-antigen 
complexes to yield Th1 or Th2 cells. This selection appears to depend on the origin of 
the activated dendritic cell that interacts with the CD4 cell. Th1 cells produce pro-
inflammatory cytokines, such as interferon gamma, interleukin-2 and tumour necrosis 
factor ~ (TNF- ~) , and stimulates production of cytotoxic T lymphocytes (CTl). Th2 cells 
produce interleukin-4 and interleukin-10 cytokines that favour antibody production and 
class-switching, and also inhibit Th cells from entering the Th1 path75, Presentation by 
antigen-presenting cells of MHC-I-antigen complexes to CD8+ T cells results in 
activation of COB cells to produce cytotoxic T lymphocytes; following recognition of 
MHC-I-antigen complexes, cytotoxic T lymphocytes bind to target T cells and insert 
perforins into their ceU membrane, delivering granzymes into the cell cytoplasm and 
initiating a process leading to cell apoptosis58. 76 , 
For an adjuvant to be useful for induction of cytotoxic T lymphocytes, it must facilitate 
incorporation or persistence of an appropriate peptide into MHC-1 . The most effective 
way to achieve this is for the adjuvant to interact in some way with cell membranes so 
that antigen associated with the adjuvant is deposited within the cytosol in a form 
suitable for normal processing in the proteosome53• An alternative mechanism for 
induction of cytotoxic T lymphocytes is by direct attachment of peptide to empty 
externally exposed MHC-1 . In this instance, a water-in-oil (w/o) formulation is prepared 
in which the aqueous phase contains peptide and a universally recognised protein such 
as tetanus toxoid77 , The water-in-oil emulsion creates a depot which, in addition to 
attracting dendritic ceUs, protects the peptide from proteolysis53• The tetanus toxoid will 
cause dendritic cells to migrate to lymphoid tissue and, while presenting tetanus-derived 
peptides, T -cells will be attracted, some of which will be cytotoxiC T-cells (Tc) which 
recognise the original peptide derived from cytotoxic T lymphocytes53• The ability of 
adjuvants to preserve the conformational integrity of an antigen and present it to the 
appropriate antigen-presenting cells has three major benefits , Firstly it maximises the 
amount of conformationally relevant antibody, secondly it influences the affinity of the 
antibody and thirdly it can influence the duration of the immune response7B , 
Understanding the different ways in which an adjuvant functions at a molecular level is 
important because if the pathogenesis of a disease is known, an adjuvant which can 












respectively. CD4 cells interact with antigen-presenting cells carrying MHC-II-antigen 
complexes to yield Th1 or Th2 cells. This selection appears to depend on the origin of 
the activated dendritic cell that interacts with the CD4 cell. Th1 cells produce pro-
inflammatory cytokines, such as interferon gamma, interleukin-2 and tumour necrosis 
factor j3 (TNF- 13). and stimulates production of cytotoxic T lymphocytes (CTL). Th2 cells 
produce interleukin-4 and interJeukin-10 cytokines that favour antibody production and 
class-switching, and also inhibit Th cells from entering the Th1 path75• Presentation by 
antigen-presenting celts of MHC-I-antigen complexes to CD8+ T cells results in 
activation of coa cells to produce cytotoxic T lymphocytes; following recognition of 
MHC-I-antigen complexes, cytotoxic T lymphocytes bind to target T cells and insert 
perforins into their cell membrane, delivering granzymes into the cell cytoplasm and 
initiating a process leading to cell apoptosis58, 78. 
For an adjuvant to be useful for induction of cytotoxic T lymphocytes, it must facilitate 
incorporation or persistence of an appropriate peptide into MHC-1. The most effective 
way to achieve this is for the adjuvant to interact in some way with cell membranes so 
that antigen associated with the adjuvant is deposited within the cytosol in a form 
suitable for normal processing in the proteosome53• An alternative mechanism for 
induction of cytotoxic T lymphocytes is by direct attachment of peptide to empty 
externally exposed MHC-1. In this instance, a water-in-oil (w/o) formulation is prepared 
in which the aqueous phase contains peptide and a universally recognised protein such 
as tetanus toxoidn . The water-in-oil emulsion creates a depot which, in addition to 
attracting dendritic cells, protects the peptide from proteolysis53. The tetanus toxoid will 
cause dendritic cells to migrate to lymphoid tissue and, while presenting tetanus-derived 
peptides, T-cells will be attracted, some of which will be cytotoxic T-cells (Tc) which 
recognise the original peptide derived from cytotoxic T lymphocytes53• The ability of 
adjuvants to preserve the conformational integrity of an antigen and present it to the 
appropriate antigen-presenting cells has three major benefits. Firstly it maximises the 
amount of conformationally relevant antibody, secondly it influences the affinity of the 
antibody and thirdly it can influence the duration of the immune response78• 
Understanding the different ways in which an adjuvant functions at a molecular level is 
important because if the pathogenesis of a disease is known, an adjuvant which can 












formulation53• The following section focuses on aluminium adjuvants as well as 
alternative adjuvants currently being developed for use in human vaccines. 
1.5 Adjuvants used in human vaccines 
In recent years, researchers have gained a better understanding of the molecular basis 
for the action of adjuvants, the role of cytokines and different types of cells involved in 
the immune response. This has led to development of adjuvants which can selectively 
modulate the immune response and even selectively elicit T~cells only. This basic 
knowledge is important for developing suitable vaccines for emerging diseases such as 
AIDS andlor for new vaccine candidates against infectious agents, cancer, fertility , 
allergic and autoimmune diseases57. It is likely that because of their excellent track 
record of safety, aluminium adjuvants will continue to be used with current human 
vaccines. However, aluminium adjuvants cannot elicit cell-mediated immune responses 
such as cytotoxic T-cell responses and therefore there is a need for alternative 
adjuvants; particularly for diseases for which ceJl-mediated immune responses are 
important for prevention or cure57. Recently, several adjuvant formulations such as 
OS_21 79 , MF_5S80, MPL-based adjuvants81 . 82, liposomes83 and biodegradable polymer 
microspheres8<l and a strategy for making combination protein-polysaccharide conjugate 
vaccines have been described. Thus, it appears that the range of adjuvants accepted 
for human vaccines will expand in the years to come. 
1.5.1 Aluminium compounds 
The ability of aluminium compounds to act as an adjuvant was first reported by Glenny 
and co-workers in 192685• These authors reported that the addition of potassium alum to 
diphtheria toxoid resulted in the formation of a precipitate. Injecting this precipitated 
diphtheria toxin into guinea pigs resulted in a higher antigenic response compared to the 
fluid toxoidae. 87 . The range of aluminium compounds which have since been 
investigated for their adjuvant properties include aluminium chloride which has been 
used in antisera against cobra venomae. 89. Fujimaki and co-workers have investigated 
the role of aluminium silicate in inducing an IgE response90. Other aluminium-based 
adjuvant preparations which have been studied include gamma inulin complexes with 
aluminium hydroxide, known as Algammulin91 . 92 and aluminium monostearate93. 9-4 , used 
as a co-stabiliser in Adjuvant-65. Here, the aim of the aluminium compound is to allow 












The most commonly used forms of aluminium adjuvant in vaccines include aluminium 
hydroxide, aluminium phosphate and alum (KAl(SO.h.12H20)87. Aluminium hydroxide is 
a crystalline aluminiumoxyhydroxide that is positively charged at physiological pH. 
Aluminium phosphate is an amorphous aluminium hydroxyphosphate which is negatively 
charged at physiological pH95. Aluminium-based adjuvants were the first adjuvants to be 
approved for use in human vaccines52 . 
Aluminium hydroxide and aluminium phosphate adjuvants are generally prepared by 
exposing aqueous solutions of aluminium ions to alkaline conditions under very 
controlled ci rcumstances, which in the case of aluminium phosphate takes place in the 
presence of phosphate ions, Various soluble aluminium salts can be used for the 
production of these adjuvants, but the experimental conditions - temperature, 
concentration and even rate of addition of reagents - strongly influence the results87, 
Alhydrogel™ is a commercially available preparation which was chosen in 1988 as a 
research standard87, 
The original model proposed for aluminium hydroxide was based on a six-membered 
ring-structure, each member consisting of A13+ surrounded by six coordinated water 
molecules in an octahedral shape96. The coordinated water molecules are oriented with 
the oxygen toward the aluminium ion. The high charge of A13+ is believed to enhance the 
removal of protons, especially under alkaline conditions96, The alkaline conditions assist 
deprotonation leading to the initial formation of dimers by dihydroxyl bridges between 
octahedrons and later to the formation of the six-membered ring structure and even 
larger structures. In this process the ratio of aluminium to hydroxide approaches 1:397 . 
The above model is a generalised one that does not take into consideration the 
crystalline forms or inclusion of other ions. When inclusion of other ions originating from 
the salts used in the preparation was taken into consideration, aluminium hydroxide 
precipitated from aluminium chloride was described as AI(OHh.55(CI)o.45. existing as a 
polymer of ten fused six-membered rings. However. if precipitated from aluminium 
sulphate the adjuvant exists as AI(OHh.30(S04)o,35 and is based on three fused six-
membered rings96. 
Aluminium adjuvants have been used primarily in human vaccines for tetanus, 












hepatitis A and hepatitis B virus vaccines87, Other vaccines containing aluminium 
include Iyme disease, anthrax and rabies103 , The immunostimulating effect of aluminium 
adjuvants has been attributed to the formation of a depot at the injection site from which 
the antigen is slowly released. In a Cynomolgus monkey model, alum was detected in 
the muscle up to 6 months after intra-muscular injection of a OT-TI vaccine and it was 
hypothesised that the alum-adsorbed antigen could also persist longer than if it was 
administered alone104, However, the depot effect has been questioned by Holt who 
demonstrated that the excision of the DT -alum treated site soon after subcutaneous 
vaccination did not change the immune response to the antigen 105. Another study 
showed that 14C_labelled TT is released very rapidly from the alum complex at the 
injection site106. Furthermore, it has been proposed that antigens adsorbed to alum are 
presented in a particulate multivalent from, which is more immunogenic and more 
efficiently internalised by antigen-presenting cells. In vitro experiments lent support to 
this model and showed that although dendritic cells can engulf antigens in solution 
through macropinocitosis, they are more efficient in internalising alum-adsorbed antigens 
through phagocytosis in a process dependent on the size of the aggregate57, 104, 107.109, 
Other suggested mechanisms of alum adjuvanticity include the activation of the 
complement cascade and the generation of a local inflammatory environment at the 
injection site characterised by the recruitment of blood cells 110,111. 
Recent studies on alum have demonstrated that besides antigen delivery functions, 
these classes of adjuvants can also activate innate immunity pathways in vivo, 
generating an immunocompetent environment at the injection site. The molecular target 
for alum pro-inflammatory activity has been identified as NOD-like receptor protein 3 
Phagocytosis of alum crystals induced phagosomal swelling, 
destabilisation and rupture, finally resulting in the release of lysosomal proteins into the 
cytosol. Cathepsin e, a lysosomal protease, was shown to be involved in caspase 1 
activation and interleukin-1 P release in macrophages in response to alum and silica. 
These results suggested that phagosome destabilisation preceded the activation of the 
NLRP3 inflammasome112. 
A major advantage of aluminium adjuvants is the development of earlier, higher and 
longer-lasting immunity after primary immunisation compared to soluble vaccines57 , In 












vaccines which continue to save millions of lives annually,03. The ability of the body to 
eliminate aluminium-containing adjuvants may contribute to the excellent safety record 
of these adjuvants 113, Some adverse reactions have been reported with aluminium 
containing vaccines, but none of these reactions have been sufficiently frequent to 
arouse concern98. 1'4-117. 
There are certain instances where the use of aluminium adjuvants is not ideal. For 
example, aluminium adjuvants are ineffective when used with typhoid vaccines' 18 and 
influenza haemagglutinin antigen119. Moreover, the the inability of aluminium adjuvants 
to elicit cell mediated immune responses, particularly cytotoxic T cell responses53, may 
be a significant limitation for vaccines against intracellular parasites and viral infections 
such as human immunodeficiency virus (HIV)s7, Studies on booster injections, 
conducted over a 10-year period, revealed that children who received aluminium-based 
vaccines were more prone to have local reactions such as redness, swelling and itching 
compared to those who received the unadsorbed vaccines for primary immunisation, 
This is because aluminium adjuvants increase the production of IgE antibodies and may 
promote IgE mediated allergic reactions 120, Other limitations stem from the fact that as 
inducers of Th2 type responses, aluminium adjuvants are not likely to provide protection 
against diseases for which Th1 immunity and MHC class I restricted cytotoxic T cells are 
essential for protection e,g, with tuberculosis 121 , Studies have indicated that aluminium 
adjuvants are ineffective in raising high antibody titres against small-sized peptides 122, It 
is possible that they cause the antigens to be proteolytically degraded more efficiently 
thus causing these peptides to lose their antigenicit,,87, In the case of foot-and-mouth 
disease aluminium adjuvants result in the partial degradation of epitopes due to 
adsorption 123, Conjugation of the peptide to a carrier prior to adsorption helps overcome 
this problem123, Aluminium hydroxide when added to Haemophilus influenzae type b 
(Hib) conjugate vaccine has been found to result in catalytic depolymerisation of 
polyribosylribitolphosphate (PRP) which is the active ingredient in the vaccine l2"', There 
is thus a need for alternative adjuvants, especially for diseases in which cell-mediated 












1.5.2 Calcium compounds 
Calcium phosphate adjuvant was developed at the Pasteur Institute and is a viable 
alternative to aluminium adjuvants. In addition to having similar adjuvant properties to 
aluminium adjuvants, calcium phosphate has the added advantages of being a natural 
component of the body and of not increasing IgE production125, It is used to potentiate 
the immune response of vaccines in two ways12fi, Firstly, the depot mechanism allows 
the antigen to be adsorbed during the preparation of the vaccine and slowly released 
following injection. Secondly, it presents the adsorbed antigen to APes as a particulate 
antigenS3 , The chemical structure of calcium phosphate has been investigated by X·ray 
diffraction, Fourier-transform infrared spectroscopy and thermal analysis126. The CatP 
molar ratio obtained identified commercial calcium phosphate adjuvant as a non-
stoichiometric hydroxyapatite complex, Ca10-x(HPO.M Po..)s-x(OHh .• , where x varies from 
o to 2 12S. At physiological pH, it is negatively charged and electrostatically adsorbs 
positively charged antigens. In addition, the presence of hydroxyls allows calcium 
phosphate adjuvant to adsorb phosphorylated antigens by ligand exchange with surlace 
hydroxyls 12fi. 
1.5.3 Oil emulsions 
The first oil emulsion to be used as an adjuvant was Freund's complete adjuvant (FCA), 
which consisted of mineral (paraffin) oil mixed with killed Mycobacteria54. 51. Because of 
its toxicity, FCA was later replaced by Freund's incomplete adjuvant (FIA) which did not 
contain Mycobacteria and was formulated with the surlactant Arlacel A. In mice, FIA has 
been associated with side-effects such as local reactions at the injection site, oil-induced 
neoplasmas and Ar1acel A induced carcinogenicity55. In humans, FIA has been used 
with influenza and killed poliomyelitis vaccines enhancing their immunogenicitl5. 127. 
Despite the absence of tumour formation in 18 000 recipients of FIA-based influenza 
vaccine monitored for up to 18 years, further use of this adjuvant was discontinued due 
to carcinogenicity of Arlacel A in mices1 . 
The unacceptable toxicity caused by Freund's adjuvant prompted researchers to pursue 
alternative approaches to the development of particulate adjuvants. One with 
exceptional results in recent years is MF59. The emulsion is made up of small 
(approximately 160 nm), uniform and stable microvesicles128 and each oil droplet is 












component of cell membranes; found in human sebum (a skin surface lipid) and a 
naturally occurring hydrocarbon precursor of cholesterol. Squalene droplets are 
stabilised by addition of two non-ionic surfactants, a low hydrophilic-lipophilic balance 
(HBl) surfactant, Polysorbate 80 (Tween 80), which is widely used as an emulsifier in 
foods , cosmetics and pharmaceuticals, and sorbitan triolate (commonly called Span 85) 
(Fig 1.2). After manufacturing and filtration of the emulsion through a 0.22 J..Im, the mean 
particle size, composition and pH of MF59 remained unchanged compared to initial 
values for at least 3 years at 2-8 OCt providing an excellent stability profile. Another 
important feature was the low concentration of large droplets of MF59 which remained 
stable for the same period of time 128. 
SPAN 85 -• 
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Figure 1.2: MF59 adjuvant emufsion129. 
The adjuvant properties of MF59 have been evaluated with several types of antigens 
including bacterial toxoids (e.g. tetanus toxoid and diphtheria toxoid), outer membrane 
vesicles (e.g. Neisseria meningitidis) , polysaccharide conjugates (e.g. meningococcal C 
conjugate vaccines), recombinant antigens (e.g. hepatitis a surface antigen, 
meningococcal a, Herpes Simplex Virus [HSV]-2 g02) and viral antigens (e.g. influenza 
antigens)130-136. In 1997, almost 70 years after the introduction of aluminium as adjuvant, 
MF59 became the first new adjuvant to be licensed for use in humans as part of an 
enhanced influenza vaccine (Fluad) for the elderly, and is now commercially available in 












The precise mechanism of MF59 adjuvanticity is still under investigation. Studies 
conducted with f1uorescently labelled MF59 have shown that 4 hours after intramuscular 
administration, only 36 % of injected adjuvant was still present in the muscle and that the 
peak of localization in the corresponding lymph nodes was reached 2 days after 
injection. The presence of adjuvant did not influence the distribution of co-administered 
Herpes Simplex Virus [HSV]-2 902) antigen, which was cleared from the site of injection 
independently of MF59. Two days after intramuscular injection, MF59 localised in the 
draining lymph node was shown to be partially located in T cell areas within lymph node-
resident cells that had the characteristics of antigen-presenting cells,28, 
Administration of MF59 also induced a significant influx of macrophages at the site of 
injection, which was significantly suppressed in mice deficient for chemokines receptor 
2137-139, Thus, it is likely that one of the effects of MF59 is to trigger the production of 
chemokines in cells resident at the injection site'38, ' 39, Irrespective of its mechanism(s) 
of action, results obtained from mice studies strongly suggest that MF59 enhances 
functional and protective antibody responses 13' -'33 and/or induces a strong T cell 
response, 
1.5.4 Monophosphoryl lipid A (MPL) 
MPL is isolated from bacterial cell walls and is a detoxified form of lipid A derived from 
the lipopolysaccharide (LPS) of Salmonella minnesota R595 that has shown potential as 
a vaccine adjuvant'·o.,·s, Because of MPL's ability to activate monocytes and 
macrophages, vaccine antigens are more readily phagocytised, processed and 
presented'·l, These cells also release tumor necrosis factor a (TNF a), interleukin-1 , 
and granulocyte-macrophage colony stimulating factor GM-CSF in response to MPL '.3, 
These monokines in turn lead to the recruitment and maturation of dendritic cells in the 
lymph nodes, where the dendritic cells can effiCiently present antigen to T 
lymphocytes'·', Thus, MPL assists the immune system in regulating Th1 and Th2 
response'." 1.2, 
MPL can be formulated as an aqueous vehicle or an oil-in-water emulsion (o/w), The oil-
in-water emulsion results in a more vigorous response for several reasons. Emulsions 
can cause tissue damage at the injection site leading to non-specific inflammation, 












associated with oil droplets in an emulsion becomes more particulate, is more readily 
trapped in the lymph node and taken up by macrophages and dendritic cell , leading to 
enhanced antigen presentationM • The particulate nature of the antigen/oil droplet may 
also increase the presentation of the antigen by major histocompatibility complex (MHC) 
class I molecules resulting in cytotoxic T -lymphocyte (CTL) induction '.7. 
1.5.5 Saponin, Quil A, Q521 and immunostimulating complexes (ISCOMs) 
Trends in modern vaccine development towards the use of highly purified recombinant 
proteins which are often poorly immunogenic when given alone or in combination with 
aluminium salts, have driven research on saponin adjuvants'48. Saponin is derived from 
the bark of the Quillaja saponaria tree and has long been known as an immunostimulator 
(Fig 1.3)" . 
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Figure 1.3: Chemical structure of Quillaja sapont/s (R" R2• R" and 
R .. represent differen t substftution patterns of individual molecules) '*. 
The crude extract is not added to vaccines directly because it results in adverse side 
effects but is purified by HPLC to yield MQuil A- a very potent adjuvant with several 
unique features such as the ability to stimulate both the humoral and cellular branch of 












0821 a potent water soluble adjuvant with minimal or reduced toxicity which can be 
used in vaccines with or without emulsion type formulations57 , 
ISCOMs refer to non-covalently bound complexes of Quit A adjuvant and cholesterol. 
Amphipathic proteins together with an additional lipid (e.g. phospholipid) can be 
incorporated to form a highly immunogenic antigen complex's, . If the ratio of Qui! A to 
cholesterol is low, the micelles do not exist as individual particles152, Hydrophobic 
interactions cause aggregation and sheets of micelles to form i.e. a precipitate forms. 
The presence of phospholipid makes the micelles more fluid and permits the formation 
of spherical structures: empty ISCOMs consisting of about 14-on9 like micelles1S', Thus, 
the interior of ISCaMs has an open connection with its surroundings. It is for this reason 
that ISCaMs can only contain antigens if contact with the structure can be established 
and that ISCaM-matrix and antigen associate after mixing,s2. 
Quil A molecules have three distinct areas with respect to polarity: hydrophilic-
hydrophobic-hydrophilic'53. The hydrophilic region is part quillaic acid. It is thought that 
this three-block structure enables the formation of non-bilayer structures like ISCaMs 153, 
Centrifugation and dialysis were the first two methods described in the literature for the 
preparation of ISCOMs. More recently, however, ISCOMs have been prepared by 
reversed-phased HPLC's-t, by hydration of a cholesterol/phospholipid film with an 
aqueous solution of Quil A lSI or containing a mixture of two purified low toxicity Quillaja 
saponin fractions I SS, 
1.5.6 Liposomes 
The classical view of a liposome is that it consists of a phospholipid bilayer structure to 
which cholesterol is often added to increase stability by increasing bilayer rigidity152. 
Liposomes can be prepared in two ways. Charged liposomes may be prepared by the 
incorporation of charged lipids. A second way of preparing liposomes is by detergent 
removal from a solution of mixed micelles'52, 156. The efficient incorporation of antigen 
into the prepared liposomes is difficult and may require extensive optimisation 
experimentation in order to be achieved. The '!iposome' group can be broken down into 
liposomes83, virosomes 157, transferosomes 158, archaeosomes 159, niosomes 160-162, 












Compared to ISCOMS, liposomes have enormous variation with respect to composition, 
size, physicochemical and immunological characteristics which permits flexible design in 
order to maximise functionalityS1, 152. This has led to the development of many liposome-
like structures for antigen delivery152, Unlike ISCOMS, liposomal structures (with the 
exception of cochleates) contain an internal space separated from the environment. 
This allows the incorporation of hydrophilic antigens or adjuvants. Liposomes also differ 
from ISCOMS in that they have an inherent modest adjuvant activity152, 
1.5.7 Biodegradable polymer microspheres 
Biodegradable polymer microspheres can be prepared from a variety of polymers such 
as poly (Iactic-co-glycolic) acid (PLGA) and polyanhydrides60 · ~. Microspheres made up 
of PLGA have the advantage of a long saf/ ty record from the use of PLGA as surgical 
sutures in humans51 and in several commercial formulations, such as Lupron Depot (a 
drug commonly used in the treatment of uterine fibroids) 167. Polyanhydrides have also 
been approved for use in humans and have been used to deliver proteins and model 
antigens 168. 
Both PLGA 167 and polyanhydrides 169 are insoluble in water and must be dissolved in 
organic solvents such as methylene chloride or ethyl acetate to facilitate microsphere 
formation . The antigen is then mixed by homogenisation or sonication to form a fine 
dispersion of antigen in polymer/organic solvent (emulsion) 161. 169. After immunisation, 
this emulsion forms a controlled release system which enhances the immune response 
by providing a long-term reservoir for the antigen127. 170. Such a controlled release 
system can provide a release of antigens for weeks to months, a time far exceeding the 
depot effect of aluminium salts or water-in-oil emulsions such as Freund's adjuvant167 . 
Microspheres less than 10 !-1m in diameter are readily ingested by macrophages and 
processed via the MHC class II pathwayl71. Recent studies have confirmed that 
encapsulation of antigen within particulates112.17", or on their surface175 , can lead to 
antigen presentation by the MHC class I pathway as well. Additionally, microspheres 
are capable of protecting antigens from rapid destruction in vivo thus allowing 
presentation of the antigen in its native conformation to the immune cells 112.174. Native 
antigen is important in order for B-celJs to produce antibody with the highest affinity for 












via the oral route. The antigen is shielded from destruction by the low pH, of the 
stomach and the high levels of proteases and bile salts in the intestines7• 167. It has been 
established that a percentage of microspheres smaller than 1 0 ~m in diameter are taken 
up from the intestine into the immune-inductive environment of the Peyer's patches 
where they can induce both mucosal and systemic immune responses176, 177 . Finally, 
microspheres can deliver adjuvants or be made of polymers that break down into 
adjuvant-active molecules, thus providing long-term delivery of antigen associated with a 
vaccine adjuvant for further potentiation of the immune system 161, 
1.5.8 Carrier proteins 
Conjugation of nonimmunogenic antigens with immunogenic foreign protein carriers has 
been applied to induce immune responses against a variety of antigens, including 
bacterial polysaccharides, and have been approved for use in infants176.118.179. Invasive 
infections cause by Haemophilus inf1uenzae type b (Hib), Neisseria meningitidis and 
Streptococcus pneumoniae have their highest incidence in early childhood 180. After 
identifying that the polysaccharide capsule is an important determinant for virulence, 
vaccines containing the purified polysaccharide were developed and tested in humans 
and their immunogenicity and protective efficacy in adults was demonstrated. However, 
polysaccharide vaccines were not immunogenic in young children. This observation 
triggered the development of polysaccharide-protein conjugated vaccines that are 
immunogenic in infants 181. Conjugate vaccines consisting of capsular polysaccharide of 
Hib bacteria covalently linked to a carrier protein (diphtheria, tetanus or pertussis toxoid, 
CRM I97 protein or meningococcal outer membrane protein complex), have been 
demonstrated to be safe, immunogenic in infants, able to induce immunologic memory 
and protective against invasive Hib infections 180. Commercially available meningococcal 
and pneumococcal multivalent vaccines are prepared in the same way as Hib conjugate 
vaccines. Protein-polysaccharide conjugates therefore have potential to be used for a 
safe and potent combined diphtheria-tetanus-acellular pertussis-Hib vaccine. Such a 
combination vaccine would simplify immunisation schedules, increase immunisation 
coverage and reduce the cost and stress of immunisation32• 57. 
1.5.9 Bacterial CpG DNA 
Bacterial DNA contains unmethylated-CpG dinucleotides (uncommon in mammalian 












activity for systemic and mucosal immune responses182, 183. CpG DNA is most often 
administered in the form of synthetic oligodeoxynucleotides (CpG DON) that are made 
with a nuclease-resistant phophorothioate backbone. CpG containing DNA binds to TaIl-
like receptor 9 (TLR-9) and stimulates B cells to proliferate, secrete immunoglobulin (19) , 
interleukin-6 and interleukin-12, and induces protection from apoptosis'84.186, In addition, 
it enhances expression of class II MHC and 87 co-stimulatory molecules1B7, 188, 
Furthermore, CpG DNA also directly activates monocytes, macrophages and dendritic 
cells to secrete various cytokines and chemokines, which can provide T-helper functions 
(Fig 1.4)186, 188. 189, 
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Figure 1.4: Bacteriai DNA and synthetic cJigodeoxynucieotides 
containing CpG motifs (CpG-ODNJ are strong activators of both adaptive 
and innate immunitylflO. 
Immunisation of animals against a variety of antigens delivered parenterally (e.g. 
intramuscularly or subcutaneously) demonstrated that addition of CpG DNA induces 
more Th-1-like responses as indicated by strong cytotoxic T lymphocytes (CTL), high 
levels of IgG2a antibodies, and predominantly Th1 cytokines (e.g. interleukin-12, and 
IFN-y but not interleukin -4 or interleukin _5)'81. 188. 191-194. Oral administration of CpG 
OON with tetanus toxoid demonstrated strong systemic responses with mucosal 












(lgG1 , IgA) at mucosal sites, and Th1 systematically (CTLs, IgG2a). Intranasal 
administration with a hepatitis B surface antigen elicited similar results 182, Human trials 
of CpG DNA have demonstrated its efficacy as an adjuvant for human use '95. However, 
the d~velopment of CpG DNA vaccines faces several challenges 196 . Most importantly, 
results obtained from murine studies cannot be used to predict human immune 
responses because human and mouse immune cells are optimally stimulated by 
different CpG motifs197 , and major differences in TLR-9 distribution exists between 
species'98. Moreover, CpG DNA is known to stimulate mild-transient inflammatory 
responses upon i njection '~ ' \99 , 
1.5.10 Pheroid™ 
Pheroid™ (previously Emzaloid™) is a micro-emulsion formulated using plant and 
essential fatty acids emulsified in water saturated with nitrous oxide. Pheroid™ was first 
discovered when it was used as a basic formulation for the treatment of psoriasis. One 
of the basic ingredients of this first formulation was present in banana peel extract and 
was identified as essential fatty acids200. The fatty acid component consists of oleic, 
linoleic and linolenic fatty acid ethyl esters and PEG hydrogenated castor oil. Also 
included is the anti-oxidant dl-a-tocopherol 21J '. A variety of Pheroid™ types can be 
formulated depending on the composition and method of manufacturing. The 
manufacturing process and the various types of Pheroid™ formed is shown in Fig 1.5. 
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Figure 1.5: A schematic representation of the PherokJD'f manufacturing 
process, as indicated by the supplier. Vesicle (a), pro-Propheroids (b) 












The size and shape of the vesides can be reproducibly controlled (typically between 
0.5-1 .5 ~m) , whereas those of the microsponges usually ranges between 1.5-5 jJm. The 
sizes of reservoirs or depots are detennined by the amount of pro-Pheroids contained in 
the reservoirs200. The microsponges and depots support prolonged release according to 
a concentration gradient201 • Pheroid™ can entrap. transport and deliver 
pharmacologically active compounds and other useful molecules. Depending upon the 
clinical indication, it can also act in synergism with such compounds or molecules 
resulting in an enhancement of therapeutic action. The Pheroid™ drug delivery system 
differs significantly from conventional macromolecular carriers, such as liposomal 
delivery systems. Table 1.1 provides a comparison of some of the differences and key 
of Pheroid™ over other lipid-based or liposomal drug delivery systems201 . 
Table 1.1: Similarities and differences of lipid-based delivery systems and Pheroid™201 
Lipid-based delivery systems Pheroid'" technology 
Contains of substances foreign to the body Consists mainly of essential fatty acids, a 
such as artificial polymers and natural and essential ingredient of the 
lysolecithin202. body'''. 
Most if not all lipid-based delivery Pheroid 'M contains no cholesterol but the 
systems contain phospholipids and interior volume is nevertheless stably 
cholesterol202. 204. 205. maintained. 
Some liposomal formulations have been Cytokine studies demonstrated that 
shown to elicit immune responses in Pheroid™ elicited no immune responses in 
man202.204. man. 
Cytotoxicity and impaired cell integrity are Pheroid I M causes no cytotoxicity because 
common problems with substances that it is part of the natural biochemical 
enter the body. pathways. Rather, it assists with cell 
maintenance203. 
Specific binding and uptake mechanisms An affinity exists between Pheroid '" and 
by mammalian cells have not been cell membranes because it is comprised of 
described. fatty acids, thus ensuring penetration and 












A comparative study was undertaken in mice to investigate the efficacy of a 
commercially available rabies vaccine versus the vaccine formulated with PheroidTt,l. 
The rabies vaccine was prepared by inactivation of the virus. For the comparative 
animal study. different formulations of the virus were used, namely the inactivated virus, 
the inactivated virus with aluminium hydroxide adjuvant and the inactivated virus 
incorporated into Pheroidn". The Pheroid™-adjuvanted rabies vaccine showed a 9-fold 
increase in the antibody response over the unadjuvanted sample. This study was 
repeated four times with similar results20 ' , 
A similar study was conducted using a commercially available hepatitis B vaccine and 
the vaccine formulated with PheroidTlol • Non-recombinant hepatitis B vaccines are 
generally based on the use of the surface molecules of the virus as antigen. For the 
comparative animal studies, different formulations of this peptide-based vaccine were 
used (the peptide, the peptide with aluminium hydroxide adjuvant and the Pheroid™-
entrapped peptide). The use of Pheroid™ as a delivery system led to more than a 10-
fold increase in the efficacy of the peptide-based hepatitis B vaccine as measured by 
antibody response. Thus, PheroidTu has a dual role in vaccinology, firstly as a delivery 
system for disease specific antigens, and secondly as an immuno-stimulatory 
adjuvanfO' . 
As part of the preclinical studies on Pheroid™, physicochemical techniques which had 
not previously been applied to the study of Pheroid™ were employed to characterise the 
composition and size of this novel adjuvant. Nuclear magnetic resonance (NMR) 
spectroscopy provides a window into the structure of organic molecules and 'H- and 13C_ 
NMR spectra were used to profile the raw materials used to prepare Pheroid™ and to 
study the composition of Pheroid™ formulations. Coulter Counter analysis was used to 
investigate particle volume-size and particle number-size distributions of different 












1.6 Regulatory consideration of new adjuvants 
Due to the limitations of currently available aduvants, greater emphasis by vaccine 
manufacturers is now being placed on the discovery, development and testing of new 
adjuvants for use with modern vaccines80, 201. In addition to being fully characterised for 
its chemical properties, all new biological products must undergo pre-clinical evaluation 
prior to being used in humans80· 2<19. Besides establishing their biological properties and 
evaluating their possible risk to the public, these pre-clinical trials form the basis for 
subsequent clinical trials from which safety and efficacy can be evaluated210. No 
adjuvant is licensed as a medicinal product, but only as a component of a particular 
vaccine; as such preclinical and appropriate toxicology studies are designed on a case-
by-case basis to determine the safety profile of the adjuvant or adjuvanVvaccine 
combination210 . Finally, clinical studies are performed on the adjuvant(s) alone and on 
its combination with the antigen(s) in order to determine that: 
1. Inclusion of the adjuvant is justified. 
II. Potentiation of immune response occurs without undue increase in local and 
systemic reactions. 
iii. The risk-benefit relation for a modified product is at least as favourable as for the 
existing product. 
The various clinical scenarios to be considered for confirmatory clinical studies are 












Table 1.2: Requirements for the evaluation of new adjuvants in vaccines - clinical 
aspects210 
Scenario Expected study approach 
• Changes to licensed vaccines Studies to demonstrate: 
• Removal of one or more adjuvants from a • Superiority for safety (if possible) 
licensed vaccine (without replacement) or • Non-inferiority for immune response(s) 
reduction in the adjuvant content in order to 
improve the safety profile 
• Addition of one or more novel or estabtished Studies to demonstrate: 
adjuvant(s) 10 a licensed vaccine or increase • Superiority for immune responses to the 
in the amount of adjuvant(s) in order to antigen or to at least one of the antigens 
enhance the immune response · Non-inferiority for responses to any 
antigen(s) 
• Replacement of one or more adjuvant(s) in a If primary aim is to enhance immunogenicity, 
licensed vaccine with one or more novel or studies to demonstrate: 
established adjuvant(s) • Superiority for immune response to the 
antigen or to at least one of the antigens 
• Non-inferiority for responses to any other 
antigen(s) 
If primary aim is to enhance safety, studies to 
demonstrate: 
• Superiority for safety (if possible) 
• Non-inferiority for immune response(s) 
With the introduction of new technologies, regulators are faced with issues that cannot 
be easily addressed during development, pre-clinical and even clinical studies, using 
existing models and technologies. Currently, very little is known about the possible 
modes of action of existing and new adjuvants and even less is known about their 
possible interactions. It is difficult to generate useful comparative studies in current 
animal models to adequately provide information on the effectiveness of adjuvants6o. 210. 
However, as knowledge of fundamental biological mechanisms increase and genetic 
engineering becomes applicable to a widening range of species, the construction of 













1.7 Conjugate Vaccines 
Several bacterial pathogens, including Haemophilus influenzae, Streptococcus 
pneumonia and Neisseria meningitidis, possess a polysaccharide capsule which 
protects the bacterium from phagocytosis and complement-mediated lysis and is a 
potent virulence factor2' 1. Vaccines which result in the production of antibodies have 
been shown to confer protection against these bacterial pathogens. The first generation 
vaccines against infectious diseases such as Haemophilus influenzae type b (Hib), 
Streptococcus pneumonia and Neisseria meningitidis were polysaccharide vaccines 
which elicited type-specific antibodies. Unfortunately, the polysaccharide vaccines were 
found to be poorly immunogenic in children less than 18-24 months of age, and this is 
the age of highest incidence of disease in non-immunised populations212• Pioneering 
studies by Landsteiner in 1924 demonstrated that whereas a small hapten was non-
immunogenic, immunisation with the hapten linked to a protein antigen induced an 
antihapten antibody response212. In 1929 Avery and Goebel showed that by conjugating 
a bacterial polysaccharide to a carrier protein, a stronger antibody response to the 
carbohydrate moiety was obtained213• 
Two types of carrier protein are most commonly chosen for use in conjugate vaccines. 
The earliest and most widely used group have been bacterial toxoids, including tetanus 
and diphtheria toxoid. These proteins were already licensed for human use. Another 
popular carrier is CRM ,97, a geneticallv toxoided variant of diphtheria toxin, as chemical 
toxoiding is not required and the vaccines are simpler to characterise and control , and 
there is Jess variability possible in carrier protein production. An alternative approach is 
to choose a carrier protein which will induce an immune response that complements the 
role of anti-saccharide antibodies2 14. For example, Streptococcus pneumoniae causes 
acute otitis media in childred under 2 years of age. The polyvalent pneumococcal 
capsular polysaccharide vaccine is not immunogenic in this age group, however 
conjugation of the Streptococcus pneumoniae capsular polysaccharide to a recombinant 
non-lipidated fonn of protein 0 from non-typeable Haemophilus influenzae reduces 
nasopharyngeal carriage of both Streptococcus pneumoniae vaccine serotypes and non-












Polysaccharides require activation before attachment to the carrier protein. It may be 
necessary to also activate the carrier protein. The optimum means to activate the 
polysaccharide depends on its structure. For example, periodate oxidation of the Hib 
polysaccharide and meningococcal group C polysaccharide creates aldehydes at either 
end which are attached to the free amino groups of lysine residues in the carrier protein 
by reductive amination217. Both the Hib and the meningococcal group C polysaccharides 
are susceptible to mild acid hydrolysis, generating a protected aldehyde group at the 
reducing end. This reducing end can be activated, for example by reductive amination, 
and a linker attached which allows covalent attachment to the carrier protein - this 
approach has been used by Chiron Vaccines (now Novartis)218. The polysaccharide 
from Salmonella typhi and Staphylococcus aureus, in contrast, have few free hydroxyl 
groups and are extremely resistant to hydrolysis. These polysaccharides have been 
activated by the addition of bifunctional reagent to the uronic acid carboxyl group, which 
allows conjugation to a suitable activated carrier protein219-221. 
Treatment of a polysaccharide with cyanogen bromide or a cyanogen bromide analogue 
such as 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP)222, results in 
random activation of hydroxyl groups to which a bifunctional linker, such as adipic acid 
dihydrazide, can be attached222. This linker is then attached to asparagine or glutamate 
carboxyl groups on the carrier protein by treatment with a water-soluble carbodiimide214. 
Reaction of a carboxylate-containing capsular polysaccharide with an amine in the 
presence of carbodiimide is a means to attach a reactive group - such as a protected 
thiof - to the capsular polysaccharide. This can be conjugated to a complementary 
reactive groups pre-attached to the carrier protein to create the polysaccharide-protein 
complex11•. Another conjugation chemistry that has been used involves partial 
de-N-acetylation of an N-acetylglucoseamine residue in the repeating unit of the 
capsular polysaccharide from Streptococcus pneumonia type 14. Treatment with nitrous 
acid leads to the formation of an anhydromannose residue with a free aldehyde group, 
suitable for conjugation by a lysine residue in an appropriate carrier protein223. 22.. The 
effectiveness of this strategy depends on the nature and substitution pattern of the 












Table 1.3: Summary of conjugation chemistries214 
Conjugation Chemistry 
1. Reductive amination: 
INA . INA ----;> 11NA\ ----;> 
i . Period ate 0 0 HO NH-Proteln 
H2 N-Prolein ,. NaCNB~ 
2. NaBH. 
2. Active ester chemistry MM ----;> MMoH ----;> NM-NH-Protein 
Bifunclionallinker 
~Protein 




1. CNBr, ADH 1InkE!f 
2. HOOC-PfOtein, carbodiimide 
4. Disulphide chemistry eaOH • f~NHCH2CH2SS.'inker.Protein 
~ ---? 
1. Cysteamine, caftlodiinide· taoH eaOH 
2. H5-inker-Protein 
At present, there is a lack of good animal models for predicting the potency of 
conjugates in humans. Therefore, physicochemical methods such as chromatography, 
spectroscopy and hyphenated techniques are used by the vaccine industry and control 
agencies to test the quality of the vaccine intermediates and the final product225. These 












1.7.1 Haemophilus influenzae 
Haemophilus influenzae type b (Hib) is a respiratory pathogen which causes several 
diseases in humans, the most common and most serious being meningitis and 
pneumonia, mainly in children under 5 years of age '8O, 226, Hib also causes epiglottitis, 
septicaemia, facial cellulitis , septic arthritis, osteomyelitis and pericarditis·8. 211. The 
capsular polysaccharide is a polymer made of repeating units of -(P02H--+3)-P-D-Ribf-








Figure 1.6: Hib Polysaccharide repealing unit 
[-(P02H->3)-~-D-R ibf-(1 -> 1 )-D-Ribitol-S-> 1" 
Before the availability of vaccines, an estimated 20 000 to 25 000 people developed 
invasive Hib disease annually in the United States and until 1992 when conjugate 
vaccines were used for routine immunisation of infants, Hib was the most common 
cause of bacterial meningitis228. Population~based studies in other industrialised nations 
showed an incidence of Hib disease that is approximately one third to two thirds that in 
the United States. In Sweden229-2J2, Finland229, 233, 234, the Netherlands235 and 
Australia238, it was the most common cause of bacterial meningitis. It also ranked as the 
leading cause of bacterial meningitis in Canada, which has a disease incidence similar 
to that in the United States237,238. An exceptionally high rate of invasive Hib disease has 
been reported among Aboriginal children in central Australia237. 239. 2-«1 and among Native 
Americans241. 
Although population~based data for developing countries are limited, Hib also appears to 












Most studies in Africa show rates in meningitis and invasive disease similar to those in 
the United States, while data from South America and the Middle East demonstrate 
rates of disease similar to those found in Western Europe. A study in Niger reported a 
rate of Hib meningitis of over 200 cases per 100 000 infants less than a year oldz4r. Hib 
disease is also prevalent in The Gambia248, 249, Many studies of hospitalised patients 
with presumed bacterial meningitis throughout Asia (Indonesia, Singapore250, China251 , 
Hong Kong252 , the Philippines253, 254, Taiwan255, Thailand, India2S6, Vietnam, Korea and 
Japan257) consistently show Hib to be the leading cause of bacterial meningitis in 
children228 . 
The first vaccine against Hib consisted of the purified polysaccharide 
polyribosylribitolphosphate (PRP) alone; however it failed to induce protective antibodies 
in children under 18 months old. Immunogenicity against Hib could be improved 
dramatically by covalently linking PRP to a protein carrier48. Four Hib conjugates 
(PRP-D, PRP-T, HbOC and PRP-OMP) were licensed and have been used to immunise 
tens of millions of infants worldwide 180. 211. These conjugates from different 
manufacturers differ in the size range of the polysaccharide, the identity of the protein 
carrier and the method of conjugation2<8. 
The mechanism by which glycoconjugates stimulate an immune response involves an 
initial binding of the conjugate to the surface immunoglobulin (slg) of B cells with 
appropriate specificity for the saccharide hapten. This complex is internalised and the 
carrier protein degraded by proteolytic enzymes. Suitable peptides are transported to 
and displayed by MHC II complexes. The peptide-loaded MHC II complex is recognised 
by T cells, which then provide appropriate signals through direct interaction of cell 
surface proteins and through cytokine signalling processes, to induce maturation of the 
8 cell into an antibody secreting plasma ce1l258. The T cell dependent response to a 
conjugate results in both serum IgG antibodies and memory 8 cells, even in infants. In 
general, immunogenicity of a polysaccharide-protein conjugate, in contrast to the native 
polysaccharide, does not depend on the size of the conjugated polysaccharide; 













The generation of mucosal immune responses by Hib conjugate vaccines has been 
investigated in animal models. Bergguist and co-workers reported that intranasal 
immunisation of Hib vaccines gave rise to both mucosal and systemic anti-PRP antibody 
responses260, Similar results have been reported in more recent studies and support the 
rationale for Hib conjugate vaccines which can be administered to infants and young 
children via mucosal routes261.262. 
In populations where one of the Hib conjugates have been in use as a universal infant 
vaccine for several years, including the United States, United Kingdom, Finland, Iceland 
and Australia, a rapid sustained reduction of all Hib infections was observed211 , 263-267, 
The WHO recommends that the Hib conjugate vaccine should be included in national 
immunisation programmes wor1dwide~8. 
1.7.2 Neisseria meningitidis 
Although there are several different bacteria that can cause meningitis, meningococcus 
is one of the most important because of its potential to cause epidemics259. 268. 
Meningitis caused by Neisseria meningitidis accounts for an estimated 171 000 deaths 
worldwide269 . The meningococcus has both an outer and inner (cytoplasmic) cell 
membrane that is separated by a peptidoglycan cell wall. The outer membrane is 
surrounded by a polysaccharide capsule that is essential for pathogenicity as it confers 
resistance to phagocytosis270• 271 and complement-mediated lysis and offers protection 
against environmental injuries. Although there are 12 serogroups, essentially ali 
meningococcal disease is caused by serogroups A, B, C, W135 and y 259, The 
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The relative importance of each serogroup varies with geographical region, At present, 
group A is a problem mainly in Africa213 and Asia27., and occasional outbreaks have 












past half centurf75, In industrialised nations, group B meningococci cause 30-70 % of 
cases of sporadic meningococcal disease273 , 276. 277 and have been responsible for 
pockets of persistently increased rates of disease278-260. Group C meningococcal 
disease affects individuals of all age groups, but the highest incidence is in children less 
than 5 years old, and especially among infants aged 3-12 months276• Group Y disease is 
uncommon in the United Kingdom, but accounts for up to 30 % of cases in the United 
States; rates of Y disease may also be on the increase in parts of Canada277. 
Occasional sporadic disease caused by W135 meningcocci had been largely ingnored 
until a recent large outbreak among pilgrims to the Hajj in 2000261 , 
Epidemics caused by N meningitidis are usually characterised by a predominance of a 
single meningococcal genotype, higher incidence rates, and a shift of cases toward older 
age groups. For more than 100 years group A2B2 and, to a lesser extent group C2B3 
strains have been responsible for recurrent epidemics in countries of the meningitis belt 
of sub-Saharan Africa2S4 . These epidemics take place in regular cycles every 5-12 
years, and last for two to three dry seasons, dying out during the intervening rainy 
season. These epidemics can be enormous, with up to 400-800 cases per 100 000. In 
1996, in the largest epidemic ever recorded, there were more than 200 000 cases and 
20 000 deaths"'. 
Concurrent epidemics caused by group A and W135 have been associated with the Hajj 
pilgrims in Saudi Arabia, with 53 % of the cases caused by group W135. Additional 
cases of group W135 meningococcal disease arose concomitantly in countries outside 
of Saudi Arabia, including countries in the African meningitis beleae. 287. In 2002, a large 
W135 meningococcal outbreak was reported in Burkina Faso, with more than 8 000 
cases285 . 
Large outbreaks of group A disease occurred frequently in China and Mongolia during 
the 70s, and disease occasionally reached Nepal and India. Large outbreaks of group A 
disease were also recorded in Mongolia in the mid-90s. However, in the past 20 years, 
rates of disease in China have declined, coincident with introduction of meningococcal 
polysaccharide vaccine283. Rates also declined in Hong Kong, Nepal and India275 in the 
absence of widespread vaccination. By contrast, with the abrupt onset and short 












gradually over several years and last up to a decade or more289• These epidemics have 
happened in Europe (Belgium, Iceland, Norway and Spain)292.ns, the United States and 
some middle income countries of the Americas (Brazil , Chile, Columbia Cuba)296-299. 
Since 1991 New Zealand has been experiencing an epidemic of group B meningococcal 
disease with incidence rates reaching ten times background incidence, and with much 
higher age-specific, area-specific and ethnic-specific rate. Without an efficient vaccine, 
the incidence rate still remains high28S• It is still unclear why group B epidemics are so 
rare in Africa and other areas of the developing world 3OO. 301. The polysaccharide capsule 
of serogroup B meningococcal is a homopolymer of sialic acid, which is chemically 
identical to polysaccharides found in human tissues during development302• Hence, the 
B capsule is seen by the immune system as a self antigen and is thus poorly 
immunogenic, even after conjugation to a protein carrie~l . Consequently, conventional 
approaches to develop a vaccine for group B stains have been largely unsuccessful and 
various alternative strategies are being investigatedl O4 . 
Polysaccharide vaccines against serogroups A, C, W135, and Y have been available 
since the mid-1980s and are effective in children 5 years of age or older and adults. A 
tetravalent polysaccharide vaccine that provides protection against serogroups A, C, 
W135 and Y is also available but is not recommended for routine childhood vaccination 
because meningococcal polysaccharides, like most other bacterial polysaccharides, do 
not effectively stimulate the immune system in young children and are largely non-
immunogenic in infants, who have the highest risk of sporadic disease259. 305-308. The 
exception is the group A meningococcal polysaccharide, which for reasons not well 
understood, is immunogenic in infants as young as 6 months of age, primed for a 
boosted response, and is effective when used in infants and toddlers in a two-dose 
immunization schedule309. 
As with Hib conjugate vaccines, serogroup A, C, W135 and Y meningococcal 
polysaccharides have been covalently linked to carrier proteins (such as diphtheria and 
tetanus toxoids, meningococcal outer membrane protein complex or protein D from non-
typeable Haemophilus influenzae) . These meningococcal conjugate vaccines induce a 
T cell dependent response, resulting in an improved immune response in infants, 
priming immunologic memory, and leading to a booster response to subsequent 












C (Meningtec, Menjugate and Neis Vac_C)225. 259, 310. A tetravalent conjugate vaccine 
against groups A, C, W135 and Y was licensed in the United States in 2005 for use in 
adolescents and adults3\1 . Clinical studies assessing the immunogenicity of this vaccine 
in infants showed modest results , suggesting a need for alternative presentations, 
perhaps with the addition of adjuvants312• Nearly a decade ago the Meningitis Vaccine 
Project (MVP) was created as a partnership between PATH (Program for Appropriate 
Technology in Health) and the WHO with the goal of eliminating meningococcal group A 
epidemics in Africa through the development, licensure, introduction and widespread use 
of group A N. meningitidis conjugate vaccine. A phase I study of the vaccine in India 
has shown that it is safe and immunogenic. Phase II studies are currently underway in 
Mali and The Gambia313. 
1.7.3 Pneumococcal and other conjugate vaccines 
Pneumococcal infections elicited by Streptococcus pneumoniae (which include 
pneumonia, otitis media, sinusitis, meningitis) are frequently occurring diseases that are 
associated with considerable morbidity even in developed countries31 <4. Of the ninety-
one different serotypes described, approximately 20 serotypes are responsible for more 
than 70 % of invasive pneumococcal disease in all age groups315, and approximately 10 
or 11 serotypes account for at least 70 % of invasive paediatric infections in all regions 
of the world316. In 2005, the WHO estimated that 1.6 million people a year die from 
pneumococcal disease, including up to 1 million children less than 5 years 01d317 • 
The pneumococcal polysaccharide vaccine, PPV23, is licensed for use in adults 
(especially the elderly) and children over 2 years old who have certain underlying 
medical conditions, for the prevention of pneumococcal disease. It is a blend of 23 
serotype-specific polysaccharides which account for 65-90 % of all cases of 
pneumococcal disease2H. 225. 315. As a polysaccharide vaccine, it was poorly 
immunogenic in infants and children under 2 years of age and did not induce immune 
memoifl5. A prophylactic conjugate vaccine became available for this age group with 
the licensure of Prevenar in 2000318. This 7-valent pneumococcal conjugate vaccine 
contains the serotypes Pn 4, 68, 9V, 14, 16C, 19F and 23F214 : In contrast to the pure 
polysaccharide pneumococcal vaccine, the conjugate vaccine stimulates a robust T cell-
dependent immune response that allows for generation of protective anti-pneumococcal 












The success of the Hib conjugates and the potential shown by the meningococcal and 
pneumococcal vaccines under development has inspired the application of this 
technology to other bacterial diseases319 • Group B streptococcus (G8S) represent the 
leading cause of neonatal septicaemia and meningitis in industrialised countries. 
Capsular polysaccharides from GBS types la and Ib32D, type 11132 \ and types VI and VIII , 
conjugated to carrier proteins, have been shown to be effective in preclinical studies. 
Furthermore, tetanus toxoid·based conjugates of types la, Ib and II were immunogenic in 
humans320• 322, Similar attempts are undelWay to make immunogenic and safe vaccines 
against the Vi polysaccharide capsule of Salmonella typhi323 , Escherichia colil2'., Shigella 
dysenteriae type 1325, Shigella sonnei and Shigella f1exneri 2a326 and Vibrio cholerae327 . 
1.8 Aims and objectives 
The aims of this thesis is to characterise an experimental adjuvant called Pheroid™ 
which has been developed in South Africa , to develop methods for analysis of the 
integrity of conjugate vaccines, to apply these methods to combination vaccines and to 
evaluate the effect of adjuvants on the stability and integrity of conjugate vaccines. The 
objectives of this thesis can be stated as follows: 
.:. To investigate size, structure and composition of Pheroid™ using NMR 
spectroscopy and Coulter Counter; 
.:. To investigate different methods of free saccharide separation and quantification 
of saccharide for meningococcal group A conjugate vaccine; 
.:. To apply the methodology developed to evaluate the integrity of a Hib 
monovalent vaccine; 
.:. To investigate methods for PRP and Hit>-TT processing in the presence of 
Pheroid™ and aluminium-containing adjuvants; 
.:. To investigate the applicability of the free saccharide assay to Hib pentavalent 
vaccine containing sucrose formulated with Pheroid™ or aluminium-containing 
adjuvant and subjected to a thermal stability study; and 
.:. To apply the assay to an aluminium phosphate-adjuvanted pentavalent liquid 
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DESCRIPTION OF PHYSICOCHEMICAL TECHNIQUES FOR 
THE CHARACTERISATION OF ADJUVANT AND VACCINE 
COMPONENTS 
2.1 Analysis of Pheroid™ and raw materials by NMR spectroscopy and Coulter 
Counter 
2.1.1 NMR spectroscopy 
NMR spectroscopy is a technique that provides infonnation about the electronic environment 
(composition) of a molecule and its structure. A sample dissolved in a suitable solvent and 
placed in a powerful magnetic field is irradiated with a short pulse of radiofrequency energy 
which disturbs the equilibrium balance of the ' H and 13C nuclei: some nuclei absorb the 
energy and are promoted to a higher energy level. When these nuclei fall back down to the 
lower energy level, the previously absorbed energy is released and quantified using a 
sophisticated radio receiver. In the 10 spectrum (Fig 2.1). the NMR signals are displayed as 
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The samples used in this study were dissolved in do-OM SO (dipole moment = 3.96 D) or 
CDCb (dipole moment = 1.01 0)3, Peaks for de-DMSO in 'H- and 13C_NMR spectra occur at 
2.5 and 39.5 ppm respectively. CDCr, produces peaks in tH_ and 13C-NMR spectra at 7.26 
and 77.0 ppm respectively. 'H- and 13C_NMR spectra obtained in both solvents were 
compared to ascertain which solvent gives the best spectra. 
The spread of frequencies is caused by the different chemical (and hence magnetic) 
environments, therefore the signals are described as having a chemical shift (6) from some 
standard frequencl. Tetramethylsilane Si(CH3). or TMS, was used as the reference sample 
and thus given a chemical shift of 0 ppm. Fig 2.2 shows the regions that ' H-NMR spectra 
can typically be divided into. Tables of chemical shift data are available from published 
literature!. 
protOflS on protons on protons on saturated saturated 
unsaturated unsaturated unsaturated CH, CH, 
carbons next carbons: carbons: CH, CH, 
to oxygen: benzene. a'""" CH CH 
aldehydes aromatic next to not next to 
hydrocarbons oxygen oxygen 
10.5 ••  ••  •• ' .0 o (ppm) 0.0 
Fig 2.2: Regions of ' H-NMR spectrat.. 
All 1lC_NMR spectra can be divided into four major regions: saturated carbon atoms 
(0-50 ppm), saturated carbon atom next to oxygen (50-100 ppm), unsaturated carbon atoms 
(100-150 ppm) and unsaturated carbon atoms next to oxygen, i.e. C=O groups 
(150-200 ppm)'. 
20 correlation spectroscopy (COSY) can be used to provide useful structural information 
and consists of a plot of the 10 spectrum along the horizontal and vertical axes. Cross 
peaks obtained from the diagonal show scalar coupling between neighbouring protons". In 
heteronuclear single quantum correlations (HSaC), the proton spectrum is correlated with 
the carbon spectrum. This permits assignments to be made and allows correlation between 
1lC and the proton to which it is directly attached and confirms whether a proton signal and 
more importantly the integration is due to one or more proton. The long range 'H_1l C COSY 
spectrum also known as heteronuclear multiple bond correlation (HMBC) allows connection 












chemical shifts of protons separated from them by two CH - C - 13C) and three CH - c - c 
- 13C) bonds", Technical details of the standard pulse sequences used in this study (COSY, 
HSQC, and HMBC) have been published and are provided in appendix A (pages 249-251 )'-
9, In the present study, emphasis is placed on the application of these pulse sequences to 
analyse the raw materials used to manufacture Pheroid™ and different Pheroid™ 
formulations . 
2.1.2 Size analysis (Coulter Counter) 
The Coulter Counter has been used to determine droplet size in oil-in-water emulsions 10-1., 
Particles suspended in a weak electrolyte solution are drawn through a small aperture, 
separating two electrodes between which an electric current flows (Fig 2.3). 
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Figure 2.3: Scliematcs of a Coulter Counler, used 'br analysis of particle size 
distributions in a suspension, with an analysis range of 0.4 - 1 200 pm ". 
The voltage applied across the opening creates a ~sensing zone~. As a particle passes 
through the opening (or ~sensing zone~) . it displaces its own volume of electrolyte, briefly 
increasing the resistance across the aperture. This change can be measured as a current 
pulse that is digitally processed in real time. The Coulter principle states that the pulse is 
directly proportional to the three-dimensional volume of the particle that produced it. 
Analysing these pulses enables a size distribution to be acquired and displayed in volume 












Figure 2.4: A typicalpartic/e volume-size distribution obtained using a CoulterCounter'6, 
Furthermore, a metering device is used to draw a known volume of the particle suspension 
through the opening and a count of the number of pulses then yields the concentration of 
particles in the sample17. Consequently, particle number-size distribution curves are 
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Figure 2.5: A typical particle number-size distribution obtained using 8 CoulterCounterl9. 
10 
Particle size is an important attribute of the adjuvant and was profiled by use of Coulter 
Counter analysis. Measurement using a Coulter Counter is fast and sizing rates of up to 
10000 particles per second are possible. Aperture size typically ranges from 15-2000 I.Im. 
Each aperture can be used to measure particles within a series range of 2-60 % of its 
nominal diameter. Therefore, an overall particle size range of 0.4-1 200 I.Im is possible20. 
The ability of the technology to analyse particles is limited to those particles that can be 
suitably suspended in an electrolyte solution. The selection of the most suitable aperture 
size is dependent upon the particles to be measured. For example, a 30 I.Im aperture can 
measure particles from about 0.6-18 I.Im in diameter. A 140 I.Im aperture can measure 












single aperture can measure, two or more apertures can be used and the test results 
overlapped to provide a complete particle size distribution20• 
2.2 Analysis of conjugate vaccines 
It is customary to use quantitative methods (e.g. colorimetric assays) and biological assays 
including immunogenicity in animals for testing the quality control of different vaccine 
batches. However for Hib conjugate vaccines, immunogenicity in animals such as mice 
does not correlate well with protective immunity in children21•23. As such, consistency of 
different batches is assessed by determining the sugar-to-protein ratio, size distribution and 
integrity by free saccharide quantification23• For a conjugate vaccine to elicit an immune 
response in children, the oligo- or polysaccharide should remain attached to the carrier 
protein24• Degradation and depolymerisation of the saccharide chain reduces the 
immunogenicity of the vaccine. Thus, the integrity of a conjugate vaccine can be monitored 
by measuring the amount of free saccharide presenrS-27. Physicochemical assays such as 
ribose, phosphorus and high performance anion exchange chromatography with pulsed 
amperometric detection (HPAEC-PAD) can be used to quantify the capsular polysaccharide 
_ 5-D-ribitol-(1-1)-J3-0-ribose-3-phosphate28• In addition, high pertormance size exclusion 
chromatography (HPSEC) can be used not only to monitor molecular size distributions for 
batch-to-batch consistency, but also to assess the stability of the vaccine over time by 
tracking changes in the molecular size distribution due to degradation21l• 
2.2.1 Phosphorus detennination 
The ascorbic acid method is a technique most commonly used for phosphorus quantification 
in vaccines. All forms of phosphorus are converted to orthophosphate using a cocktail of 
perchloric and sutfuric acid. Orthophosphate reacts with molybdate to form 
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The intensity of the colour is directly proportional to the concentration of phosphorus. A 
modification of Chen's method was used to determine phosphorus concentration in Hib and 
meningococcal A (Mn A-TT) conjugate vaccines. Details of the procedure followed to 
prepare reagents for the phosphate assay are provided in appendix B. 
2.2.2 Orcinol method 
Addition of a strong acid to a PRP-containing sample and subsequent heating at 100 DC 
hydrolyses the glycosidic and phosphodiester bonds in PRP to release the ribose moiety. 
Ribose in tum undergoes dehydration and the resulting furfural derivative forms coloured 
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Figure 2.7: The Orcinol Method fordetermination of ribose in v8ccines33. 
This colorimetric method can thus be used to detennine the saccharide content in Hib 
conjugate vaccines. The procedure followed to prepare stock and working reagents required 
for the ribose assay are presented in appendix D. 
2.2.3 High perfonnance anion exchange chromatography (HPAEC) 
In recent years HPAEC-PAD methods have been developed and applied to the analysis of 
glycoconjugate vaccines. It allows direct quantification of underivatised carbohydrates at 
potentially low picomole levels with minimal sample preparation and clean-up. HPAEC-PAD 
takes advantage of the fact that carbohydrates are weakly acidic at high pH. In a strong 
alkaline solution, the sugar hydroxyl groups are ionised oxyanions, The CarboPac series of 
columns (by Dionex) are packed with a strongly basic anion exchange pellicular resin for 
separation and analysis of mono-, oligo- and polysaccharides34 , There are several factors 
that detennine a molecule's affinity to the anion exchange column and thus provide a basis 
for the separation of molecules; these are effective charge, pKa values, steric effects, 
hydrophobic interactions and mass-te-charge ratios35, 
In general, the retention of a molecule on an anion exchange column is proportional to the 
amount of effective charges on the molecule, The affinity of carbohydrates to the CarboPac 
columns under alkaline elution conditions nonnally follows the order polysaccharides > 
oligosaccharides > monosaccharides, which is based on the number of oxyanions generated 
on these molecules in alkaline eluents35, 36, However, exceptions to this trend have been 
reported36, 
Another factor which influences the affinity of an anionic moiety to an anion exchange 












example, an acidic carbohydrate such as mannose-6-phosphate is retained much longer on 
the column than mannose itself, and neutral monosialyl . disialyl and trisiatyl oligosaccharides 
are eluted in that orders. Similar trends were observed in earlier studies conducted using 
anion exchange chromatography, where the main acidic groups used in the chromatographic 
process were those of stronger acids (phospho-, sulfo- or sialyl derivatives) which are 
anionic under neutral or weakly acidic pHs38. HPAEC can also be used to separate 
carbohydrates based on subtle differences between the pKas of their OH-groups39-i1 I an 
example is the separation of N-glycolyl-neuramic acid from N-acetyl-neuramic acid. 
Separation of galactose, mannose and glucose are possible by HPAEC despite similarities 
in their overall molecular size and the number of hydroxyl groups311. 
Since each of the hydroxyl groups on a monosaccharide has a slightly different pKa value, 
substitution of different hydroxyl groups by glycosylation would generate products with 
different affinities36, ,(0. The anomeric hydroxyl group has a much lower pKa value than the 
other hydroxyl groups and thus contributes significantly to the molecule's retention41 , For 
example, the reduced retention of alditols as compared to the parent reducing sugars is 
based on acidityl8. Since the anomeric hydroxyl group is the most acidic among all the OH-
groups, replacing it with an ordinary OH-group (which is less acidic) would naturally result in 
less retention. Inositols are not well retained because of their lack of acidic anomeric 
hydroxyl group, Alkyl glycosides are not retained as much as the parent sugars for the same 
reason38. Similarly, the loss of hydroxyl groups, such as in rhamnose or fucose. reduces 
retention times. This also applies to the amino sugars, in which an OH group is replaced 
with amino or acetamido groups38, The pKa values of some alditols and saccharides are 

























Lactose 11 .98 
Maltose 11 .94 
Accessibility of the oxyanions on carbohydrates to the functional groups of the stationary 
phase (sterie effects) is another important factor in determining the chromatographic 
behaviour of carbohydrates in HPAEC35• 
Carbohydrates show varying retention behaviour on the different pellicular anion exchange 
columns. The CarboPac PA-1 column is the most widely used for monomer analysis and 
quantification in oligo- and polysaccharides. It can withstand extreme conditions such as 
1 M NaOH and 1 M Hel; therefore contaminants can easily be removed by washing with 
these solutions. One major limitation of the CarboPac PA-1 column is that the presence of 
organic solvents above 2 % can cause collapse of the column bed lS, 
The properties of the CarboPac MA-1 column differ from the CarboPac PA-1 column in that 
the MA-1 column not only has much higher anion exchange capacity but is operated under a 
lower flow rate (0.4 ml/min). The high capacity and low flow rate of the MA-l column make 
switching of ionic fonns of the column (e.g. from OAc' fonn to OH' form) difficult, requiring a 
very long regeneration time. For that reason, application of the MA-1 column is mostly 
limited to analysis of reduced mono- or disaccharides, which can be eluted with NaOH; but is 












A strong alkaline solution is required as the mobile phase for the ionisation of the hydroxyl 
groups of carbohydrates to Qxyanions and for carbohydrate detection by the pulsed 
amperometlic detector. The sodium hydroxide/sodium acetate (NaOAc) eluent system is the 
most widely used system for HPAEC-PAD. Under alkaline elution mode, dilute NaOH alone 
provides satisfactory separation of weakly bound monosaccharides. For the elution of 
polysaccharides or acidic saccharides, a stronger eluting agent such as nitrate or acetate is 
used3S, 
2.2.4 Size exclusion chromatography (SEC) 
Size exclusion chromatography (SEC) is a non-interactive mode of separation whereby the 
particles of the column packing have various pore sizes and pore networks, so that solute 
molecules are retained or excluded on the basis of their hydrodynamic molecular volume. 
As the sample passes through the column, the solute molecules are separated. Very large 
molecules cannot enter many of the pores and thus travel mostly around the exterior of the 
packing and elute at the bed void volume of the mobile phase. Very small molecules diffuse 
into aU or many of the pores accessible to them . With a larger column volume at their 
disposal, small molecules exit the column last. Between these two extremes, intermediate-
size molecules can penetrate some passages but not others and, consequently, their 
progress down the column is retarded and they exit at intermediate times43. Thus, solutes 
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Figure 2.8: SEC separates molecules on the basis of differences in 












The microparticulate sorbents (average particle diameter range between 5-13 IJm) that are 
available for high performance SEC (HPSEC). usually in prepacked columns of length 25 or 
30 em, 4-8 mm I. D., are highly efficient and such columns have plate numbers of 
10 000-50 000 per metre. Optimisation for fractionation of samples containing a wide 
distribution of molecular weight can be achieved by coupling columns containing stationary 
phases of the same type but differing in porosity (optimal length ranges between 
50-100 em)". The type of column packing depends on the manufacturer". Silica-based 
columns produced by Merck have a fractionation range of 103 - (>10\ Agarose-based 
columns can be obtained from Pharrnacia and have a fractionation range of 103 - 4 X 107 . 
Columns obtained from Waters are methacrylate-based with a fractionation range of 
<103 - 7 X 106• The Waters Ultrahydrogel column used in this study had a fractionation 
range of 102 - 7 X 106• 
The pore volume in the stationary phase determines the maximum volume available for 
chromatographic separation. The relative pore volume of the modem sorbents for SEC is in 
the range 52-97 % of the column volume, the lower range being typical for silica-based 
materials and the larger values for polymeric sorbents"5. The lower pore volume of sitica-
based stationary phases limits the number of peaks that can be resolved by the column, so 
that the resolution achieved is generally inferior to those of polymeric sorbents. Polymeric 
sorbents are also preferred over silica-based types for HPSEC because they are more 
stable at elevated temperatures and at high pH (conditions that may be necessary in SEC of 
polysaccharides of low solubility in water at room temperature). 
The molecular size distribution of conjugate vaccines is a critical parameter that can be used 
to demonstrate batch-to-batch consistency and, over time provides an indication of the 
vaccine's stability29 " 6-i6. This feature of conjugate vaccines has been evaluated by gel 
filtration chromatography with soft gel such as Sepharose, fast protein liquid chromatography 
(FPLC) and recently by high performance size exclusion chromatography (HPSEC)29. " " '. 
Exposure of the vaccine to degrading conditions such as elevated temperatures would result 
in hydrolysis of the saccharide moiety and a reduction in the size of the conjugate. As a 
result, the retention time of the conjugate would be expected to increase. Exposure of the 
vaccine to elevated temperatures can also cause slight unfolding and modification of the 












conjugate. Thus, changes in the molecular size distribution of the vaccine indicate both 
instability of the protein and loss of the attached saccharide2V• 
2.2.5 BeA protein assay 
The SeA (bicinchoninic acid) assay involves the reduction of Cu2+ (blue) in an alkaline 
environment to Cu+, which forms a chelate complex with peptides in the sample. This is 
commonly known as the biuret reaction. Peptides containing three or more amino acids 
residues form a chelate complex while single amino acids do not. In the next step of the 
reaction, the Cu· ion is chelated by two molecules of SeA to form a purple coloured complex 
which exhibits linear absorbance at 562 nm with increasing protein concentrationso. 











Figure 2.9: Schematic representation of the eGA assay showng the 
reduction of copper by protein in an alkaline medium and the chelation of 
two BGA molecules by one cuprousion5 j . 
The SCA method was used (in chapter 5) to detennine the presence of protein in ultrafiltered 
samples. The procedure followed to prepare stock and working solutions for the SCA assay 
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CHARACTERISATION OF PHEROID™ AND RAW 
MATERIALS BY NMR SPECTROSCOPY AND COULTER 
COUNTER ANALYSIS 
3.1 Introduction 
Adjuvants can be used to enhance vaccine efficacy and to elicit specific immune 
responses to antigens 1. Aluminium containing adjuvants have had the widest use in 
vaccines licensed for humans and thus the longest safety record2. In vaccines against 
diseases such as tuberculosis, which require cell-mediated immune responses for 
prevention and cure, aluminium adjuvants are inadequate3• Additional limitations include 
local reactions, production of IgE antibodies and ineffectiveness for some antigens3. 
Due to these limitations, there is an ongoing search for better adjuvants that would 
induce a broader immune response, permit lower amounts of antigen to be used and 
possibly require fewer immunisations". A patented fatty acid-based formulation 
containing nitrous oxide results in a submicron emulsion (Pheroid™) which has shown 
potential for drug delivery and use as an adjuvant for viral vaccines5-7. Emulsions such 
as Pheroid™ are dispersions of at least two immiscible liquids stabilised by the presence 
of a surface active agent (surfactant) typically with both hydrophilic and hydrophobic 
moieties (See page 24 for a schematic representation of the materials used in 
Pheroid TM)8. 
In view of the fact that full physicochemical characterisation and pre-clinical studies of 
Pheroid™ are required prior to clinical evaluation9 , the present study investigated the 
application of NMR spectroscopy to profile the raw materials used to prepare Pheroid™ 
and to study the composition of Pheroid™ formulations. This study also investigated 
whether NMR spectroscopy could be applied as a quick and easy method to monitor the 
consistency in production of PheroidTIol formulations. In addition. the Coulter Counter 
method, which had not been used in previous studies of Pheroid™, was investigated as 












3.2 Pheroid™ components 
3.2.1 011 phase 
(al Unsaturated fatty acids 
A mixture of fatty acid ethyl esters of oleic, linoleic and linolenic acid is used in the 
formulation of Pheroid™. Some functions of the fatty acid component of Pheroid™ are 
maintenance of cell membrane integrity, energy homeostasis and modulation of the 
immune system through amongst others, the prostaglandins/leukotrins7. The numeric 
designation used for fatty acids comes from the number of carbon atoms, followed by 
the number of sites of unsaturation. The site of unsaturation is indicated by the symbol 
MOM and the number of the first carbon of the double bond (e.g. oleic acid is an 18-carbon 
fatty acid with one site of saturation between C9 and C10, and is designated 18: 1 ~1 0. 
Chemical structures for the fatty acid ethyl esters are shown in Table 3.1. 
Table 3.1 : Numeric designation and structure of the fatty acid ethyl esters10. 
Symbol Common Name Structure 
18:1[)g Oleic acid ethyl ester '""1 
18:209. 12 Linoleic acid ethyl ester v)' v'V'V 













Surface-active agents or surfactants are molecules distinguished by the presence of 
both a polar and a nonpolar region (Fig 3.1). 
Hydrophobic portion 
Hydrophilic portion 
Fig 3.1: Hydrophilic and hydrophobic regions on a surfactant". 
The molecule's hydrophobic section will dissolve in or be in contact with the oil phase, 
whereas hydrophilic portion can dissolve in or be attached to the aqueous phase of the 
emulsion. As a result of their structure, they are attracted to both the oil phase and the 
aqueous phase and will preferentially reside at the interface12• The nature of the 
hydrophilic group is used to classify surfactants into four categories: (a) non-ionic 
surfactant such as the polyoxyethylene (POE) derivatives; (b) cationic surfactants, the 
most important members being the quaternary nitrogen bases and amines, which can 
ionise to assume a positive charge; (c) anionic surfactants which bear a negative charge 
when dissolved in water and include the alkyl sulfates and the soaps; (d) amphoteric 
surfactants such as those containing both amino and carboxylic acid groups 13. The 
surfactant used in Pheroid™ is the polyethylene castor oil derivative, a non-ionic 
surfactant. 
Non-ionic surfactants differ from ionic surfactants in the absence of a charge on the 
molecule. The hydrophobic portion may include saturated and unsaturated fatty acids or 
fatty alcohols. The hydrophilic region may include polyoxyethylene, polyoxypropylene or 
polyol derivatives and the hydroxyl group. The balance between the hydrophilic and the 
hydrophobic properties of a surfactant is known as the hydrophil~lipophile balance (or 
HLB) and provides a practical and rational means for identifying combinations of 
emulsifiers and facilitates the formation of stable emulsions. Most non-ionic surfactants 












soluble in oil while an HLB value of 20 signifies that it is soluble in water. Suriactants 
with low HLB values are good stabilisers for water-in-oil emulsions, while those with high 
HLB values serve as good stabilisers for oil-in-water emulsions 13. 
Commercially available polyethylene glycol (PEG) hydrogenated castor oil (also known 
as Cremophor® RH 40 and available from BASF, Germany) is the surfactant used in the 
production of Pheroid™. It is manufactured by reacting hydrogenated castor oil with 
ethylene oxide. The reaction yields a complex mixture with glycerol polyethylene glycol 
oxystearate (Fig 3.2 (a» as the main constituent and ethoxylated glycerol (Fig 3.2 (b». 










(c)Felty KkleslMl ~PEG 
PEG hydrogenated castor oil has an HLB value in the range of 14-16 and approximately 
75 % of the components of the mixture are hydrophobic. These comprise of the fatty 
acid esters of glycerol polyethylene glycol and fatty acid esters of polyethylene glycol. 
The hydrophilic section consists of polyethylene glycols and glycerol ethoxylates 15. 
(c) Anti-oxidants 
Many oils and fats used in emulsion formulation are obtained from plants or animals and 
can be susceptible to oxidation by atmospheric oxygen or by the action of micro-
organisms. The resulting rancidity is manifested by the formation of degradation 
products of unpleasant odour and taste. Oxidation by micro-organisms is controlled by 
the use of antimicrobial preservatives and atmospheric oxidation by the use of 
anti-oxidants HI. The term anti-oxidant refers to a substance that when present at low 
concentrations compared to those of an oxidisable substrate significantly delays or 
prevents oxidation of that substrate. Butylated hydroxyanisole (BHA) is a widely used 
antioxidant for the protection of fixed oils and fats at concentrations of up to 0.02 % and 












a concentration of 10 ppm. Other anti-oxidants include propyl, octyl and dodecyl esters 
of gallic acid, recommended for use at concentrations of 0.001 % for fixed oils and fats 
and up to 0.1 % for essential oils 16, In Pheroid™, dl-a-tocopherol is the anti-oxidant 
used to protect against atmospheric oxidation. 
3.2.2 Aqueous phase of Pherold™ components 
(a) Nitrous oxide saturated water 
Nitrous oxide (N20), also called laughing gas, is a colourless gas with a sweet odour and 
taste17 , Fonnal charge considerations suggested that the most important resonance 
structure is [N-=N+=O] +-+ [N:N+-Ol Despite the large difference in electronegativity 
between nitrogen and oxygen, the molecule is only slightly polar. The low polarity of the 
gas makes it both fat and water soluble1t1• At 20 °C and 2 atm, one litre of the gas 
dissolves in 1.5litres of waterHI. Prior to the fonnulation of Pheroid™, water is gassed 
with N20 gas for four days because studies perfonned using confocal laser scanning 
microscopy (CLSM) showed that the presence of N:zO is necessary for the fonnatlon of 
clearly defined, ordered and stable droplets!!. However, the precise mechanism by 
which this role is provided is still under investigation. After fonnulation, Pheroid™ is 
stored in the fridge at 2-8 °C and usually discarded after 6 months. 
3.3 General properties of emulsions and Pheroid T1lll 
NMR spectroscopy can potentially be used to study the chemical structures of the fatty 
acid based component of Pheroid™. l H_ and 13CNMR have been used to detennine the 
fatty acid composition in mixtures e.g. plant extracts20-22. Stoffel and co-workers have 
presented the 13C-NMR data for the fatty acids palmitic, stearic, oleic, linoleic, a-linolenic 
and arachidonic acid23. Miyake and co--workers reported the use of l H_ and llC_NMR for 
the quantification of specific fatty acids in vegetable OilS22. In a more recent study, 
Knothe and associates have outlined a method by which infonnation on the amounts of 
individual fatty acids can be obtained using lH-NMR spectroscopy in an oil or fat sample 
or in the fonn of derivatives such as methyl esters21. 
Emulsions such as Pheroid™ do not fonn spontaneously but rather require an input of 
energy and are therefore thennodynamically unstable24. Processes that can destabilise 












represents the metastable state before the onset of instability. The droplets can be 
polydisperse and in real systems are animated by thermal events in the continuous 
phase (Brownian motion)25. 
(a) Original Emulsion •• • • • • •••• 
• ••• • • 
(b) Flocculation (c) Coalescence 
• •• 
Fig 3.3: Majorinstabifityprocesses that emulsions undergci4• 
(d) Creaming 
.... T ,..,.. , 
. ' ~ '. 1 • 
• 
Flocculation occurs when there is a net attractive force between droplets which is large 
enough to overcome thermal agitation and cause persistent aggregation (Fig 3.3 (b» . 
This is distinct from being close together because of a chance encounter due to 
Brownian motion. Whilst the droplets are held together they are not in intimate contact 
and are usually separated by a layer of sulfadant. When the surfactant fails, their 
contents flow together and bigger droplets are formed. This process is called 
coalescence and the coalescing emulsion is characterised by a wide size distribution of 
the droplets, but no clusters are present (Fig 3.3 (C» 25. 
Creaming occurs when there is a difference between the density of the dispersed and 
continuous phases. Under the influence of gravity. separation occurs with the most 
dense phase collecting at the bottom and the less dense phase at the top 
(Fig 3.3 (d»25. Flocculation usually leads to enhanced creaming because flocs rise 
faster than individual drops due to their larger effective radius. Flocculation is enhanced 
by polydispersity since the differential creaming speeds of small and large drops cause 
them to come into close proximity (and hence possibly aggregate) more often than 
would occur in a monodispersed system26• These processes must be minimised to 
enhance the stability of an emulsion. For example creaming in a dilute emulsion can be 
inhibited by reducing the average drop size, reducing the density difference of the 
phases or by increasing the viscosity of the continuous phase26. Another technique by 












which protects the newly formed drops from re-coalescence. An emulsifier is a 
sunaetant which facilitates emulsion formation and aids in stabilisation through a 
combination of surface activity and possible structure formation at the interface2B. 
Zeta potential measurements provide information on the stability of an emulsion. Zeta 
potential is defined as the difference in potential between the surface of the tightly bound 
layer of ions on the particle surface and the electroneutral region of the solution. When 
the zeta potential is high (25 mV or more, absolute value) the repulsive forces exceed 
the attractive van der Waal's forces (or London forces). The particles are dispersed and 
the system is deflocculated. When the zeta potential is low (less than 25 mY, absolute 
value), the attractive forces exceed the repulsive forces. The particles come together, 
leading to flocculation . Particle charge is an important attribute of the adjuvant and has 
been profiled using zeta potential measurements. The stability of Pheroid™ is related to 
the zeta potential of the system. Its value reflects the stability of the emulsion in a 
chosen environmenf?' . Previous studies in which zeta potential measurements of 
Pheroid™ samples containing varying amounts of fatty acid were taken demonstrated 
that all Pheroid™ particles were negatively charged and that this property enabled the 
fonnation of a stable emulsion by providing steric repulsion between droplets to prevent 
flocculation and creaming of the dropletss. s. 
The average size and the distribution of sizes are very important properties of an 
emulsion since they determine the safety of the preparation in the case of intravenous 
preparations or the release properties of the active ingredient in topical 
fonnulations21-31 . Turbidity measurements obtained for any given Pheroid™ formulation 
provide a reflection of the number and size of particles and can be used routinely to 
monitor formulations. The turbidity measurements of activated Pheroid™ samples at 
different concentrations of surfactant or different fatty acid concentrations recorded over 
2-4 weeks revealed that the size and number of Pheroid™ particles per volume can be 
tailor-made by changing the composition of the Pheroid™ formulations. The present 
study investigated the Coulter Counter method as an alternative for analysis of particle 












3.4 NMR analysis of Pheroid™ components 
Pheroid™ raw materials were provided by the North West University (Potchefstroom) 
and consisted of a mixture of fatty acid methyl esters, vegetable oil containing ricinoleic 
acid·PEG and dl-a-tocopherol. The composition and identity of these raw materials were 
investigated by NMR spectroscopy. 
2 drops of each was thoroughly mixed with 500 ~I of ds-DMSO and subjected to analysis 
by 1H_ and l'C_NMR spectroscopy. With the exception of dl-a-tocopherol, the above 
procedure was repeated in 500 ~I of CDCI, in order to determine which solvent gave the 
best spectra. ds-DMSO is hygroscopic and so all spectra obtained using this solvent 
showed a water peak at 3.33 ppm32• A description of the samples analysed is displayed 
in Table 3.2. 
Table 3.2: Sample description 
Sample Name Description 
Fatty acid ethyl esters Mixture of oleic, linoleic and linolenic fatty acid ethyl esters 
Vegetable oil PEG hydrogenated castor oil 
dl-o~tocopherol Surfactant 
NMR spectra were acquired in ds·OMSO and COCI, and recorded at 300 K. 'H·NMR 
spectra were obtained at 400 MHz using a Varian Unity 400 instrument and a probe 
temperature of 300K. The relative intensities of signals were detennined by electronic 
integration. 13C and 2-D NMR spectra were obtained using a Varian Mercury 300 
instrument. The HSQC experiment was optimized for J = 140 Hz. The HMBC experiment 
was optimized for J = 8 Hz. Spectra were processed using standard Mestrec software. 
3.4.1 Oleic, linoleic and linolenic fatty acid ethyl esters 
High resolution NMR spectroscopy has been used for the determination of fatty acid 
composition21 . 22. 33, 30*. In the present study, the sample consisted of a mixture of oleic 
(18:1 09), linoleic (16:209, '~ and linolenic (18:309. 12. 15) fatty acid ethyl esters. Although 
these fatty acid ethyl esters have the same chain length, they contain different numbers 
of double bonds. lH· and 13C-NMR spectra were recorded in COCb and d6~OMSO. The 
20 experiments pelformecl were COSY, HSQC and HMBC (details provided in section 












be presented and discussed. The lH_NMR spectra obtained in CDCI3 and de-OMSO are 
presented in Fig 3.4 and some characteristic proton assignments are indicated. 
Assignments were made by inspection and consultation of literature and confirmed by 
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Fig 3.4: 1 H-Nr.tR spectra (400 MHz) for a mixture of oleic, linoleic and 
linolenic fatty acid ethyl esters in COCI, and d"OMSO. Some characteristc 












The 'H-NMR spectra obtained in CDCI3 and de-DMSO had similar peak resolution. The 
carbon atoms in the fatty acid were numbered from C1 (carbonyl carbon) to C18 
(tenninal carbon) while those of the ester were numbered C1 ' and C2' and the 13C 
spectrum was well dispersed (Table 3.4). Protons were labelled H and have numbers 
corresponding to that of the carbon atom to which they are attached. 
The 20 'H, 'H COSY spectrum recorded in COCI, and d,-OMSO for the fatty acid ethyl 
esters were similar and so only the 20 spectrum obtained in COCh is displayed in 














5.5 5.0 4.5 4.' 3.5 3.0 2.' 2.0 1.5 1.0 ••• f2 (ppm) 
Fig 3.5: COSY spectrum (300 MHz) for 8 mixture of alec, linoleic and !inolanc 
fatty acid ethyl esters in CDC/J recorded at 300 K. Some crosspeaks are labelled 
! 
t: 
Crosspeaks in the COSY spectrum show scalar coupling between neighbouring 
hydrogens. Major cross peaks between allylic (2.02-2.07 ppm,), bis-allylic (2.77-2.80 
ppm) and olefinic (5.33-5.37 ppm) protons were identified. The quartet at 4.13 ppm 












observed for H2 (2.28 ppm) which is coupled to H3 (1.60 ppm). The effect of the 
electronegative oxygen atom of the carbonyl group resulted in a downfield shift of the 
signal from H2 compared to H335, The functional group assignments and integrations for 
oleic, linoleic and linolenic fatty acid ethyl esters in eOCh and d6-DMSO are displayed in 
Table 3.3. HSQC data (presented in Appendix A, page 252-253) confirmed the proton 
assignments and methylene pairs. Initially, it was thought that the mixture contained 
only ethyl esters of oleic, linoleic and linolenic fatty acids. However, it was later 
discovered that saturated fatty acids of varying chain lengths were also present. 
Therefore the calculation of relative amounts of each fatty acid, based on peak 
integration, could not be determined. 
Table 3.3: lH_NMR functional group assignments and integration for oleic, linoleic and 
linolenic fatty acid ethyl esters 
ppm 18:1 18:2 18:3 Integration Integration 
(COCI:a) (dc-DMSO) 
0.89 (t) H18..cHI H18..cHI - 6.72 3.' 
0.98 (t) . - H18..cH, 3 3 
1.25 (t) H2' (..cH,) H2' (-CH,) H2' (-CHI) 2-4.20 12.5 
1.28-1.31 (m) (..cH,). (-CHI),. (-CH1). 33.72 33.3 
1.80 (m) H3 (-CH,) H3 (-CHI) H3 (-CHd 5.81 ••  
2.02-2.07 (m) H8, H11 (-CHdl 
H8, H14 H8, H17 
11 .35 10.5 
(..cHJ)z (..cHd2 
2.28 (t) H2 (-CHI) H2(-CHI) H2 (-CHJI 6.25 ' .1 
2.n-2.80 (m) H11 (-CHI) 
H11, H14 
6.10 - ••  (..cHzh 
4.13 (q) H1' (.cHt) H1 ' (-CH,) H1' (-CHzI 6.78 ••  
HI, H10, H12, 
H9, H10, H12, 
5.33-5.31 1m) HI, H10 (-CHh H13, H15, H16 11 .90 9A 
H13 (aCH)4 
(-CH). 
According to Knothe and co-workers, the ' H-NMR signals that may be used for the 
quantification of unsaturated fatty acids are those from the olefinic protons (5.33-5.37 
ppm), protons attached to the bis-allylic carbons (2.77-2.80 ppm), protons attached to 
the allylic carbons (2.02-2.07 ppm) and the terminal methyl group protons21 . The 
terminal methyl group protons of linolenic acid resonated downfield (0.98 ppm) 
compared to those of oleic and linoleic acid (0.89 ppm), due to the proximity of the 
C15-C16 double bond. Its signal is therefore unique and was assigned a relative 












and -CH (5.33-5.37 ppm) in each solvent (Table 3.3) was used to determine whether the 
integration was intemally consistent and therefore reliable; the expected ratios being 
1:1:2 respectively. Integration values obtained in CDCI3 gave the expected ratio of 1:1:2 
and therefore were internally consistent while those obtained in ds-DMSO (1 :2:2 
respectively) differed from the expected values and so were inconsistent. This was 
because better peak resolution in COCh enabled them to be integrated accurately. The 
Signal from H2' in CDC!, (1 .25 ppm) ovenapped slightly with the methylene protons 
(1.28-1 .31 ppm) and therefore had a higher integration value (24.2) than expected 
(10.2). 
The 1H_ and 13C chemical shifts for the mixture of oleic, linoleic and linolenic fatty acid 













Table 3.4: tH and 13C~NMR data for a mixture of oleic, linoleic and linolenic fatty acid 
ethyl esters in COCh 
Atom Proton and Carbon Chemical Shifts (ppm) 
18:1 18:2 18:3 
H·1 . . . 
C·1 173.9 173.9 173.9 
H·2 2.28 2.28 2.28 
C·2 34.43 34.43 34.43 
H·3 1.60 1.60 1.60 
C·3 25.02 25.02 25.02 
H .. 1.28-1 .31 1.28-1 .31 1.28-1.31 
c .. 29.15-31.95" 29.15-31.95' 29.15-31.95' 
H·' 1.28-1 .31 1.28-1.31 1.28-1.31 
C·. 29.15-31.95' 29.15-31.95' 29.15-31 .95' 
H-6 1.28·1.31 1.28-1.31 1.28-1.31 
C-6 29.15-31.95" 29.15-31.95' 29.15-31.95" 
H·7 1.28-1.31 1.28-1 .31 1.28-1.31 
C·7 29.15-31.95' 29.15-31 .95" 29.15-31.95" 
H-6 2.02-2.07 2.02-2.07 2.02-2.07 
C-6 27."" 27.24 27.24 
H·' 5.33-5.37 5.33-5.37 5.33-6.37 
C·. 121.2_132.0D 127.2-132.0b 127.2-132.0b 
H-10 5.33-5.37 5.33-5.37 5.33-5.37 
C·10 127.2-132.0b 127.2_132.0b 127.2_132.0b 
H·11 2.02-2.07 2.77-2.80 2.77-2.80 
C-11 27.24 25.68 25.68 
H-12 1.28-1.31 5.33-5.37 5.33-6.37 
C-12 29.15-31.95" 127.2-132.0b 127.2_132.0b 
H-13 1.28-1.31 5.33-5.37 5.33-5.37 
C-13 29.15-31.95" 127.2_132.0b 127.2_132.0b 
H-1" 1.28-1 .31 2.02-2.07 2.77-2.80 
C-1" 29.15-31.95" 21.24 25.68 
H-1! 1.28-1.31 1.28-1.31 5.33-6.37 
C-15 29.15-31.95' 29.15-31.95" 127.2-132.0b 
H-16 1.28-1.31 1.28-1.31 5.3U.37 
C-16 29.15-31.95" 29.15-31.95" 127.2-132.0b 
H-17 1.28-1.31 1.21l-1 .31 2.02-2.07 
C-17 22.71 22.60 20.59 
H-18 0.89 0.89 0." 
C-18 14.11-1"'.29~ 14.11_14.29t" 1".11-14.29~ 
H-1' 4.13 4.13 4.13 
C-1' 60.16 60.16 60.16 
H-2' 1.25 1.25 1.25 
C-2' 14.11_14.29': 14.11_14.291: 14.11_14,29': 
"Resonances are. 29.15, 29.19, 29.38, 29.55, 29.63, 29.73, 29.81 , 31 .57, 31 .95 ppm, Resonances are. 127.18, 127.79. 
127.97, 128.10, 128.34, 129.80, 130.09, 130.25, 130.31. 132.00 ppm; "Resonances are: 14.11 . 14.29 ppm 
The 13C assignments were compared with those of Stoffel and associates who 












Enriching particular carbon atoms with 88-99 % 13C allowed the accurate assignment of 
the chemical shifts of the carbon atoms and also increased sensitivitY3 , The 13C label of 
C 14 in linoleic acid showed that the unequivocal chemical shift of this C atom was 
27.0 ppm. The same was observed for oleic acid 13C_enriched in C8 and C11 . Their 
conclusion therefore was that carbon atoms in juxtapositions pointing to the carboxy and 
methyl ends of cis-olefinic bonds are characterised by this resonance. In the present 
study, the chemical shift of these aUylic protons, as confirmed by HSQC and HMBC was 
26.5 ppm, which is close to the value reported by Stoffel and co--workers23, It has been 
observed however that the chemical shift for C17 of a-linolenic acid occurs at higher 
field23• Our result of 19.94 ppm for this C atom is therefore in agreement with reported 
literature and confirmed by HSQC correlation between 'H at 1 .~2 . 0 ppm and 13C at 
20.6-22.7 ppm. The chemical shift for the bisallyllc groups is in the range 
25.02-25.12 ppm and is very close to that reported in the literature of 25.5 ppm23. other 
characteristic resonances include that of the carbonyl function at 172.7 ppm and the cr-
and f3-carbon atoms at 33.5 and 24.4 ppm respectively and are in agreement with those 
measured by Stoffel and ccrworkers23• 
NMR spectroscopy has been successfully applied to study the composition of a mixture 
of oleic, linoleic and linolenic fatty acid ethyl esters dissolved in CDCI3 or ds-DMSO. 
Signals due to unsaturated carbons (at 5 .3~5. 37 ppm and 127-132 ppm in the 'H and 
"c spectra respectively) and ethyl ester (Ht '/H2' at 4.13/1 .25 ppm and 60.2114.1 ppm in 
the ' H and 'lC spectra respectively) confirmed the presence of the above unsaturated 
fatty acid ethyl esters. The relative ratios of -CH3• -CH2 and -CH signals in each solvent 
were compared in order to establish consistency. Compared to ds-OMSO, the 













3.4.2 PEG hydrogenated castor all 
In this study, the compounds present in commercially available PEG hydrogenated 
castor oil was analysed in both CDCb and ds-DMSO by 'H- and 13C-NMR. The 
assignment of all proton and carbon atoms was achieved using COSY, HSQC and 
HMBC spedra. Data from the 'H, 13C and COSY experiments are presented and 
discussed. The 'H-NMR spectra obtained in CDC!, and de-DMSO are displayed in 
Fig 3.6 and some characteristic signals are labelled. Assignments were made by 
inspection and consultation of literature and confirmed by 20. However, the presence of 































OMSO Fatty acid 
eslefof 
PEG 
, , , , , ... ... ., ., 'A U f1 (ppm) 
H3,11.t3 
(-CH~h 
\ H18 (-CH3) 
U • •• 
Fig 3.6: 'H·NMR spectra (400 MHz) for PEG hydrogenated castor oil in 
CDCI, (I'J and d .. DMSO (S) raconlad at 300 K. Some chalBCtaristic proton 












Numbering of the carbon atoms in the fatty acid started at the carbonyl carbon (C1) and 
ended at the terminal carbon (C18). Again , protons were labelled H and have numbers 
corresponding to that of the carbon atom to which they are attached. Carbon atoms in 
the glycerol backbone were labelled C 1' , C2' and C3'. Better peak resolution was 
obtained in COCI3_ 
The 20 'H, 'H COSY spectrum in CDC!, and d,-DMSO for PEG hydrogenated castor oil 
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Fig 3.7: COSY spectrum (300 MHz) for PEG hydrogenated castor oil in CDCJ, 
recordedat 300 K. Some crosspeaks are labelled 
The spectrum is dominated by resonances from the polyethylene glycol (PEG) moiety. 
However, crosspeaks between H18 protons and the methylene protons were detected. 
Cross peaks were also identified for proton coupling between H2 and H3. The large 
PEG signal overlapped with signals for H12 (of glycerol polyethylene glycol oxystearate) . 












The 'H-NMR functional group assignments, as confinned by HSaC (data presented in 
Appendix A page 254), and integration values for PEG hydrogenated castor oil in CDCI3 
and d6""DMSO respectively are provided in Table 3.5. 
Table 3.5: ' H-NMR functional group assignments and integration for glycerol 
polyethylene glycol oxystearate 
6 (ppml Glycerol polyethyle08 glycol Expected Integration In Integration In 
oxysteanrte integrMSon COCh d.-OMSO 
0.82 It) H18 (3 x -CH,) • • • 
1.20-1 .22(ba) H4-10 and H14-11 (3 x (-CHlnd .. 65.38 69.78 
1.37-1 .44 1m) H11, H13 (3 x (-CHIh) 12 18.34 
12.36 
1. 56 1m) H3(3x (-CHd • 6.75 
2.26 It) H2 (3 x (-CHJ) • 6.82 5.42 
2.73 (bI;) PEG (3 xOHI 3 .... -
3.0&1-3.76 1m) {-CHrCHrOJ,., H1 ', H3 ' (2 x -CHz) - 211 2" 
4.16 (d) HZ' (-CHI 1 3.72 1.81 
UO(m) 
H12 (..cHI of the fatty acid ester 
1 1.37 0.51 
afPEG 
The terminal methyl group (-CH 3) in each fatty acid of the triacyl glyceride molecule was 
assigned an integration value of three and so their combined integration value was 
expected to be 9. The 1H-NMR spectrum exhibited signals at ~ 0.82 (t, 9H , tenninal 
-CJ::!,) , 1.20-1 .22 (bs, 66H, methylene protons [3 x (-CJ::!,),,) , 1.37-1 .44 (m, 12H, 
-CH,CJ::!,CH(OR)), 1.56 (m, 6H, -C!::!z-CH,..C=O), 2.26 (t, 6H, -CJ::!,-C=O), 2.73 (bs, 3H, 
-CH,-CH,Ol:! (PEG), 3.41-3.76 (m, 3H , (-CH,CH,C!:!{OR)) signal overlaps with that of 
[-CJ::!,-CJ::!,O), (PEG) and -CJ::!,CHCJ::!,- (glycerol CH,), 4.16 (m, lH . -CH,Cl:!CH, (glycerol 
CHI, 4.80 (m, lH , (-CH,CH,C!:!{OR) (the fatty acid ester of polyethylene glycol). The 
signal at 4.80 ppm originates from H12 of the fatty acid ester of polyethylene glycol 
because it was coupled to H11 and H13 in the COSY spectrum and has an integration 
value of approximately 1. The H12 proton of glycerol polyethylene glycol oxystearate 
would have an expected integration value of 3. Variations between the expected and 
experimental integration values for glycerol polyethylene glycol oxystearate is probably 
due to the fact that the sample was a complex mixtUre and contained small amounts of 
ethoxylated glycerol , fatty acid esters of polyethylene glycol and polyethylene glycols. In 
CDCh, not only was better peak resolution obtained but the integration values were also 












obtained in CDCI) were used for proton and carbon assignments and as the basis for 
any conclusions drawn. 
The signal from the PEG hydroxyl protons, though not detected in d&-DMSO, was 
detected in CDCll _ The expected integration was 3 since there were 3 attached PEG 
groups for every triglyceride molecule. The higher integration value obtained (5.64) 
could indicate the presence of free PEG in the sample. Other possible components 
include ethoxylated glycerol and fatty acid esters of polyethylene glycol (derived from 
the reaction of hydrogenated ricinoleic acid in the castor oil sample with ethylene oxide) 
(Fig 3.2 (b) and {C» '4. 36. As a result, it will not be possible to use the integral of the PEG 
moiety to determine the number of subunits present in the polymer. 
The 'H- and 13C chemical shifts for PEG hydrogenated castor oil in CDCI3 are provided 
in Table 3.6. These assignments were confinned using HSaC and HMBC spectra (data 













Atom H end C ChamlClll Shifts (ppm) Litemurw VIIh ... (ppm) Reference 
C-1 173.85,173.78 172.23-173.23 37,38 
H-' U. 2.23-2.3& " C·, 34.12,34.87 33.3-34.1 37, 41 , 42 
H-3 1." 1.52-1 .57 " C-3 24.85,2S.18 24.3-25.3 37,38,40,41 
H .. 1.20-1 .22 1.22-1.42 " C .. 2t.12-2U~ 211.2-30.7 37, 41 
H .. 1.20-1.22 1.22-1.42 " C .. 29.12-21.8'" 28.2-30.7 37,41 
H-6 1.20-1.22 1.22-1.42 " C-6 2t.12-29.61~ 28.2-30.7 37,41 
H-7 1.20-1 .22 1.22-1.42 " C-7 29.i2-2Ui'" 28.2-30.7 37,41 
H-I 1.20-1 .22 1.22-1.42 " CO 29.12-21.87" 28.2-3D.7 37,41 
H·' 1.20-1 .22 1.22-1.42 " C·, 29.12-29.87· 28.2--30.7 37, 41 
H-10 1.20-1 .22 1.22-1.42 " C-10 29.12-29.87" 28.2·30.7 37,41 
H-i1 1.37-1 .44 - . 
C-11 29.12-29.87" 27.0-29.6 37 
H-i2 3.41-l.76 3.55 42 
0-12 70.25-73.98< 60-75 ,. 
H-U 1.37-1.44 
C-i3 29.12-29.87" 27.0-29.6 37 
H-'" 1.20-1 .22 1.22-1.42 " C-14 25.12-25.68" 27.24-29.71 37 
H-i! 1.20-1 .22 1.22-1.42 " C-1S 25.12_25.58" 21.38-29.24 37 
H-i8 1.21).1 .22 1.22·1.42 " 0-18 31.81 31.57-31.98 37 
H-17 1.20-1 .22 1.22·1A2 " 0-17 22.5& 22.62-22.74 37 
H-18 0.82 0.83-0.93 39 
0-18 14.04 13 ..... 14.8 ., 
H-1 ' 4.16 4.1()..4.32 " C-1' 81 .53, 63.29 62.1 ,. 
H-X 4.80 5.20-5.26 " 0-2' 61.16, 69.70 ... 37 
H-3 ' 4.18 4.10-4.32 ,. 
C-3' 61 .53, 63.21 '~1 ,. 
PEG: H- U1-3.76 3.54-3.70 43 
C- 70.25-73.98" 












Characteristic t3C_NMR signals for triacyl glycerols occur at 61 .2 ppm (for the a-glycerol 
carbon atoms at positions l ' and 3') and 68.9 ppm (for the p-glycerol carbon atom at 
position 2')38, As shown in Table 3.5, two values were obtained for each of these carbon 
atoms because their chemical environment in glycerol polyethylene glycol oxystearate 
(Fig 3.2 (an differs slightly from ethoxylated glycerol (Fig 3.2 (b)). 
In summary, detailed 10 CH and 13C) and 20 NMR experiments CH,'H correlation, 
COSY and ' H,13C correlation, HSQC) were conducted on a sample of PEG 
hydrogenated castor oil C3C, HSaC and HMBC spectra presented in Appendix A pages 
25~255) . The results indicated the presence of glycerol polyethylene glycol 
oxystearate. Fatty acid esters of PEG, ethoxylated glycerol and free PEG were also 
present in the sample. Analysis of the NMR data was complicated by the presence of a 













3.4.3 dl-a-Tocopherol (Vitamin E) 
Tocopherols are widely used in the pharmaceutical and food industries due to their 
antioxidative properties. Vitamin E consists of four tocopherol homologues, namely a -, 
/3-, "(- and &-tocopherol which possess different bioavailabilities (Fig 3.8)43, a-tocopherol 
has the highest biological activity. The tocopherol molecule has three chiral centres 
(positions 2, 4' and 8') and dl- a-tocopherol, the anti-oxidant used in Pheroidn~ , is 
chemically synthesised and contains a mixture of the d and I isomers of a-tocopherol 
(mixture of eight stereoisomers).oH· 
140 
P, I ' 
~8 ., 
K,! 0 8' " 
R, R, R, R. 
&-tocopherol -H -H -CH3 -H 
y- tocopherol -H -CH, -CH, -H 
fl-Iocopherol -CH3 -H -CH3 -H 
a- tocopherol -CH, -CH, -CH, -H 
Rg 3.8: Chemical structure of the tocopherol homologues43. 
A sample of dl-a-tocopherol dissolved in ds-DMSO was analysed by 1H_ and 13C_NMR 
spectroscopy. CDC!, was not used for this experiment because the residual solvent 
peak at 7.3 ppm would have interfered with the analysis. Assignments were made by 
inspection and consultation of literature and confirmed by 20 (COSY, HSaC and 
HMBC). Data from the ' H, '3C and COSY experiments are presented and discussed. 
The ' H-NMR spectrum obtained in d6-DMSO is presented in Fig 3.9 and some 
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Fig 3.9: 1 H-NMR spectrum (400 MHz) for dl-o-tocopherol in d ... DMSO 
recorded at 300 K. Some characteristic proton assignments are labelled 
The carbon atoms were numbered as shown in Fig 3.9. Carbon atoms in the aromatic 
ring were numbered 2-8 and those in the phytyl chain l ' to 12', The protons have 
numbers corresponding to that of the carbon atom to which they are attached. The lH_ 
NMR spectrum of dl-o-tocopherol (Fig 3.9) can be divided into three sections, an 
aromatic region at -7.3 ppm, a region at -2.0 ppm corresponding to the protons of the 
methyl groups bound to the aromatic ring , and a high-field region between O.B and 
1.6 ppm showing the signals of protons in the saturated phytyl side chain404 • Two 
important additional peaks are visible at -2.5 and 1.7 ppm representing protons at 
positions 4 and 3 respectively. 
The 20 lH,lH COSY spectrum for dl-aMtocopherol in ds-DMSO is shown in Figs 3.10 and 




























7.0 ••  ' .0 ••  ' .0 4.' 4.0 3.' 3.0 2.' 2.0 1.' 1.0 12 (ppm) 
Fig 3.10: COSY speclrum (300 MHz) fordl-<J-tocopherol;, drDMSO recorded 





Crosspeaks in the COSY spectrum identify scalar coupling between neighbouring 
hydrogens. Major cross peaks were detected between H3 and H4 and in the phytyl 
chains between 0.8 and 1.6 ppm (upon expansion of the spectrum). In this region there 
is coupling between the methyl, methylene and methine protons, confirming their 'H-
NMR assignments. The four methyl groups of the phytyl chain (4', 8', 12') show cross-
peaks to the methine protons. The cross peaks among the methylene protons in the 












The ' H-NMR functional group assignments for dl-a-tocopherol are presented in 
Table 3.7. 
Table 3.7: 'H-NMR functional group assignments and integration for dl-a-tocopherol 
H Chemle.l Shift (ppm) dkI Tocophe~ Integration ExpectMI tntegration 
0.85 (d) (-CHJ). 1~" 12 
1.0-1 .8 1m) H2 leHs); H1 ', H2', H3', H5', H6', Z".09 24 
Hr, Ht', H10', H11' (9 x (-CHd; 
" '.8' , 12' ,(3 x (..cHI 
1.10 It) H3 (-CHI) 2.02 2 
1.2 (a) (eHJ) . 3 
1.97-2.04 (3 x_, H5, H7, H8 (3 x -CHJI , • 
2.50 It) K4 {-CHt} ~n 2 
7.30 (a' H5tH7 (.cHI 1.02 1 
Each methyl group in the aromatic ring was assigned an integration value of three 
(combined value of nine). The following peaks were identified: !i 0.85 (d, 12H, two 
methyl groups at the end of the phytyl chain [(HI2' (2 x -CH,» and an additional two 
methyl groups within the chain [4'-, B' (2 x -CH,)J, 1.001 .B [24H, overlapping signals due 
to the methyl group at position 2, the methylene protons on the phytyl chain and the 
methine protons (4', B', 12')J, 1.20 (s, 3H, methyl group at position 2), 1.70 (t, 2H, 
protons attached to C-3), 1.97-2.04 (3x s, 9H, methyl groups attached to the aromatic 
ring) , 2.50 (t, 2H, protons attached to C-4) , 7.3 (s, -CH on aromatic ring) . 
In dl-a-tocopherol, no proton is present on the aromatic ring and therefore the signal at 
7.3 ppm indicated the presence of either ~tocopherol (one proton at position 7) or 
y-tocopherol (one proton at position 5) and not c5-tocopherol because as shown in Table 
3.6, the integration value at 7.3 ppm was 1. The HMBC spectrum (presented in 
Appendix A pages 257-259) showed coupling of the proton to C5 and C8 (consistent 
with a proton at position 7). No additional long-range coupling with C4 was observed, 
therefore it was concluded that the vitamin E sample contained dl-a-tocopherol and a 
small amount of ~tocopherol. 
The ' H- and l'C chemical shifts for dl-a-tocopherol as confirmed by HSaC and HMBC 
are presented in Table 3.8 and are in agreement with those in the literature,",4s. Peaks 












Table 3.8: ' H- and " C-NMR data for dl-<J-tocopherol in DMSO 





H .. 2." 
C .. 1\1.5 
H-' 2.00 






C .. 118 .... '22.4· 
"'" 1.0.1.8 C-1' 36.s....H ... 
... r 1.0-1.1 






C·5' 36.5-38 .... 
H .. ' 1.0-1.8 
0--6' 36.5-36.9' 
H .. 7' 1.0-1.8 
C-T 38.5-38.9' 
H .. ' 0." 
0--6' 31.8 .. 31.0 




H-i1 ' 1.0-1.8 
c.11' 3fI..5-3S." 
H·12' ... 
C-1 r 27.3 












3.5 NMR analysis of different lots of Pheroid'"" fonnulations 
Four Pheroid'" lots (labelled A. B. C and 0) were provided by North West University 
(Potchefstroom) and analysed by NMR spectroscopy to determine whether the individual 
components of Pheroid™ can be identified and quantified and whether differences 
between batches can be detected. 
10 ml of each Pheroid™ preparation was freeze-dried following which two drops of the 
resulting oil was placed in an NMR tube and 500 ~I of d,-OMSO added. The samples 
were subjected to analysis by ' H· and 13C-NMR spectroscopy. For comparative 
purposes, the above study was repeated using CDCh as solution (SOO 1-11) . The 
differences between Pheroid™ formulations are summarised in Table 3.9. 
Table 3.9: Description of the Pheroid™ formulations 
Sample Lot number Oncrtptlon 
Pheroid A NWU-B21062005 Prepared with starting material from lot NWU-A2106200S 
Pheroid B NWU-B14112005 Prepared with starting material from lot NWU·A14112005 
Pheroid™ C 
Prepared with starting material from ~t NVVU,A08022006 
NWU-BOB022006 
(formulated with dr~·tocopheror) 
Prepared in parallel with Pheroid C and with starting 
Pheroid'TM 0 NWU-COB022006 material from ~t NWU,A08022006 (formulated without 
dl~·tocopherol) 
NMR spectra were acquired in ds·DMSO and cocr) as described in section 3.4 . The'H 
spectra obtained of Pheroid'" samples A and B (prepared from lots NWU-A21062005 
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Pheroid™ B: Second Preparation 
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Fig 3,11: 'H-NMR spectra (400 MHz) for Pheroid'''' samples A and B in CDCI, 
recorded at 300 K. Some characteristic proton assignments are labelled and the 












The peak height for the terminal methyl proton of linolenic acid (sample A) was markedly 
lower than the combined signal from oleic and linoleic acid whereas in sample B, the 
signal due to terminal methyl protons of linolenic acid was higher than the other two fatty 
acids (Fig 3.11). The intensity of the PEG signal in sample A was higher than that of H1 ' 
while in sample B the signal due to Hl' was slightly higher than that of PEG. The fact 
that both spectra were similar suggested that samples A and B contained the same 
ingredients but different amounts. The lH_NMR spectra obtained in de-DMSO are 
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Fig 3,12: 'H-NMR spectra (400 MHz) for PheroId'" samples A and 8 in 
d"DMSO racOfded at 300 K. Some characteristc signals are labelled and the 













In d.-DMSO the peak height for the tenninal methyl group of linolenic acid (in sample A) 
was slightly lower than the other two fatty acids suggesting its presence in lower 
concentrations compared to oleic and linoleic acids (Fig 3.12). In sample B however, the 
opposite was observed. The peak height for the terminal methyl group of linolenic acid 
was now higher than the other two fatty acids suggesting its presence in higher 
concentrations compared to oleic and linoleic acids. Whereas the signals from H2' and 
(-CH2)1I over1apped in CDCI3• better peak resolution was obtained in de-DMSO. The 
spectra obtained of samples A and B in de-DMSO contained the same peaks but with 
slightly different intensities supporting the observation that the Pheroid™ samples 
contained the same ingredients but in different amounts. This observation was 
supported by the 13C spectra which were also similar for all the Pheroid™ formulations 
analysed (Fig 3.13). 
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Fig 3.13: Typical "C-NMR sp6Ctrum obtai1ed for PheroicJ1U formulations in COO,. 
Spectrum shows a carbonyl signal (174 ppm). signals for the unsahJl8ted carbon atoms 
(127-132ppm), the PEG signal (10-74 ppm)and signals forgfycerol(68.9 and 62.1 ppm). 
The function group assignments and integration values for Pheroid™ samples A and B 












Table 3.10: 1H chemical shifts and integration of Pheroid™ Samples A and B in COCl3 
and d, -DMSO 
Pheroidr. S.mpie A 
Glycerol 
ppm 18:1 18:2 18:3 
poIy.thy*- Int-Sration In IntltgnItJon In 
glycol CDC!. drOMSO 
OxystNfllte 
0.87 (t) H18 (-CH) H18 (.eH) - H18 (-CHll .... 3.81 
0JI7 (t) · · H18 (..eH,) · 3 3 
1.22- H2'I-CHJ), H2' (-CHz). H2' (..eH,), (-CHll. 82.&3 4'.71 
1.34 (1:1&) (-CH!) ... (-CHI)". (-CHz)., 
1.81 (t) H3 (-CHzl H3 (-CH,) H3 (-CHzl · 11.21 5.01 
2.03 1m) 
H8, C11 H8, H14 H8, H17 
12.78 .... 
(-CHz)' (-CHI):! (-CHili -
2.27 (I) H2(-CHz) H2(-CHd H2 (...cHd - 8.37 3.83 
2.78 1m) · H11 (-CHI) 
HI' , H14 - ... 0 3.'4 (-CHlh 
3.81-
[..cH,..cHa-OJ., 
3.15 (bII) · · · H8-H12 (eHh. IU5 18.05 H2' (-CHUl 
4.0 (q) H1' (-CHII H1' (-CH.!:) H1' (..cHII - 7.21 3.78 
4.1 It) · - · HI' (-CHII 0.39 0." 
HII, H10, 
5.3(m) 
HI. H10 H9, H10, H12, H12, H13, - 8.75 6.07 (-eH), HI3,-CH)4 HIS, HIli 
(-eH). 
PMroldTll s.mple B 
0.89 (t) H18 -CHI H1I -CHI · HI81-CH) 8.78 .... 
0.17 (t) · - H18 -CHI - 3 3 
1.1.23- H2' I-CH,), H2' (-CH) , H2' I-CHJI, 
57.15 47.03 
1.31 (bII) I-CH,)., (-CH,)., (-CHz),., · 
1.81 It) H3 (-CHz) H3 (-CHz) Hl (-CHz) - 6.42 ~ .. 
2.05 1m) 
H8, H11 H8, H14 H8, H17 
10.48 7.74 
(-CHJ)z (-CHdz I-CHz)! 
· 
2.28 (t) H2 (-CHz) H2 (-CHz) H2 (-CHI) · • .43 '.38 
2.79 1m) - H111-CHz) H1' , H14 - .... 4.72 (-CHz), 
3.61-
{-CHrCHrOJ." 
3.15 (bII) - - - Ht-H12 (CHII, 7.70 18.51 
HT (-CHzh 
4.11 (q) H1' (-CH,) H1' (-CHz) H1 ' (-CHd 6.17 3." 
4.20 (t) - · - Hi' (-CH2) 0.17 0.48 
Hi, H10, 
5.38 1m) 
Hi, H10 HI, H10, H12, H12, H13, 
11 .08 7.87 













This investigation has established that 'H-NMR spectroscopy can be used as a 
qualitative method to confirm the identity of Pheroid™ components and that the same 
ingredients were used to formulate Pheroid™ samples A and B. The spectra obtained 
for samples A and B were similar. with small differences in the intensities of the signals 
indicating slight differences in the relative amounts of these components. Of the two 
solvents used to dissolve Pheroid™. ds-DMSO gave better peak resolution than CDCI:). 
Immunogenicity studies will be required to determine what effects, if any, these 
differences have on the adjuvant activity of the emulsion. 
'H-NMR spectroscopy was then applied to study two Pheroid™ samples C and 0 which 
were prepared in parallel from the same starting materials; however, sample C 
contained dl-a-tocopherol whereas D did not. The anti-oxidant properties of 
dl-a-tocopherol help to stabilise the Pheroid™ emulsion. The spectra obtained in CDCI3 
are displayed in Figs 3.14. There was a problem with sample D. The concentration of 
dissolved sample D was very low compared to sample C and so the intensity of the 
signals obtained especially at 0.89, 2.0, 2.76 and 5.3 ppm (indicated by the stars) were 
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Pherold™ 0: Tocopherol absent 
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Fig 3.14: ' H-NMR spectra (400 MHz) for Phero!d'" samples C and 0 in COCI, 
recorded at 300 K. Some characteristic signals are labelled and the stars 












The spectra obtained in dr DMSO are displayed in Figs 3.15. The lH_NMR spectra of 
both Pheroid™ formulations in c:4!-OMSO were similar. The terminal methyl group signal 
for linolenic acid was consistently lower in intensity than that of oleic and linoleic acids. 
One significant difference is that in sample C, the peak height of the signal due to 
protons on H2' (1 .17 ppm) is greater than that of the methylene protons (1.23 ppm). In 
sample 0 however, the reverse is true. So again there is evidence that even though 
samples C and 0 were prepared in parallel using the same ingredients, the fatty acid 
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Fig 3.15: 'H·NMR spectra (400 MHz) for Pherokf'" samples C and 0 in 
doDMSO recorded at 300 K. Some characteristt signals are labelled and the 












Table 3.11 shows the functional group assignments and integration values for Pheroid™ 
samples C and 0 in CDCb and de-DMSO. 
Table 3.11: Proton chemical shifts and integration for Pheroid™ Samples C and 0 in 
CDC(, and d, -DMSO 
Ppm 18:1 18:2 18:3 ~COI ,-- Integration In InCDCb dr-DMSO 
~ - , , '.,5-,." 
~ 
H~~::I, HI~I;:;~I, (.cHt>~ &1.00 33.39 
1"'1 
' .60 It I H' I.eH,) - 'J' u, 
Z.05Im) ~ 7~~,~ ~~,~ -
U2 .... 
~27lt H21.eH,1 - ~ 
"i,;,)" - Hi1 (-CH,) HI~H~~' - ~73 ~,. 





'.10 It - - · H" 
5.32-5.3' HI, HiD 
HI, HiD, ~,'2. ~~O;, 
Hi2, H13 - 6.52 4.11 Iml (-CHit (ooCH). ~8 
· ' .24 .... 
0.93 It I - - Hto.eH, - - , 
"'I~i20 "i.e" H:~;::,)::I, 
~ 
I.cHa). 47.36 57.78 
H' 
2..00(m) H'"' " 7~~,~' - 3.43 7." 
~ 
HI~'H::' 2.75 (m) - Hi1 (.cHd - 1.33 4.30 
3.51-3.74 - - - H12 ~.- 21 .45 76.22 
I.eH" 





















The 'H-NMR spectrum of Pheroid™ contained characteristic signals due to the fatty acid 
ethyl esters at 1.2 ppm (H2'), 4.0 ppm (HI ') and 5.3 ppm (olefinic protons). The 
presence of PEG hydrogenated castor oil was ascertained from the PEG signal at 
3.6 ppm. A characteristic peak for dl-o-tocopherol would be the 3 singlets at 2.0 ppm for 
the methyl groups in the aromatic ring of a-tocopherol. However, they would overlap 
with the signal for the allylic protons in the fatty acid ethyl esters. Altematively , a peak at 
1.7 ppm (in d,-DMSO) should have been observed for the H3 protons of dl-a-tocopherol, 
but is not. The fact that only approximately 0.3 % dl-a- tocopherol is added to Pheroid™ 
formulations means its concentration is probably below the limit of detection by NMR. 
The region between 0.8-1.0 ppm contained signals from the fatty acid ethyl esters and 
PEG hydrogenated castor oil, therefore it was not possible to use these signals to 
determine the ratio of linolenic acid to the other fatty acids in the Pheroid™ formulations. 
Also, the PEG signal at 3.6 ppm overlaps with signals from HI2 of glycerol polyethylene 
glycol oxystearate and so these signals could not be used to determine the ratio of the 
fatty acid ethyl esters to PEG hydrogenated castor oil. Another consequence of 
overlapping signals was that the integration values in Tables 3.8 and 3.9 could not be 
used to determine quantitative differences in the amounts of each component present in 
the Pheroid™ preparation. Thus, l H_NMR spectroscopy was limited because 
overlapping peaks hindered quantitative determination of each component. In addition, 
it was not sensitive enough to detect dl-a-tocopherol in the formulation. However. lH_ 
NMR analysis of Pheroid™ formulations provided a structural fingerprint of the 
formulations and although the method was not quantitative for the individual 
components, it indicated the relative proportions of the major components present. 
Therefore. similarities in the lH_ and llC-NMR spectra of different production lots of 
Pheroid™ can be used to confirm manufacturing consistency. While reliable integration 
values were obtained for the fatty acid ethyl esters in CDCI3• ds-DMSO gave better peak 
resolution for the Pheroid™ preparations. 
The results obtained from the present study demonstrated that NMR spectroscopy (in d&-
DMSO) can be used as a qualitative method to monitor batch-to-batch consistency of 
Pheroid™ formulations. However, it permitted the analysis of composition alone and the 
procedure used was invasive as it resulted in the destruction of the Pheroid™ emulsion. 












characterising colloidal systems46• With respect to emulsions, pulsed field gradient 
(PFG) NMR now offers a variety of unique insights into both molecular orientation and 
transport kinetics within the various phases. Moreover. it provides a non-invasive means 
of measuring the droplet size distribution of emulsions. This is achieved via its ability to 
quantify molecular self diffusion using pulsed field gradients technique4ll • Therefore, an 
area worth investigating in future studies is the characterisation of the particle size 
distribution of Pheroid™ emulsions by pulsed field gradient NMR methods in order to 













3.6 Coulter Counter analysis of Pherold™ 
1H_ and 13C_NMR analysis of Pheroid™ yields infonnation on its composition, but 
provides no information on its partide size distribution which is considered to be 
important for antigen uptake, delivery and activity of the adjwant'. Confocal laser 
scanning microscopy studies established that the presence of nitrous oxide (N20) in 
Pheroid™ facilitated particle formation and provided some indication of the range of 
particle size in the formulation8 • Data from turbidity studies showed that the 
concentration of the different components in a Pheroid™ formulation affected the size of 
droplets'. The stability of the emulsion is kinetically driven, therefore in a stable 
emulsion there is no discernible change in the number, size distribution and spatial 
arrangement of droplets within the experimental timescale which can vary from a few 
seconds to years2e. Coulter Counter analysis is one method by which the stability of the 
emulsion can be assessed. The Coulter Counter yields partide size distribution as 
average partide volume-size and number-size distributions and was investigated as a 
possible complimentary method to turbidimetry or confocal laser scanning microscopy. 
3.6.1 experimental 
Pheroid™ samples A and B, prepared from lois NWU-A21062005 and NWU-A14112005 
respectively, were subjected to anatysis by Coulter Counter to investigate the effect of 
Pheroid™ concentration and activation on particle size distribution. A Coulter Counter 
(Malvern Ins1rumenls Lid ., Worceslershire, UK) fitted wilh a 140 ~m orifice (2.8-90 ~m 
particle size range) was used to measure the particle size distribution in Pheroid™ 
samples, resulting in partide volume-size and particle number-size distributions. 20 ml 
of 0.001 , 0.01 and 0.1 % concentrations of PheroidTU samples A and B were prepared in 
50 ml beakers using either milli-Q water (control) or nitrous oxide saturated water 
(activated samples). The samples were incubated in an oven set at 37 °C after which 
Coulter Counter measurements of particle volume-size and particle number-size 
distributions were taken (in triplicate). The mean particle size and standard error were 













3.6.2 Particle size distribution In PheroldT'M/milll-O water 
Investigation of the average size distribution of Pheroid™ particles was initially measured 
in milli-Q water in order to establish a baseline. Three different concentrations were 
selected in order to detennine the effect of concentration on the average size distribution 
and the performance of the instrument at the different concentrations (especially at low 
concentration). The analysis was performed three times at each concentration 
(represented by the pink, blue and green peaks). 
The particle volume-size distribution curves obtained for PheroidTJrl A in milli-Q water is 
displayed in Fig 3.16. 
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As the concentration of Pheroid™ was increased, it was expected that the total particle 
volume would also increase. This was indeed the case as Fig 3.16 shows that particle 
volume increased with increasing Pheroid™ concentration from approximately 400 
(x 1 03 IJm3) in the 0.001 % sample to 600 (x 103 IJm3) in the 0.01 % sample and finally to 
nearly 800 (x 103 1Jm3) in the 0.1 % sample but greater variability was observed at 0.001 
and 0.01 % Pheroid™ concentration. At low concentrations (0.001 and 0.01 %). the 
average size distribution of particles was in the range 6-12 IJm. At the higher 













The particle volume-size distribution curves obtained for Pheroid™ B in milli-Q water is 
presented in Fig 3. 17. 
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As with Pheroid™ A, particle volume increased with increasing PheroidTU B 
concentration from approximately 300 (x 103 ~m3) in the 0.001 % sample to about 
400 (x 1 0' ~m') in lhe 0.01 % sample and finally to nearly 1 000 (x 10' ~m') in the 0.1 % 
sample (Fig 3.17) and again the data obtained at 0.001 % Pheroid™ concentration 
showed greater variability. The range of particle sizes obtained in the inactive Pheroid™ 
B samples was 5-10 IJm which was similar to that of the Pheroid™ A preparation. At low 
concentration (0.001 and 0.01 %) the main difference between the particle size 
distributions in sample A (Fig 3.16) compared to B (Fig 3.17) was that sample A showed 
less uniformity in the size of particles present and had a wider distribution of particle 
sizes. This observation was supported by the number-size distribution curves obtained 
for the control (Fig 3.20, blue peaks). The difference in particle size distributions of 
Pheroid™ formulations prior to the addition of N20 has been noted in previous studies 
and addition of N20 resulted in an increase in the mean particle size, presumably due to 
the inclusion of N20 8. In summary, a similar range of droplet sizes (5-12 IJm) was 
obtained in both preparations in the absence of N20 . However, at low Pheroid™ 













3.6.3 Particle size distribution in PheroidTII/N10 saturated water 
A key prerequisite for Pheroid™ formation and activation is saturation with nitrous oxide 
(N20 )8. It has been suggested that addition of N20 stabilises the emulsion by imparting 
the required size distribution of droplets and zeta potential47. N20 would also cause 
floes to disaggregate to individual droplets. This would be manifested by a decrease in 
total particle volume while the total particle number would increase. The particle 
volume-size distribution curves obtained for PheroidT'M A in N20 saturated water is 
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Again, increasing concentration resulted in an increase in total particle volume (150 x 
10' ~m' at 0.001 %, 300 (x 10' ~m') at 0.01 % and nearly 950 (x 10' ~m') at 0.1 %). 
The range of particle sizes obtained for the activated Pheroid™ A samples was 5-9 ~m . 
It was expected that the presence of N20 would stabilise the emulsion by causing a 
decrease in total particle volume (by decreasing aggregation or flocculation) and an 
increase in the total particle number. 
The results presented in Fig 3.18 and 3.18 were compared in Fig 3.19 and showed a 
decrease in the total size volume at 0.001 and 0.01 % Pheroid™ concentration but not 
when the concentration was 0.1 %. In general, better reproducibility of the particle 
volume-size distribution curves was obtained for the activated samples. Dilution of 
sample A with N20 saturated water to a final concentration of 0.1 % yielded no 












samples were similar. Incubation of the samples at 37 °C could contribute to the loss of 
N20 in activated samples and in the absence of a method to confirm N~ saturation in 
activated samples, it is uncertain whether the N20 levels in the activated samples were 
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A summary of the results obtained for sample A are presented in Table 3.12. Generally 












Table 3.12: Mean size of Pheroid™ A particles before and after activation with 
N20 saturated water 
Pheroid'" A (CTRL) Phemid'" A (Activated) 
Pheroid™ A Ave size.SE (~m) Ave size.SE (~m) 
0.001 % 6.07±1 .72 5.46.0.01 
0.01 % 7.89±1 .87 5.83.0.01 
0.10 % 9.12.0.01 9.09±O.01 
The effect of N20 on the Pheroid™ fOO1lulation has been investigated in earlier studies 
using confocal laser scanning microscopy (CLSM) and an increase in the size of the 
particles was obselVed upon addition of N20 . Based on that observation, it was 
suggested that the nitrous oxide may form part of the structure of the Pheroid™ particles. 
However, it is still unknown how N20 interacts with the other components in the 
formulation. The Coulter counter data obtained for sample A contradicted those 
obtained using CLSM. The analysis by Coulter Counter was complicated by the fact that 
there is currently no method developed to measure the degree of N20 saturation prior to 
analysis. It would be worthwhile investigating the application of techniques such as 
infrared spectroscopy and gas chromatography with electron capture detector for 












The number-size distribution for Pheroid™ A is shown in Fig 3.20. Each sample was 
analysed in triplicate and the results for the control samples are shown in blue while the 
activated samples are in pink. Uniform number-size distribution curves were obtained 
for all activated samples. The control samples yielded number-size distribution curves 
with poor reproducibility at 0.001 and 0.01 % Pheroid™ concentration. However, at 
0.1 % Pheroid™ concentration. the control samples 
distribution similar to that of the activated samples. 
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The particle volume-size distribution curves obtained for PheroidJ1rt B in N20 saturated 
water is shown in Fig 3.21 . Once again, an increase in total particle volume occurred 
when the concentration of the emulsion was increased (300 x 103 ~ml at 0.001 %, 400 x 
10' ~m' at 0.Q1 % and nearly 1800 x 10' ~m' at 0.1 %). The range of particle sizes 
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The distribution curves obtained here were compared with the control sample in Fig 3.17 
to detennine whether addition of N20 resulted in disaggregating of the emulsion droplets 
and consequently a decrease in particle volume or not (Fig 3.22). 
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Unlike sample A, sample B showed an increase in the mean particle size following 
activation. The trend observed here is similar to that observed with CLSM, however, 
further investigation is required to ascertain the saturation level of N20 in the formulation 
and whether the differences observed between samples A and B were the result of 
differences in the level of N20 saturation and/or the composition of the two formulations . 
Table 3.13: Particle size of PheroidT1rf B before and after activation with 
N20 saturated water 
Pheroid'" B (CTRL) PheroidTIoi B (Activated)_ 
PheroidlM B Ave size±SE (um) Ave sizetSE (um) 
0.001 % 5.59±0.84 7.04:t1 .05 
0.01 % 7.29±O.01 6 .92±O.01 












The number-size distribution for Pheroid™ B at concentrations of 0.001 , 0.01 and 0.1 % 
is shown in Fig 3.23. Results for the control samples are shown in pink while the 
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At 0.001 and 0.01 % the number-size distribution curves for the control were similar to 
those of the activated sample. Dilution of Pheroid™ with N20 saturated water in 
previous samples had resulted in little or no effect in the volume-size and number-size 
distributions, thus it was surprising that at 0.1 % Pheroid™ 8 concentration, a distinct 
shrrt in the number-size distribution was observed after addition of the N20 saturated 
water. 80th the decrease in particle number and accompanying increase in the average 
particle size point not to a more stable emulsion but rather to a less stable one in which 
flocculation may have occurred. 
In summary, conflicting data was obtained for the effect of N20 on the particle volume-
size distribution curves of Pheroid™ fonnulations. At low concentrations (0.001 and 
0.1 %), addition of N20 saturated water resulted in a decrease in the peak particle 
volume for sample A , while no change was observed for sample 8. When the 
concentration of Pheroid™ was increased to 0.1 %, addition of N20 saturated water 













Inconsistencies were also observed in the number-size distribution curves, especially at 
0.1 % PheroidTU concentration. In sample A, activation yielded no change in the 
distribution of the curve while in sample S, activation caused a decrease in the total 
particle number and an accompanying increase in the particle size, indicating a less 
stable emulsion. Interpretation of the data was complicated by the fact that no method 
has been developed to measure the saturation level of N20 in activated samples 
especially after incubation at 37 °e. In addition, it has been reported that dilution may 
distort the dispersion characteristics of the emulsion such as rheological properties, 
particle size and sulface chemistry2<!' 48, 49, thus it would be preferable to analyse 
Pheroid™ in its original concentrated form and since the Coulter Counter method 
requires sample dilution, it is not recommended for the characterisation of Pheroid™ in 
future studies. Acoustic and electroacoustic spectroscopy are two new ultrasound-
based techniques which offer a unique opportunity to characterise concentrated 
dispersion, emulsions and microemulsions in their natural state without dilution because 
ultrasound can propagate through samples that not transparent to light~8. "9. The 
interaction of an ultrasound pulse with dispersed particles causes it to attenuate. An 
acoustic spectrometer measures this attenuation for a set of frequencies and calculates 
the corresponding particle size. An ultrasound pulse also disturbs the particle double 
layer. Consequently, the particles generate an electric current, referred to as the colloid 
vibration current. An electroacoustic spectrometer measures this current and calculates 
the zeta potential. It has been reported that the combination of acoustic and 
eleclroacoustic spectroscopy provides a reliable and complete characterisation of 
concentrated dispersed systemsso. These techniques maybe better suited to 













NMR spectroscopy has been successfully employed to confirm the identity of the starting 
materials used in formulating Pheroid™, The high polarity of d6""DMSO resulted in slight 
changes in chemical shifts compared to those obtained in CDeI3 . The mixture of fatty 
acid ethyl esters contained oleic, linoleic and linolenic fatty acid ethyl esters. The PEG 
hydrogenated castor oil sample contained a complex mixture of compounds including, 
glycerol polyethylene glycol oxystearate, ethoxylated glycerol, fatty acid esters of 
polyethylene glycol and polyethylene glycols. CDCI, was found to be a better solvent 
than DMSO for NMR analysis of the fatty acid-based components, because it gave well 
resolved peaks and internally consistent integration values for the different functional 
groups. 
However, for the Pheroid™ samples, better peak resolution was obtained in d6-DMSO. 
The lH_ and 1JC_NMR spectra obtained for all Pheroid™ samples were comparable and 
showed the presence of the major components. Characteristic signals due to the fatty 
acid ethyl esters occurred at 1.2 ppm (H2'), 4.0 ppm (Ht ') and 5.3 ppm (olefinic protons). 
The presence of PEG hydrogenated castor oil was ascertained from the PEG signal at 
3.6 ppm. A minor component , dl-o-tocopherol (± 0.3 %), was probably below the limit of 
detection. Overlapping signals prevented the use of this technique to quantitatively 
detennine the ratio of the individual components in the different Pheroid™ preparations. 
In addition, the process was invasive because Iyophilisation of Pheroid™ prior to 
analysis by NMR resulted in the destruction of the emulsion. Nevertheless, NMR 
spectroscopy provides a structural fingerprint of Pheroid™ fonnulations and indicates the 
relative proportions of the major components. For future studies, low resolution pulsed 
field gradient NMR spectroscopy would be recommended in addition to classical NMR 
spectroscopy because it permits the structural elucidation of complex multicomponent 
mixtures while preserving their structure. The collection of measurement capability 
available via low resolution pulsed field gradient NMR spectroscopy (droplet sizing, 
spatially resolved concentration and droplet size mapping) coupled with rheological 
measurements, has tremendous potential to explore the link between microstructure 
(droplet size) distribution and emulsion rheology or stability. 
Previous studies conducted using turbidimetry demonstrated that the droplet size of 












effect of N20 on the Pheroid™ formulation , investigated using confocal laser scanning 
microscopy, showed an increase in the size of the particles following addition of N20 . In 
this study. evaluation of the particle size distribution of Pheroid™ was performed using a 
Coulter Counter. In both Pheroid™ preparations analysed, the total particle volume 
increased with increasing Pheroid™ concentration. The range of particle sizes obtained 
in Pheroid™ A samples prepared in milli-Q water and N20 saturated water was 6-12 and 
5-9 ~m respectively. Similany, the range of particle sizes obtained in Pheroid™ B 
samples prepared in milli-Q water and N20 saturated water was 5-10 and 6-14 ~m 
respectively. The similarity between the volume-size distribution curves of control and 
activated samples raised the question of whether the water was indeed saturated with 
N20 and highlighted the need to develop other methods such as gas chromatography 
with electron capture detector which can be used to test the saturation levels of N20 in 
activated samples51 • 
Sample dilution is a major drawback of the Coulter Counter method because it can 
distort the dispersion characteristics of the emulsion such as its rheological properties, 
particle size and surface chemistry. This may be one reason why the effect of dilution 
with N20 saturated water gave conflicting results in the two Pheroid™ formulations 
studied. For example dilution of Pheroid™ with N20 saturated water to a concentration 
of 0.1 % caused no change in the peak particle volume of sample A relative to the 
control, while that of sample B increased. Also, the number-size distribution curves at 
0.1 % Pheroid™ concentration showed no difference between the control and activated 
sample A, while in sample B, activation cased a decrease in the total particle number 
and an accompanying increase in the particle size, indicating a less stable emulsion. 
Due to the above discrepancies, it was concluded that the Coulter Counter method is not 
ideal for studying Pheroid™ formulations. 
Alternative techniques which permit the analysis of concentrated emulsion without 
dilution, such as acoustic and electroacoustic spectroscopy will be worth investigating for 
future studies. The acoustic spectrometer generates sound pulses that pass through a 
sample system and are then measured by a receiver which detects the sound energy 
losses (attenuation) and the sound speed. The attenuation data is used to calculate 
particle size distributions. Electroacoustic spectroscopy deals with the interaction of 












fields. The colloid vibration current is used to calculate zeta potential taking into account 
the particle size calculated from the acoustic measurement as well as particle 
interaction. Therefore, both acoustic and electroacoustic spectroscopy can potentially 
be used to characterise the particle size, zeta potential and other properties of Pheroid™ 
and would be worth investigating in future studies. 
Studies on Pheroid™ have investigated the effect of processing parameters such as 
emulsmcation rate and temperature of the aqueous phase, number of days the aqueous 
phase was gassed and the concentration of the surfactant on the particle size 
distribution and zeta potential of the resulting emulsion8 . At present, no studies have 
been conducted to investigate the relationship between the physicochemical properties 
of Pheroid™ and its adjuvanticity because until recently, focus has been primarily on the 
use of Pheroid™ as a drug delivery system52, 53, It would be worthwhile investigating the 
link between selected physicochemical properties of Pheroid™ (such as particle size, 
charge and viscosity) and its adjuvanticity. For example, apoptosis (an active form of 
cell death) has been recognised as an important trigger and regulator of the immune 
responseS4• The apoptotic and necrotic responses induced by surfactants in vaccine 
adjuvants have therefore been suggested to play important roles in the immunological 
effects elicited by surfactant-containing adjuvants, Pheroid™-induced apoptosis and 
necrosis, investigated in cell viability studies using MIT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reduction and LDH (Lactate Dehydrogenase) release 
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INVESTIGATION OF AN INTEGRITY ASSAY FOR 
ANALYSING MONOVALENT CONJUGATE VACCINES 
4.1 Introduction 
The introduction of Haemophilus influenzae type b (Hib) conjugate vaccines into routine 
childhood immunization programmes has greatly reduced the incidence of invasive Hib 
infections in young children and infants. Chemical conjugation of the active ingredient 
polyribosylribrtolphosphate (PRP) to a carrier protein such as diphtheria toxoid (PRP-D), 
a diphtheria toxoid-like protein (PRP·CRM1W) , tetanus toxoid (PRP-T) or meningococcal 
outer membrane protein (PRP-OMP), converts the normally T-cell independent PRP 
antigen into a T-cell dependent immunogen 1, 2, Thus, conjugate vaccines induce an 
antibody immune response in infants under two years of age who are the major group at 
risk of meningitis infection3 , 
The disease has largely disappeared from Western Europe, Canada, the United States, 
Australia and New Zealand, where Hib conjugate vaccines have been in use since the 
1990s. The effectiveness of Hib conjugate vaccines has also been demonstrated in 
developing countries such as Chile, Uruguay and the Gambia 1. The vaccine is usually 
administered in infancy as repeated doses together with diphtherialtetanuslpertussis 
(DTP) and other vaccines of the national childhood immunization program'. Children in 
South Africa currently receive vaccines against DTP, Hepatitis B (HBV) and Hib at 6, 10 
and 14 weeks" . Combining these vaccines into one pentavalent vaccine would be 
advantageous because it would spare patients the discomfort of multiple injections, 
result in reduced clinic visits, use of syringes and needles and decrease the requirement 
for cold storage of vaccines" 5. 
A local vaccine manufacturing company is in the process of developing a tetravalent 
DTP-HBV vaccine as well as a liquid pentavalent DTP-HBV-Hib vaccine. The DTP, HBV 
and Hib vaccines can be obtained as bulk products and formulated together as required. 
As new formulations, these combined vaccines will have to be tested again after 
formulation for lack of interference and for safety and immune responses. Traditionally, 
biological tests including immunogenicity in animals have played a major role in the 
quality control of vaccine batches6. However, the Hib vaccine is a semi-synthetic 












well with protective immunity in children and therefore various in vitro physicochemical 
procedures are used as an indicator of the vaccine's in vivo specificity and 
immunogenicity1.10. In this study, the Hib vaccine contains the purified PRP attached to 
tetanus toxoid. PRP must remain conjugated to the carrier protein in order to be 
immunogenic in infants. In vaccines formulated with aluminium-containing adjuvants. 
factors such as temperature and interactions with the adjuvant may result in hydrolysis 
of the phosphodiester bond between PRP monomers and the generation of free PRP 
fragments", Investigating the stability and integrity of Hib conjugate vaccines requires 
determination of the total saccharide and unbound or free saccharide which is expressed 
as the percentage of free saccharide presentll . In formulated vaccines, total and free 
saccharide analysis requires a high degree of selectivity (since the saccharide must be 
isolated from all other vaccine components) , a high degree of sensitivity (because 
vaccine dose concentrations are usually low and the detection of even smaller amounts 
of free saccharide is necessary) and accuracy that provides the true concentration 12. 
The primary objective of this study was to develop a free saccharide assay for evaluating 
the structural integrity of the Hib conjugate in combination vaccines. The challenge was 
that the Hib conjugates available to this study either contained thiomersal or sucrose, 
both of which interfere with the phosphate or ribose colorimetric assays used to quantify 
Hib. Therefore, model compounds such as human serum albumin (HSA), 
meningococcal A capsular polysaccharide (PsA) and the corresponding conjugate 
vaccine (Mn A-IT) were used to investigate methods of free saccharide separation by 
solid phase extraction (SPE). acid precipitation using deoxycholate (DOC/HCI) and 
ultrafiltration (UF). The phosphate or high performance anion exchange 
chromatography (HPAEC) methods were used to determine the amount of saccharide 
present and descriptive statistics such as mean and standard error (SE) are reported. 
P-values are not reported due to the small sample size. Validation of the free 
saccharide assay was not possible because no vaccine intermediates were available. 
Thus, a thermal study was performed. 
4.2 Analytical methods to detect polysaccharide concentration 
The free saccharide assay is a key indicator of the stability of the conjugate vaccine 10. 
Free saccharide is separated from conjugate and quantified using a method sensitive 
enough to detect low levels of free saccharide and specific enough to determine the 












colorimetric assay for phosphorus or by monomer determination using high performance 
anion exchange chromatography (HPAEC) coupled to pulsed amperometlic detection 
(PAD). Methods for the separation of free from bound saccharide depend on the nature 
of the conjugate (polysaccharide- or oligosaccharide-based), matrix and adjuvant13, 14, 
Solid phase extraction. gel filtration , ultrafiltration, ultracentrifugation, hydrophobic 
chromatography, acid precipitation and precipitation with carrier protein-specific 
antibodies are all methods that have been used to separate free from bound 
saccharide10. 11 , 1S-19. In the present study, solid phase extraction (SPE), selective 
precipitation and ultrafiltration were investigated as methods to effect separation of free 
saccharide from conjugate. 
4.2.1 Phosphate assay 
The amount of PRP in Hib vaccines can be quantified by determining the phosphorus 
content'o. Like PRP. the repeating unit of Mn A polysaccharide (PsA) contains 
phosphate (Fig 4.1) and so was used for the development of this assay. Mn A 
polysaccharide standard (PsA) and conjugates were obtained from the Meningitis 
Vaccine Project (MVP)" . 
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Fig 4.1: Repeating unit N-acetyl manoosamine-6-phosphate21• 
A survey of the literature on analysis of sugar phosphates revealed a large variety of 
experimental methods regarding the temperature and heating time for release of 
orthophosphate22-24• In order to determine the length of the heating period required, a 
sample of Mn A polysaccharide standard (PsA) was heated at a chosen temperature of 













No further release of phosphorus occurred after 60 min (as indicated by the arrow in 
Fig 4.2). Therefore, heating at 250 °C for 60 min was considered to be sufficient for the 
release of organic phosphate. 
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Fig 4.2: Effect of heating time on release of phosphorus in PsA. 
Time optimisation experiments conducted from 10-60 min using Mn A-TT conjugate lots 
1-3 (Fig 4.3) confirmed that 60 min was more than adequate for complete release of 
phosphate. Fig 4.3 shows that similar amounts of saccharide were released over the 
three time periods tested, however because data from Fig 4.2 showed the amount of 
saccharide released to increase until 60 min, an incubation time of 60 min was adopted. 
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Fig 4.3: Effect of heating time on release of phosphorus in 












The phosphate assay was subsequently applied to determine the total saccharide 
content of Mn A-IT conjugate development lots 1-3 and the results obtained are 
displayed in Table 4.1. 
Table 4.1: Total saccharide content of Mn A-TT conjugate lots 1-3 as determined by the 
phosphate assay· 
Teet conjugata Total Saccharide (JlQlml) (MaantSE) n-value 
lot 1 607.8 6 
Lot 2 454±7 4 
Lot 3 525.8 4 
Data presented In appendIX B 
·SE = Standard error and describes the uncertainty of how the sample mean 
represents the population mean 
The amount of total saccharide in each vaccine lot, as determined using the phosphate 
assay, was in agreement with the values sent by the supplier which were determined 
using a validated phosphorus assay (Table 4.1). This protocol can therefore be used to 
determine total saccharide content in Mn A-IT samples. However, a disadvantage of 
the assay was the large standard errors obtained. 
4.2.2 High performance anion exchange chromatography with pulsed 
amperometric detection (HPAEC-PAD) 
In the current study, stock solutions of three different development lots of Mn A 
conjugate (Lots 4-6) were diluted using milli-Q water to a final concentration of 
100 ~g/ml. 450 ~I Mn A samples (in duplicate) to which 150 ~I of 8 M TFA (Saarchem) 
(final TFA concentration: 2 M) had been added were hydrolysed at 100 °C in closed 
screw-cap tubes. The samples were allowed to cool to room temperature and then 
neutralised with 600 ~I of 2 M NaOH (Sigma). Samples were filtered through 0.22 ~I 
nylon filters (National Scientific) and directly analysed by HPAEC-PAD on a CarboPac 
PA-1 column as follows: 0 to 200 mM NaOAc (Merck) in 100 mM NaOH over 12 min, 
200 to 300 mM NaOAc over the next 13 min, then to the Original 100 mM NaOH after 
28 min and 7 min of equilibration. The NaOH concentration is maintained throughout the 












Carbohydrate analysis of Mn A samples was performed on a Dionex Siole ion 
chromatograph system equipped with an AS50 autosampler (Rheodyne rotary injection 
valve with a 25 ~I PEEK sample loop), an ED50 electrochemical detector, LC30 oven 
and GS50 pump. The detector ceU incorporated a gold working electrode and a pH 
AgJAgCI reference electrode. Chromatographic data were recorded on a personal 
computer equipped with Chromeleon software. 
The mannosamine-6-phosphate (M6P) peak eluted at approximately 18 min. The 
chromatograms obtained under the elution conditions used show a split peak because 
the anomeric proton can be oriented in either alpha or beta positions (Fig 4.4). The total 
peak area was used to detennine the MSP content. The PsA standard (1, 5, 10, 25, 50 
and 1 00 ~glml). hydrolysed as outlined above, was used to obtain a standard curve of 
peak area versus PsA concentration. The total saccharide content of lots 4-6 as 
detennined by HPAEC-PAD was 94.3, 9S.4 and 98.5 ~g/ml respectively. 
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Fig 4.4: HPAEC-PAD chromatograms for Mn A lots 4-6 showing 












4.3 Methods of separation 
In developing the free saccharide assay, it is important that unconjugated and free 
saccharide be separated from the conjugate in a selective and reproducible manner 11. 
The following section investigates three of these techniques namely solid phase 
extraction, selective precipitation and ultrafiltration. The lack of an appropriate Hib 
conjugate was a major limitation in the present study. As a result, the selective 
precipitation and ultrafiltration methods were further evaluated and the data obtained 
presented in chapter 5. 
4.3.1 Solid phase extraction (SPE) 
Reversed phase SPE cartridges have been applied to the separation of conjugated 
saccharide from unconjugated saccharide in vaccine samples17, The stationary phase 
consists of alkyl or aryl-bonded silicas of various chain lengths to which the carrier 
protein binds via van der Waals interactions. The SPE device is considered to be 
efficient if it retains at least 90 % of the conjugated saccharide and allows 90 % or more 
of the unconjugatect saccharide to pass through as effluent 11. 
For quantitative analysis, the amount of sample passed through the SPE device should 
not exceed its breakthrough volume, i. e. the point at which the sample volume exceeds 
the retention capacity of the sorbent. The breakthrough volume for a given sample can 
be detennined by plotting a breakthrough curve, in which a sample of fixed concentration 
and at a constant velocity enters the SPE device and the effluent analysed. The 
retentate is quantitatively retained during the initial phase by the sorbent until the 
moment in which the sample volume exceeds the retention capacity of the sorbent. The 
point on the curve at which some of the retentate is detected at the outlet of the SPE 
device is the breakthrough volume 11. 
In the current study, the SPE device was selected to retain the conjugated saccharide 
while the unconjugated or free saccharide passed through as effluent. To determine the 
breakthrough volume of the C18 cartridge used in this study, it was pre-conditioned by 
washing sequentially with 1 column volume of methanol (Kimix), three column volumes 
of milli-Q water and 1 column volume of 0.9 % NaCI (Saarchem). As a water miscible 
organic solvent, methanol wets the surface of the sorbent and penetrates bonded alkyl 












A solution of HSA was passed through the C18 cartridge to determine the breakthrough 
volume. 3 ml of 0.1 mg/ml solutions of HSA were prepared in 0.1 M. 0.5 M and 1 M Nacl 
to determine whether the amount of protein retained is affected by the concentration of 
salt. The samples were passed through C18 cartridges under gravtty and 0.5 ml aliquots 
were collected and their 00280 nm readings taken. The capacity of the sorbent was 
defined as the maximum amount of carrier protein retained by 200 mg of C1 B. The 
breakthrough curves are displayed in Fig 4 .5. 
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HSA breakthrough curve In 0.1 M NaCI 
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HSA breakthrough curve In 0.5 M NaCI 
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Fig 4.5: SPE using HSA in different concentrations of 












Of the 0.3 mg of HSA loaded onto the cartridge, SPE in 0.1, 0.5 and 1 M NaCI resulted 
in the adsorption of only 0.210 (70 '!o) , 0.152 (51 '!o) and 0.111 mg (37 %) of HSA 
respectively by 200 mg of sorbent. Under the conditions used, protein binding did not 
improve with increasing NaCI concentration. It appeared that the lower the salt 
concentration, the more protein was adsorbed, however when the above experiment 
was performed using milli-Q water in place of NaCl, protein was detected in the first 
aliquot collected (data not presented). 
This investigation demonstrated that SPE on reversed phased cartridges is not 
applicable to toxoid~based vaccines because only a maximum of 70 % was retained by 
the sorbent. However, it can be applied to oligosaccharide-based Hib conjugates 
manufactured using CRM I97 as the carrier protein, with 90 % retention being reported !7. 
For reversed phased SPE procedures on bonded silicas, optimum retention occurs if the 
analyte is not charged25• Proteins are typically retained after they have been denatured 
for example after acid treatment, which was not the case for the HSA samples. 
Lowering the pH could improve protein retention but would not be applicable to Hib-IT 
samples because it could induce PRP hydrolysis. The binding capacity of the cartridge 
was very low under the conditions used and so this method was not investigated further. 
4.3.2 Acid precipitation and ultrafiltration 
Acid precipitation with deoxycholic (DOC) sodium saltlHCI and u~rafittration (UF) are two 
published methods for the separation of unbound saccharide from conjugate and were 
investigated in this study. 
DOCIHCI precipitation has been used for the separation of free saccharide in conjugate 
vaccines14, le. 17. Deoxcholate binds to the protein component of the conjugate which is 
then precipitated by Hel resulting in co-precipitation of the conjugate leaving the free 
saccharide in the supematant. The advantage of this method is that it is fast, simple and 
suitable for use on an analytical scale and does not result in dilution of the sample. The 
disadvantages are that it may also precipitate charged polysaccharides or the acid used 
to precipitate the DOC may cause hydrolysis of the saccharide during the analysis. To 
precipitate conjugate, 1 00 ~I of 1 % DOC solution (Sigma) at pH 6.B was added to 1 ml 
of sample and incubated in the fridge for 30 min. 50 ~I of 1M Hel was added to the 
mixture which was then centrifuged at 10 000 rpm for 15 min. The supematant was 












consisting of a centrifuge, refrigerated vapour trap and vacuum pump. The sides of the 
Eppendorf tubes were washed once with 200 ~I saline and spin-evaporated to dryness 
again. This served to concentrate the samples and thus improved the sensitivity of the 
assay. The pellet was reconstituted in saline for analysis by use of the phosphate or 
HPAEC-PAD methods <as described in sections 4.2.1 and 4.2.2 respectively) . 
Ultrafiltration is another simple and effective method of separation11, 13, The membrane 
used in this study had a 100 kDa molecular weight cutoff (Millipore) . TT has a molecular 
weight of 150 kDa and so the protein and the saccharide to which it is attached should 
be retained on the membrane, whereas any saccharide chains smaller than 100 kDa 
would pass through the membrane. The Mn A-TT vaccine manufacturing process 
includes diafiltration using a 100 kDa membrane for conjugate purification supporting the 
choice of this molecular weight cutoff. A filter preconditioned by washing twice with 500 
IJI milli-Q water and once with 500 IJI saline, was used to separate free from bound 
saccharide. 500 IJI of sample was placed into a pre-washed filter and spun at 10 000 
rpm for 10 min or until the membrane was almost dry. This process was repeated once 
more and then the membrane was washed with SOD IJI saline. Filtrate from the sample 
and washing were pooled (± 1.5 ml) in an Eppendorf tube and evaporated to dryness on 
the speed-vac system. The sides of the Eppendorf tubes were washed once with 200 IJI 
saline and spin-evaporated to dryness again in order to have concentrated samples and 
thus improve sensitivity. The pellet was reconstituted in saline for analysis by use of the 
phosphate or HPAEC-PAD methods (detailed protocols for these assays are provided in 
sections 4.2.1 and 4.2.2 respectively) . 
Total and free saccharide analysis 
Mn A-IT Conjugate/ols 1-3 
Total saccharide in 50 lJg/ml samples of Mn A conjugate development lots 1-3 
formulated in Tris buffer was determined using the phosphate and HPAEC-PAD 
methods as described in sections 4.2.1 and 4.2.2 respectively. Free saccharide was 
separated from bound in these samples using the DOCIHCI method described above 
and the amount of free saccharide quantified using the phosphate and HPAEC-PAD 
methods. The HPAEC-PAO chromatograms for Mn A conjugate-n lots 1-3 are 
displayed in Fig 4.6 and the results for the % free saccharide determinations presented 
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Fig 4.6: HPAEC-PAD chromatograms of total (Ieff panel) and free (right panel) 
saccharide for Mn A-IT conjugate fots 1-3. The arrow indicates the M6P peak. 
l. 
The left and right panels show chromatograms for total and free saccharide analysis 
respectively. The single M6P peak eluted at approximately 18-19 min without 
interference from other components and indicates that under the conditions used, M6P 
can be used for the quantification of Mn A-IT conjugates. The amount of free 
saccharide was expected to vary between the three lots which were manufactured at 
different times (in order of their lot number). This was confirmed by the free saccharide 
determinations displayed in Table 4.2 in which the % free saccharide followed the trend 
1011 > 1012>1013. 
Table 4.2: % free saccharide results obtained using phosphate assay and HPAEC-PAD 
for Mn A-IT conjugate lots 1-3· 
Test conjugate Phosphate assay (Mean t SE) HPAEC-PAD (Mean ± SE) 
MnAIo11 11±1 .1 2S±O.B 
MnAlot2 13t1 .2 10±O.6 
MnAlot3 7tO.1 1.0.0.4 
Data presented In appendix B (including hmlt of detectIOn and limit of quantificatIOn). 
Ideally the detection method used should be able to detect levels of free saccharide as 
low as 2 % of the total saccharide present'3. The results varied depending on which 












would appear that lots 1 and 2 had similar amounts of free saccharide while lot 3 had the 
least amount of free saccharide. The HPAEC-PAD method confirmed that lot 3 had the 
lowest concentration of free saccharide as expected. However, it also showed that lot 1 
had twice as much free saccharide as lot 2. The results obtained using the HPAEC-PAD 
method appears to be more reliable than the phosphate assay. The phosphate assay is 
less sensitive than the HPAEC-PAD method and the low 00 values obtained introduced 
a high margin of error (the phosphate assay yielded slightly higher standard error values 
compared to the HPAEC-PAD method). 
Mn A-IT Conjugate lots 4-6 
The free saccharide analysis methods were tested on more recently manufactured lots 
of Mn A-TT conjugate. Total saccharide in 100 ~g/ml samples of Mn A-IT conjugate lots 
4-6 was determined using the phosphate and HPAEC-PAD methods as described in 
sections 4.2.1 and 4.2.2 respectively. Free saccharide was separated from bound in 
these samples using both the DOC/HCI and UF methods described above and the 
amount of free saccharide quantified using the phosphate and HPAEC-PAD methods. 
The HPAEC-PAD chromatograms of total and free saccharide obtained for lots 4-6 were 
very similar and so only chromatograms for lot 4 are displayed in Fig 4.7. The total 
saccharide peak (A) corresponded to 94.3 !-I9/ml saccharide. Free saccharide analysis 
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Table 4.3 summarises the percentage of free saccharide obtained in Mn A-IT conjugate 
lots 4-6 by use of the different methods. 
Table 4.3: % free saccharide results obtained using phosphate assay and HPAEC-PAD 
for Mn A-TT conjugate lots 4-6. 
Ph08phate .... y (Meant:SE) HPAEC-PAD (Me.ntSE) 
Tnt conjugate Totol (IJ9/ml) DOC UF DOC UF 
MnAlot4 94::1:1 .1 4.8.0.9 11±1.1 6.5.0.8 9.9t1 .3 
MnAlotS 96<2.2 4.9t1 .3 14±1.5 6.3.0.2 8.8.0.1 
MnAlot6 99t0.5 35.0.6 12tO.5 6.1.0.1 9.7.0.1 












When the phosphate assay was used for saccharide quantification, the DOC/Her 
method yielded lower free saccharide compared to the UF method for all of the 
conjugates analysed (Table 4.3). This could be caused by entrapment of some of the 
free saccharide by the deoxycholate and co-precipitation during the acid treatment 
Moreover, since neither a washing step nor a reprecipitation step is included, it is likely 
that not all unconjugatedlfree saccharide was recovered in the supernatant. By 
comparison, when free saccharide was separated using UF, the ultrafiltration membrane 
was washed to ensure removal of all unconjugatedlfree saccharide. These factors CQuid 
account for the lower free saccharide results obtained using DOC/Her compared to UF. 
The amount of free saccharide by UF obtained by the phosphate assay was slightly 
higher than those obtained from saccharide determination by HPAEC-PAD, whereas the 
DOCIHCI results were somewhat lower. The phosphate assay involves dilution of the 
samples prior to analysis resulting in relatively low 00 values with a higher margin of 
error. 
Published studies in which conjugate vaccines have been analysed for their free 
saccharide content report the use of a single method of free saccharide separation. For 
example, Lei and co-workers used the OOCIHCI method for analysis of the free 
saccharide content of meningococcal conjugate vaccines and a non-adjuvanted Hib-IT 
vaccine'6.17. The UF method (30 kOa membrane) alone has also been applied for free 
saccharide separation in both Hib-IT and Men C-IT conjugates26. 21. The difference 
between the present study and other published studies on free saccharide separation 
was that both methods were applied. The results suggest that the DOCIHCI method 
may result in the underestimation of the amount of free saccharide present However, 
passage of conjugated saccharide through the ultrafiltration membrane would result in 
erroneously elevated free saccharide values. In the absence of appropriate vaccine 
intermediates, further investigation of both methods was conducted and is presented in 
chapter 5. 
In summary, Mn A quantification for total and free saccharide was determined by use of 
two techniques: phosphorus assay and HPAEC-PAD. Both the DOCIHCI and UF 
methods were investigated for the separation of free from bound saccharide. These free 
saccharide methods were developed on Mn A-IT test lots 1-3 and applied to lots 4-6. 












PAD method, which also appeared to give more reliable results. In general, the 
DOCIHCI method gave lower free saccharide values than the UF method; this was 
attributed to possible saccharide entrapment during the DOCIHCI precipitation step. In 
the absence of appropriate vaccine intermediates, spiking experiments could not be 
performed to confirm this postulate. Higher free saccharide recovery was obtained using 
the UF method, which included a washing step. The two separation methods for free 
saccharide determination were applied to Mn A-TT samples subjected to a thermal 
stability study. 
4.4 Accelerated thermal stability study 
A thermal stability study is used to evaluate the stability of conjugate vaccines stored 
under adverse conditions such as elevated temperatures or cycles of 
freeze-thawing26. 27. The structural stability, hydrodynamic size and molecular integrity 
can be monitored using a combination of physicochemical methods12. 13. 27. 21.1. Mn A-TI 
conjugate lot 4 was subjected to a thermal accelerated stability study and the free 
saccharide generated monitored using the methods developed in section 4.3. This 
served to evaluate both the stability of the vaccine and the performance of the free 
saccharide assay. 
Total and free saccharide assay 
100 IJglml samples of Mn A-IT conjugate lot 4 were incubated at 25 and 40 °C for a 
period of 3 and 5 weeks and thereafter evaluated for their free saccharide content. Free 
saccharide was separated from conjugate by DOCIHCI and UF (100 kDa membrane) 
and detected using the phosphate and HPAEC-PAD methods. To improve sensitivity of 
the HPAEC-PAD method. the sample loop was increased from 25-80 ~1. The 
chromatograms for DOC/HCI and UF were similar and so only those for DOC/Hel are 
presented here. The HPAEC-PAD chromatograms for total (A) and free saccharide 
using DOCIHCI at 0 (8) and 5 (C) weeks for the conjugate stored at 25 ' C are presented 
in Fig 4.8. The major peak at 18-19 min is the M6P peak and the % free saccharide at 0 
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Fig 4.8: HPAEC-PAD chromatograms at 25 °C for total (A) and free 












The HPAEC-PAD chromatograms for total (A) and free saccharide using DOCIHCI at 0 
(6) and 5 (C) weeks for the conjugate stored at 40 · C are presented in Fig 4.9. The M6P 
peak eluted at approximately 18 min and the % free saccharide at 0 and 5 weeks 
corresponds to 15 and 45 % respectively. 
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A summary of the results obtained by use of the different methods are shown in Table 
4.4. 
Table 4.4: % free saccharide results obtained using the phosphate assay and HPAEC· 
PAD for Mn A-TT conjugate lot 4 stored at 25 and 40 DC for 0-5 weeks 
% free saccharide detennlned by % free saccharide determined by 
phosphorus assay (M •• ntSE) HPAEC-PAD (M .. ntSE) 
DOC UF DOC UF 
Week 25 C 40 C 25 C 40 C 25 C 40 C 25 C 40 C 
0 810.8 810.8 26±3 26:t:3 15tO.4 15±O.4 14±O.4 14±O.4 
3 1410.5 6412 2512 110t0.5 12±O.1 33tO.7 910.7 42tOA 
5 3312 7011 2810 .8 11612 16tO.2 4S±O.B 31±1 .2 86±0.5 
The % free saccharide determined using the phosphorus assay showed large variation 
for the same conjugate sample depending on the method of separation used. The 
DOCIHCI results for the conjugate stored at 25 °C showed a 4-foJd increase over the 
5 week period (from 8 % to 33 %), whereas the samples analysed by UF had a much 
higher initial % free saccharide (26 %), which barely changed over the 5 week period. 
However, for analysis of the conjugate stored at 40 °C, both methods of separation 
showed a increase in % free saccharide after storage for 3 and 5 weeks. 
Analysis by HPAEC-PAD gave good agreement for the free saccharide determined for 
the initial sample by use of DOC/HCI and UFo The DOCIHCI results for the conjugate 
stored at 25°C showed little change over the 5 week period (15 % to 16 %) suggesting 
that the conjugate is relatively stable at this temperature. There was a problem with the 
samples analysed by UF as the analysis showed a decrease at 3 weeks (14 % to 9 %) 
followed by a sharp increase in free saccharide at 5 weeks (31 %). However, for analysis 
of the conjugate stored at 40 °C, both methods of separation showed a large increase in 
% free saccharide after storage for 3 and 5 weeks (45 % using DOC/HCI and 86 % using 
UF). 
The % free saccharide as detected by HPAEC-PAD is in broad agreement with results 
obtained using the phosphate assay and indicates that vaccine samples are stable at 
25°C for five weeks. At 40 °C hydrolysis results in a 50 % increase in free saccharide 












saccharide assay could detect increasing amounts of free saccharide generated during 
the stability study confirms that it has the potential to evaluate the stability of conjugate 
vaccines. 
Low 00 values were a major limitation of the phosphate assay. In addition, the 
OOCIHCI method may result in entrapment of some of the free saccharide by the 
deoxycholate and co-precipitation during the acid treatment. Washing of the UF 
membrane may have resulted in better recovery of free saccharide compared to the 
DOCIHCI method. Furthermore, saccharide quantification using the HPAEC-PAD 
method appeared to be more reliable than the phosphate assay and has the advantage 
of being more sensitive and specific for M6P. 
In order to corroborate the findings on the stability of the Mn A-TT conjugate, the 
samples were analysed by size exclusion chromatography (SEC) and the results 












Molecular size distribution 
High performance size exclusion chromatography (HPSEC) has been used for 
determining the molecular size distribution of conjugate vaccines and provides a 
complementary method for monitoring the stability of these vaccines. HPSEC-UV was 
applied to investigate variations in the molecular size distribution of Mn A-TT conjugate 
lot 4 stored at 4, 25 and 40°C for 5 weeks. HPSEC-UV was performed using a Waters 
U~rahydrogel 2000 column (Waters, USA) (300 mm x 7.8 mm, 12 ~m particle size) 
serially equipped with a Waters Ultrahydrogel guard column (40 mm x 6 mm). The 
fractionation range of the column was B 000-40 000 kDa and a void and total volume of 
11 .0 and 23.2 min respectively. Elution was performed at 1 ml min" with 0.1 M sodium 
phosphate, 0.1 M NaCI, pH 7 and absorbance at 280 nm. The chromatograms obtained 
are shown in Figs 4.10-12. 
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Fig 4.10: HPSEC-UV traces at (}'5 w_s of Mn A-IT bulk conjugate lot 
4 at 25 · C obtained using the Waters Uftrahydrogel 2(}()() column eluted 
with O. 1 M sodium phosphate, 0.1 M NaCI, pH 7 (flow rate lml mirr' ) . 
The HPSEC-UV method separates molecules based on their hydrodynamic size 
differences. Fig 4.10 contains the chromatograms for Mn A-IT stored at 25°C. The 
HPSEC-UV profile for the control sample (0 weeks) showed a large peak at 
approximately 9 min (for conjugate) and a smaller peak at approximately 13 min 
(assigned to unconjugated TT). The chromatograms of the conjugates stored at 25 °C 
for 3, 4 and 5 weeks showed a similar molecular size distribution, which indicated that 
the conjugate i.e. both n and the attached Mn A saccharide, is stable at this 












DOCIHCI separation and HPAEC-PAO analysis which showed that the conjugate is 
stable at 25 °C for 5 weeks. 
Fig 4.11 contains the chromatograms for Mn A-IT stored at 40 DC. After 3 weeks at 
40 DC the major peak at approximately 9 min (for conjugate) has been replaced by a 
small broad peak and there was an increase in the peak due to unconjugated IT. This 
suggests that the protein-conjugate had degraded during the storage conditions and 
most of it had denatured and precipitated although some was present as unconjugated 
TT. These findings support the results of the free saccharide assay which showed 
greater degradation of the conjugate stored at 40 °C compared to the sample kept at 
25 ' C. 
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Fig 4.11: HPSEC-UV traces at 0-5 weeks of Mn A-TT bulk conjugate lot 
4 at 40 OC ocquired using the Waters U/trahydroge/ 2000 column eluted 
with 0.1 M sodium phosphate, 0.1 M NaCI, pH 7 (flow rate lml mirr' ) . 
Results obtained from the accelerated thermal stability study are summarised in 
Fig 4.12. At 4 and 25 °C, Mn A-IT was stable, however increasing the temperature to 
40 °C resulted in possible loss of the saccharide and denaturation and precipitation of 
the conjugated protein with an increase in the peak due to unconjugated IT. Therefore, 
changes in the molecular size distribution of the conjugate can be monitored by 
HPSEC-UV. However, unlike the free saccharideJHPAEC-PAD method, the HPSEC-UV 
method is qualitative and relatively insensitive. More comprehensive results may be 
obtained by using HPSEC with both Wand refractive index (RI) detectors as the latter 














25 · C 
Fig 4.12: HPSEC-UV traces of Mn A-TT bulk conjugate lot 4 afler 
5 weeks at 4, 25 and 40 "c. The conjugate was eluted on the 
Waters Uffrahydrogel 2000 column wffh 0.1 M sodium phosphate. 
0.1 M NaCI, pH 7 (flow rate lml milT') . 
An investigation of the thermal stability of meningococcal groups A, C, Y and W135 
polysaccharides following storage at 37 and 50°C and analysis by HPSEC has been 
reported by Huno\stein and co-workers29, Following exposure to thermal stresses, the 
antigenicity of the polysaccharides was determined by reaction with group specific 
antisera. Mn A showed a change in elution profile, consistent with degradation, after 
incubation at 37 °C for only 3 days and no reaction with the group specific antiserum was 
observed. Thus, degradation of the Mn A polysaccharide led to a loss of its antigenicity. 
Meningococcal groups C, Y and W135 were stable after storage at 37 and 50 °C for 30 
days as no change in the elution curves of these polysaccharides was observed. In 
addition, they always reacted with their specific antiserum which indicated that they had 
not lost their antigenicity. Results from the accelerated stability study presented in this 
thesis (free saccharide determination and HPSEC) agreed with previous studies which 
showed Mn A conjugates to be stable at 4 °C but subject to degradation following 
incubation at 37 °C or higher17• 29. 
A recent study conducted by Lee et al. in mice investigated the effect of free saccharide 
on the immunogenicity of Mn A-n admixed with up to 400 % of free PsA 30. The 
presence of free saccharide had no effect on the immunogenicity of the vaccine and 
these researchers concluded that the vaccine contained sufficient conjugated PsA to 
induce functional antibody production in mice. Immunogenicity data obtained from real-












effect of free saccharide generation (due to hydrolysis) on the immunogenicity of the 
vaccine. 
It has been demonstrated that antibodies induced by meningococcal polysaccharide-
protein conjugate vaccines protect against meningococcal disease in humans31 • 32. 
Binding of the antigen to the target cell occurs via meningococcal-specific protein or 
carbohydrate moieties. The C1q subunit of complement component C1 binds to the Fe 
portion of the surface-bound immunoglobulin. This activates the classical pathway of 
complement that ultimately leads to lysis of the target cell (Fig 4.13)33. 34. In order for 
vaccines to be accepted for licensure, ~ 90 % of immunised subjects must have at least 
a four-fold increase in serum bactericidal antibody (SSA) titre35 . 
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Fig 4.13: The cfassi:8f pathway of complement activalbn, complement proteils bind 
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The accelerated thermal stability study has demonstrated that the free saccharide assay 
can be utilised to monitor the long term stability of conjugate vaccines. HPAEC-PAD 
was the preferred method for saccharide quantification because it is more sensitive and 
specific than the phosphate assay. It is possible to underestimate the amount of free 
saccharide using the DOC/Hel method and further investigation should be conducted to 
determine whether this is due to entrapment of some of the free saccharide by the DOC 
and co-precipitation during the acid treatment. Further investigation into the UF method 
is required to ensure that conjugated saccharide does not pass through the UF 
membrane and yield erroneously high free saccharide values. It is recommended that 
both UF and DOCIHCI should be used for comparative purposes when performing the 
free saccharide assay. Little change in the molecular size distribution was observed 
when the conjugate was stored at 4 or 25 DC for 5 weeks. However, dramatic changes 
were observed after 3 weeks at 40 DC due to saccharide hydrolysis and denaturation and 
precipitation of conjugated TT together with an increase in the amount of unconjugated 
TT present. These changes in the conjugate at 40 DC supported the free saccharide 
assay results determined by HPAEC~PAD and use of DOCIHCI and UFo 
4.5 Conclusion 
The stability of Hib conjugate vaccines is critical for its effectiveness, and therefore the 
saccharide hydrolysis must be monitored using physicochemical methods. As no 
suitable unformulated Hib conjugate vaccine was available, pSJ\ and the corresponding 
Mn A·TT conjugate vaccine (obtained from the Meningitis Vaccine Project) was used to 
investigate integrity assays for analysing monovalent conjugate vaccines. 
The saccharide content of conjugate vaccines was measured with a colorimetric assay 
for phosphorus as well as by HPAEC-PAD of the monomer after acid hydrolysis. In all 
vaccine lots tested using the phosphate assay, the total saccharide determined agreed 
well with results from the manufacturer, thus confirming that this assay can be used for 
saccharide quantification. The HPAEC-PAD method was also investigated for 
saccharide analysis in conjugate vaccines. Conjugate samples were analysed after acid 
hydrolysis on a CarboPac PA-1 column using pulsed amperometric detection. The 
HPAEC-PAD chromatograms confirmed that the column and analysis conditions were 












The stability and integrity of conjugate vaccines requires determination of the total 
saccharide and quantification of the unbound or free saccharide present. The published 
methods of free saccharide separation by DOCIHCI and UF followed by detection using 
the phosphate and HPAEC-PAD methods were investigated. The DOC/HCI assay is 
used as a release test by the manufacturer, while the UF method (100 kOa membrane) 
is applied to purify the conjugate during the manufacturing process. The OOCIHCI 
method gave low free saccharide recovery and further investigation to determine 
whether this is due to entrapment of some of the free saccharide by the deoxycholate 
and co-precipitation during the acid treatment was conducted using the Hib conjugate 
(and is presented in chapter 5) . Higher free saccharide values were obtained using the 
UF method and further investigation of whether the ultrafiltration membrane is allowing 
conjugate through is conducted in chapter 5. Unlike the phosphate assay, the HPAEC-
PAD method permitted quantification of free saccharide at low levels and afforded higher 
specificity and sensitivity for free saccharide analysis in these conjugate vaccines. For 
comparative purposes, it is recommended that both the DOCIHCI and UF methods be 
used for separation of free saccharide and HPAEC-PAD for saccharide detection. 
Validation of the free saccharide assay was not possible because no appropriate 
vaccine intermediates were available. However, proof of concept was established by 
conducting an accelerated stability study in which Mn A-TT conjugate samples were 
stored at 25 and 40 DC for 5 weeks. Quantification of the amount of free saccharide in 
these samples by the phosphate and H?AEC-PAD methods after separation using the 
DOCIHCI and UF methods showed a substantial increase in free saccharide following 
storage at 40 DC. It was concluded from this investigation that free saccharide detection 
by HPAEC-PAD gave more reliable results because the HPAEC-PAD method is specific 
for M6? quantification and has a higher sensitivity than the phosphate assay. Statistical 
analysis was limited to descriptive statistics. However, the availability of adequate 
quantities of vaccine samples in the near future will make it possible to increase the 
sample size and number of experiments in order to perform inferential statistics. 
As part of the accelerated stability study, changes in the molecular size distribution of 
the conjugate induced by exposure to elevated temperatures was monitored by 
HPSEC-UV on a Waters Ultrahydrogel 2000A column. Conjugated TT remained stable 
at 25 °C, however when kept at 40 °C, the chromatographic profile changed dramatically 












second peak at approximately 13 min for unconjugated IT increased in height. 
However, this method was limited in that it provided no quantitative indication of the 
effect of elevated temperatures on the amount of free saccharide generated. 
Nevertheless, the HPSEC-UV method was sensitive enough to monitor the molecular 
size distribution of conjugated TI. More comprehensive results could be obtained with 
the use of a refractive index detector which may provide information on the free 
saccharide generated and thus be used to corroborate the results of the free saccharide 
assay. The Mn A conjugate vaccine confers protection by inducing a humoral antibody 
response. The induced antibody protects via complement mediated bactericidal killing 
and induction of serum bactericidal antibody (SSA) is a good surrogate for efficacy. The 
applicability of the above methods to the analysis of Hib in monovalent and combination 
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PHYSICOCHEMICAL ANALYSIS OF HAEMOPHILUS 
INFLUENZAETYPE B IN MONO· AND PENTAVALENT 
VACCINES FORMULATED WITH ADJUVANT 
5.1 Introduction 
Vaccination is recognised worldwide as a cost-effective medical intervention to save 
lives and has the potential for disease control, elimination and eradication'. In recent 
years, the number of injections required to fully immunise a child has been increasing as 
national immunisation programmes endeavour to cover more vaccine preventable 
diseases. Combination vaccines can induce immunity to several diseases 
simultaneously and thus reduce the number of injections and required medical visits. 
They are convenient, ensure improved compliance, better disease control and help 
reduce the overall costs of vaccination programmes2• 
Multidisease combination vaccines are developed by mixing several antigens into a 
single formulation , The DTP (triple vaccine against Diphtheria, Tetanus and Pertussis) 
combination vaccine has been available for over 50 years and is a required paediatric 
vaccine in most countries worldwide. It is typically given 3-4 times in the first 2 years of 
life with a subsequent booster (in developing countries) , The 0 and T components are 
obtained from toxins of Corynebacterium diphtheriae and Clostridium tetani respectively 
which are purified and chemically inactivated into toxoids. The P component was 
originally developed as an inactivated whole-cell pertussis (wP) vaccine for combination 
into DTwP which has been the world's most widely used combination vaccine. 
Reactogenicity attributed to the wP component led to the development of a better 
tolerated acellular pertussis (aP) vaccine. There are 7 different aP vaccines (which have 
been developed into DTaP vaccines) that consist of mixtures of 2-5 proteins purified 
from Bordetella perlussis3 . These vaccines have been evaluated in protective efficacy 
studies, in which they showed better tolerability than DTwP but somewhat lower rates of 
efficacy", DTwP and DTaP vaccines have formed a platform for the development of 
newer combination vaccines, with added components such as hepatitis B (HBV), 












HBV vaccine is produced in several systems including recombinant yeast cells in which 
expression of the surface antigen gene results in the formation of 22-nm hepatitis B 
surface antigen (HBsAg) particles. The vaccine is administered in a 3-dose series to 
individuals of all ages; it can be administered 3 times in the first year of life in paediatric 
combination vaccines3 , Some countries have replaced the oral polio vaccine (OPV) by 
the inactivated polio vaccine (IPV) to avoid the small risk of OPV associated paralytic 
poliomyelitis5, IPV is a combination of the 3 serotypes of poliovirus, each of which is 
purified and inactivated prior to mixing. The capsular polysaccharide of Hib is not 
immunogenic in children less than 2 years of age. Therefore the polysaccharide is 
conjugated to a carrier protein (typically D or T toxoids; a diphtheria toxoid-like protein, 
CRMm: or meningococcal outer membrane protein, OMP). Immunisation of infants with 
one of these conjugate vaccines has shown to be protective against Hib meningitis 
because they induce a T-cell dependent response, rather than the T-cell independent 
response of polysaccharide vaccines8-·. 
South African children currently receive vaccines against Diphtheria, Tetanus, Pertussis 
(administered as DTP), Hepatrtis B (HBV) and Haemophifus Influenzae type b (Hib) at 6, 
10 and 14 weeks9 . The Hib vaccine is the most expensive of those administered. When 
the national immunisation programme was extended to include Hib conjugate vaccine in 
1999, the national budget for immunisation doubled. To lower the cost of immunisation, 
a local vaccine manufacturer is in the process of developing a tetravalent DTP-HBV as 
well as a liquid pentavalent DTP-HBV-Hib vaccine. This DTP-HBV-Hib vaccine will be 
introduced into the childhood immunization programme in South Africa, and possibly 
Southern Africa . The Hib vaccine is a semi-synthetic carbohydrate-protein conjugate, 
which is usually formulated as a lyophilized product due to the relative instability of the 
PRP saccharide moiety in aqueous solution 1o.12 . The disadvantage of lyophilized 
vaccines is the increased logistical requirements and the number of clinical 
manipulations required prior to obtaining a preparation suitable for administration. This 
problem can be avoided by development of a single vial liquid pentavalent DTP-HBV-Hib 
vaccine. 
The challenge is to achieve chemical stability and compatibility of the Hib antigenic 
component in the presence of the other antigens and adjuvant. Aluminium hydroxide 
has been found to catalyse the hydrolysis of PRP when added to Hib conjugate vaccines 












a need for altemative adjuvants. One such candidate is Pheroid™, This is an 
experimental fatty acid-based adjuvant which has shown potential for use as an adjuvant 
for viral vaccines. Pre-clinical studies of this promising adjuvant are required prior to 
clinical evaluation 13. 
The stability of the Hib conjugate is essential to maintain its immunogenicity and 
therefore saccharide hydrolysis must be monitored in the conjugate vaccine alone and 
when in combination with other antigens. Biological assays alone cannot be used in the 
quality control of individual vaccine batches because they do not correlate well with Hib 
irnmunogenicity in humans'4. IS, As a result, physicochemical techniques are used to 
measure the concentration, stability and purity of these conjugate vaccines16• 
The saccharide content of Hib conjugate vaccines can be measured with a colorimetric 
assay for phosphorus and ribose (orcinol method). One disadvantage of using these 
colorimetric assays for saccharide determination in vaccines is that they are not 
sensitive enough to detect free saccharide in a single vial of the final product17• Also, the 
presence of other immunogens, adjuvants, sugar stabilisers and associated buffers in 
combination vaccines results in interferences that make it difficult to monitor the stability 
of Hib in the mixture' 8. An alternative method uses HPAEC-PAD which allows 
measurement of the total PRP content in complex samples including commercial 
vaccine products'7, la.22. Minimal sample preparation is required and PAD only detects 
molecules in the mixture that are ionisable at high pH (11 -13). PRP in the vaccine is 
depolymerised by acid-hydrolysis to ribitol '7, " or by base-hydrolysis to its subunit ribitol-
ribose-phosphate18, 20. 21 and quantified by HPAEC-PA02, . The method is applicable to 
conjugate vaccines formulated with aluminium-containing adjuvants and for quantifying 
unconjugated PRP after separation from the conjugate17, 22. However. matrix effects can 
make the analysis more complicated and cause interference with detection of the 
anaiyte. 
The objective of this study is to apply the total and free saccharide methods (developed 
in chapter 4) to investigate the concentration of the Hib component in the monovalent 
and pentavalent formulation produced by a local vaccine manufacturer. To accomplish 
this, three methods were investigated for the quantification of saccharide in the locally 
manufactured Hib vaccine lots. namely the phosphate and ribose assays and HPAEC-












and are relatively inexpensive. The phosphate assay was used for the analysis of 
samples that did not contain aluminium phosphate adjuvant while the ribose assay was 
applied to quantify PRP in samples formulated with aluminium phosphate adjuvant. 
Poor sensitivity is a major drawback of these colorimetric assays and therefore HPAEC-
PAD, which is a relatively more expensive method but provides higher sensitivity and 
specificity, was investigated especially for the analysis of formulated vaccine samples 
which contain low PRP concentrations. The DOC/Hel and UF methods were 
investigated for separation of free saccharide from bound. Also presented in this 
chapter are two different methods for the pre-treatment of adjuvanted vaccines prior to 
analysis. As in chapter 4, a thermal stability study was conducted to evaluate both the 
stability of the vaccines and the performance of the free saccharide assay. The 
presence of high concentrations of sucrose in vaccine samples interfered with free 
saccharide determination by HPAEC-PAD, thus the free saccharide assay was used to 
analyse sucrose-free vaccines and fucose was investigated as an alternative intemal 
standard to sorbitol. The present study focused on developing methods for the analysis 
of Hib mono- and pentavalent vaccines, therefore a complete validation of the methods 
used will be performed in future studies and was not a primary objective of this thesis. 
However, some key parameters necessary for methods validation were established. 
5.2 Materials 
All Hib conjugates, capsular polysaccharide (PRP), tetravalent DTP-HBV and 
pentavalent DTP-HBV-Hib vaccines used in this study were provided by a local vaccine 
manufacturer. The PRP standard was obtained from the National Institute for Biological 
Standards and Control (Hertfordshire, UK) as part of a WHO studl3 . Pheroid™ was 
obtained already prepared as an emulsion from the North West University 
(Potchefstroom). 
All vaccine samples in the present study were analysed in duplicate or triplicate. 
Microsoft Excel was subsequently used to obtain descriptive statistics which included the 
mean, standard error (SE) and confidence level. P-values were not calculated because 
the sample size was too small. The sample size will be increased in Mure studies to 
enable a more comprehensive statistical analysis to be performed which include 












5.3 Methods to be Investigated 
5.3.1 Phosphate assay 
The phosphate assay was applied initially to two commercially available Hib conjugates, 
Hit>.-IT-A and Hib-TT-B, but interference with the assay occurred due to the presence of 
sucrose and thiomersal (a preselVative) respectively (results not presented). The assay 
was subsequently applied to a sample of Hib conjugate fonnulated with Tris buffer (Hib-
IT-C) which contained neither thiomersal nor sucrose. Hit; TT -C with a stock 
concentration of 1.30 mg/ml (as detennined by the manufacturer using the ribose assay) 
was diluted to target concentrations of 20 and 100 lJg/mi prior to analysis using the 
phosphorus assay described in section 4.2.1. The standard curve used for phosphorus 
quantification is shown in appendix C and good linearity was obtained (R2 :> 0.99). The 
limit of detection for the phosphate assay was 0.65 Il9/ml. The weight ratio PRPIP = 
346/31 was used to convert phosphorus concentration to PRP concentration. 
The phosphate assay confirmed total saccharide content of the samples to be 20.6 and 
1 07 ~g/ml respectively. The phosphate assay has been shown to be a valuable 
research assay for quantifying the amount of saccharide present in vaccines. However, 
its use is limited to vaccines that have not been formulated in phosphate buffer or that do 
not contain aluminium phosphate adjuvant. For such vaccines, the ribose assay was 
developed and applied to determine free saccharide content. This assay will be 
discussed in the following section. 
5.3.2 Ribose assay (Orcinol method) 
Polysaccharide vaccines can also be analysed by measuring the ribose content1e. A 
100 IJg/ml standard solution of D-ribose was prepared and used to construct a standard 
curve (2, 4, 10, 50 and 100 ~g/ml) . Details of the procedure followed to prepare 
reagents for the ribose assay are provided in appendix D. 500 ~I sample, blank and 
standards were added to separate test tubes followed by 1 ml FeCIJ.6H20 working 
solution then 100 ~I 4 % orcinol solution (in duplicate). The tubes were heated in an 
oven set at 100 °C for 20 min. Ribose (liberated from acid hydrolysis of PRP in the 
sample) reacts with orcinol reagent in a concentrated hydrochloric acid-ferric chloride 
solution to produce a green colouration24. 2s. After cooling, absorbance measurements 
were obtained using a Beckman Coulter DU 530 single cell module, Life Science UVNIS 
spectrophotometer set at 580 and 670 nm. The difference (670-580 nm) was plotted 












determined. The ribose standard curve is presented in appendix 0 and it showed good 
linearity (R' > 0.99). 
Hib-IT -C with a stock concentration of 0.9 mglml (as determined by the manufacturer 
using the ribose assay) was diluted to a target concentration of 100 ~glm1. Analysis of 
this sample using the ribose assay gave 40 ~g/ml ribose content. Conversion to PRP 
based on weight ratio PRP/ribose gave a concentration of 92 .,..gJml. The ribose assay is 
therefore a useful method that can replace the phosphate assay for analysing conjugate 
samples if prepared in phosphate buffer. 
5.3.3 HPAEC-PAD 
In the present study, saccharides were hydrolysed in Her to yield ribitol which was then 
analysed on a CarboPac MA-1 column. The CarboPac MA-1 column with its high anion 
exchange capacity is ideal for the analysis of sugar alcohols such as ribitol. A typical 
protocol for the HPAEC-PAD method is as follows: 1 ml Hib samples (in duplicate) were 
treated with 50 ~I of 6 M HCI (Aldrich) (final HCI concentration: 0.3 M). The samples 
were heated at 100 °C for 2 hours in a closed screw-cap test tube. The hydrolysates 
were allowed to cool to room temperature and then neutralised with 400 ~I of 1 M NaOH 
(Sigma). Samples were passed first through a 0.22 ~m nylon filter (National Scientific) 
to remove particulates then through a SPE reverse phase C18 column (Isolute) to 
remove proteins. Detection of PRP (as ribitol) was pennitted using HPAEC-PAD on a 
CarboPac MA 1 column (250 mm x 4 mm) coupled with a CarboPac MA 1 guard column. 
Isocratic elution with 580 mM NaOH at a flow rate of 0.4 ml/min achieved separation of 
the ribitol peak from sorbitol (Fluka) which was added as an internal standard. In final fill 
samples, isocratic elution was at 470 mM NaOH. 
Carbohydrate analysis of Hib samples was perfonned on a Dionex BioLC ion 
chromatograph system equipped with an AS50 autosampler (Rheodyne rotary injection 
valve with a 25 ~I PEEK sample loop; for the thennal stability study, the sample loop was 
increased to 80 ~I in order to improve sensitivity) , an ED50 electrochemical detector, 
LC30 oven and GS50 pump. The detector cell incorporated a gold working electrode and 
a AglAgCI reference electrode. Chromatographic data were recorded on a personal 
computer equipped with Chrorneleon software. Three different Hib vaccine formulations 
were investigated; Hib-TT -A (conjugate fonnulated with sucrose), Hib-TT-8 (conjugate 











5.3.3.1 Determining the limit of detection 
The limit of detection was determined using a stock solution of Hitr IT-B at a 
concentration of 0.405 mg/ml of the polysaccharide (based on concentration provided by 
the supplier). Progressively more dilute samples of Hib-TT-B (0.18, 0.5, 1.0, 2.5, and 5 
IJglml) were prepared and analysed in order to establish the limit of detection. Following 
acid hydrolysis, neutralisation and fittering , the samples were chromatographed on a 
CarboPac MA 1 column with isocratic elution (580 mM NaOH) and pulsed amperometric 
detection as described in section 5.3.3. Some of the HPAEC-PAD chromatograms are 
displayed in Fig 5.1 . 
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FigS.1: HPAEC·PAD chromatograms fora, 18-2,5!1f1/m/ ofHilrTT·B 
used to establish the limit of detection. Arrows indicate the ribitol peak. 
The ribitol peak eluted at approximately 18 min under the conditions used without 












5.3.3.2 Investigating the use of sorbitol as an internal standard 
An internal standard is a substance that is added at a constant concentration to all 
standards and samples. Since the internal standard is always present at a constant 
amount, it can be used to account for factors such as concentration changes during 
sample preparation and clean-up and changes in the performance and sensitivity of the 
chromatographic system26• Sorbitol was investigated as a potential internal standard 
because it has a similar structure to ribitol . It was expected to be stable and measurable 
under the condrtions used because it elutes at a different retention time to ribitol. 
Stock solutions of Hib-TI-A, Hib-IT-B and Hib-TT-C were diluted to a final concentration 
of 20 ~g1ml (based on concentration provided by the supplier) and analysed by HPAEC-
PAD as outlined in section 5.3.3. All samples were spiked with 2.32 ~g of the internal 
standard sorbitol after the hydrolysis and neutralisation steps. Total peak area was used 
to determine ribitol and sorbitol content. The PRP standard (1 , 5, 10, 25,50 and 100 
~g/ml) was used to obtain a standard curve of peak area versus PRP content. A 
calibration curve of peak area versus sorbitol content was generated using the sorbitol 
standard (1 , 5, 10, 25, 50 and 100 ~gfml) . The HPAEC-PAD chromatograms obtained 
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Fig 5.2: HPI'EC-PAD chromatograms for Hib-TT-A. Hib-TT-B. 
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Analysis of Hib-TT-A was complicated by the presence of a large amount of sucrose 
(85 000 ~g sucrose: 20 ~g Hib) which was detected as glucose and fructose after 
hydrolysis. However, the peaks for sorbitol and ribitol could be resolved and integrated 
when the chromatogram was expanded. For Hib-TT-B, there was no interference from 
thiomersal although its presence had been a problem for the colorimetric assays. 
Peaks for sorbitol and ribitol eluted close to each other in the Hib-TT-C chromatogram 
but they could be integrated separately and the large peak at 7 min is due to the Tris 
butter (Fig 5.2). In all conjugate samples, the sorMol peak eluted at approximately 
14 min while the ribitol peak eluted at approximately 16 min. Sorbitol can therefore be 
used as an internal standard because it will not interfere with ribitol quantification. 
In summary, the PRP content of three different Hib vaccines (Hib-TT-A, Hib-TT-B and 












ribitol using HPAEC-PAD. This method was found to be sensitive (detection limit was 1 
~glml) and specific because ribitol CQuid be separated and quantrfied without 
interference from sucrose (which is used as a stabiliser) , thiomersal (which selVes as a 
preservative) and Tris buffer. Sorbitol, which has a similar chemical structure to ribitol , 
was found to be a suitable internal standard. It had a different retention time to ribitol 
under the elution conditions used and could be integrated and quantified separately. 
PRP depolymerisation has been achieved in some studies by base hydrolysis in NaOH 
to yield the PRP single repeating unit (as a mixture of ribitol-ribose-3-phosphate or 
ribitol-ribose-2-phosphate) 17. 111,21.27, Other studies relied on trifluoroacetic acid (TFA) to 
hydrolyse PRP followed by ribitol quantification17, 1e. The PRP hydrolysis protocol used 
in this study varied from previous ones in that Hel was used instead of TFA. Generally, 
a single human dose (0.5 ml) contains 10 ~g of PRP conjugated to a carrier protein. 
Physicochemical methods used to measure the amount of saccharide present should be 
sensitive enough to detect as low as 2 % of the total saccharide present in the final 
product". The above HPAEC-PAD method could detect down to 5 % of the total 
saccharide of the Hib vaccines investigated; the applicability of this method is probably 












5.4 Methods of separation 
The structural integrtty of conjugate vaccines was determined by analysing the final 
formulation for the evolution of free saccharide. This section describes the total and free 
saccharide analysis of the monovalent Hib conjugates HitrTT-A and Hib-TT-C. The 
separation of free saccharide from conjugate using selective precipitation by DOC/Hel 
and ultrafiltration as described in section 4.3.2 was applied. Saccharide quantification 
was performed using HPAEC-PAD. 
5.4.1 Hib·TT·A 
Hib-TT-A samples were diluted to a target concentration of 20 ~g1ml (based on the 
concentration provided by the supplier). Separation of free from bound saccharide was 
achieved using the DOCIHCI and UF methods described in section 4.3.2. In order to 
confirm the separation efficiency of both methods, some samples were spiked 
separately with 25 and 50 % of an activated PRP intermediate (PRP-ADH). Samples 
were treated as described in section 5.3.3 and 3.3 1.19 of sorbitol was added to each 
sample prior to filtration. The HPAEC-PAD chromatograms for DOCIHCI and UF 
samples were very similar and so only chromatograms for UF are displayed in Fig 5.3. 
5ortIiIoI Ribitol 
~ .. 
Fig 5.3: HPAEC-PAD chromatograms of total and free saccharide (len panel) 
with 25 and 50 % PRP·ADH spikes (right pane/) for Hi!>- IT·A. Sorbitol and ribitol 
peaks are indicated by the green and blue 8fTOWS respectively. 
The sorbitol (internal standard) and ribitol peaks elute at 15 and 16 min respectively, 
before the large peaks derived from sucrose; use of the internal standard sorbitol 













Table 5.1: % free saccharide results obtained using HPAEC-PAD for Hitr n -A analysis 
with spike recovery 
The total saccharide concentration in the vaccine was determined as 15 jJg/ml; this is 
lower than the expected value of 20 ~g/ml determined from the concentration provided 
by the supplier. The free saccharide content determined using the DOCIHCI and UF 
methods was 1.6±O.4 and O.9±O.2 IJgJml respectively. If 5 % of the total saccharide was 
free saccharide, its concentration would be near the limit of detection of the instrument 
(i.e. = 1 jJg/ml) and therefore a larger margin of error would be expected. That would 
explain the difference in the free saccharide value between the DOCIHCI (11 %) and UF 
(6 %) samples. Vaccines demonstrating adequate immunogenicity in clinical studies 
currently contain amounts of unbound polysaccharide ranging from less than 10 % to up 
to 40 % of the total saccharide, depending on the vaccine saccharide, coupling 
chemistry, protein carrier and formulation 16. Prior to licensing, the vaccine must 
therefore be evaluated for immunogenicity in the target age group16. 
Two spiked samples were used to test the separation efficiency of the DOCIHCI and UF 
methods; 20 ~gJml Hit>-IT-A spiked with 5 ~g of PRP-ADH (25 % spike) and 20 ~gJml 
Hit>-IT-A spiked with 10 ~g of PRP-ADH (50 % spike) . Using the DOCIHCI method, the 
results showed > 90 % recovery for both the 25 % spiked sample (Le. (6.7 - 1.60)/5 x 
100 = 102 %) and 50 % spike sample (Le. (11 - 1.60)/10 x 100 = 94 %). PRP recovery 
when the UF method was used, was also > 90 %. For both the 25 % spiked sample (i.e. 
(5.7 - 0.9)/5 x 100 = 96 %) and 50 % spike sample (Le. (10 - 0.9)/10 x 100 = 91 %). 
These results indicate that the HPAEC-PAD method is capable of measuring varying 
levels of free saccharide, however because the amount of free saccharide was close to 
the limit of detection (1 ~/ml), the experiment was repeated using Hib TI-C which had a 













Hib-IT -C with a stock concentration of 1.30 mg/ml (as determined by the manufacturer 
using the ribose assay) was diluted to 50 lJg/ml and 500 IJI aliquots were used to 
conduct the total and free saccharide assay. Separation of free from bound saccharide 
was performed using UF alone. The separation efficiency was tested using samples 
spiked separately with 50 and 100 % of an activated PRP intermediate (PRP-ADH). 
Samples were hydrolysed as described in section 5.3.3 and 16 ~g of sorbitol was added 
to each sample prior to filtration . The HPAEC-PAD chromatograms for Hib-TT-C (total , 
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Fig 5.4: HPAEC-PAD chromatograms of total and free sa:;chande (leff panel) 
wffh 5(} and 100 % PRP-ADH spikes (right panel) for Hib- IT-C. SorMot and 
riMoi paaks are indicated by the green and blue arrows respectively. 
-
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Peaks for sorbitol and ribitol eluted close together at nearly 15 min but could be 
integrated separately when the chromatogram was resized. The internal standard 
sorbitol was used to correct for any ribitol lost during the sample preparation and 












Table 5.2: % tree saccharide results obtained using HPAEC-PAD for Hib-TT -C with 
spike recovery 
Conjugate PRP Conc.,SE (~g/ml)' % free % recovery 
Total 49:t1 .0 - -
Free (UF) 13.1.5 27 -
Free (UF) + 50 % spike 38.1 .0 78 100 
Free (UF) + 100 % spike 62.0.7 126 98 
• In .ppe • 
The concentration of total and free saccharide was found to be 49 and 13 IJglml 
respectively; this corresponded to 27 % of the total saccharide. Separation of PRP and 
Hit>-TT -C was tested with two mixed PRP-AOHIHit>-TT -C samples; 50 ~g/ml Hit>-TT-C 
spiked with 25 ~g PRP-AOH (50 % spike) and 50 ~g/ml Hit>-TT -C spiked with 50 ~g 
PRP-ADH (100 % spike). The former showed 100 % recovery (i.e. (38 -13)/25 x 100) 
while the laHer gave 98 % recovery (i.e. (62 -13)/50 x 100). 
This investigation has demonstrated again that free saccharide can be efficiently 
separated by UF (with> 90 % recovery) and analysed quanlitatively by HPAEC-PAD. 
This free saccharide assay would therefore be appropriate for analysing the integrity and 
stability of conjugate vaccines during development. 
5.4.3 Analysis of Hib In combination vaccines 
Analysis of Hib saccharide in combination vaccines is complicated by interference from 
the other vaccine antigens and components such as preservatives, adjuvants, buffers, 
salts and stabilisers. The challenges are vaccine specific. For example, in one study, 
evaluation of Hib saccharide using the ribose assay in a combination vaccine containing 
DTP was not be possible due to interference from the DTP component17. Even vaccines 
evaluated by base hydrolysis and quantification of the Hib subunit using HPAEC-PAD 
can be hampered by interference from DTPl1. Thus, the present study was undertaken 
to investigate a method based on HCI hydrolysis followed by the chromatographic 
separation and quantification of ribitol with an internal standard, sorbitol , on a CarboPac 
MA-l column. 
Tetravalent (DTP-HBV) and pentavalent (DTP-HBV-Hit>-TT-B) liquid non-adjuvanted 
vaccines were supplied by a local vaccine manufacturer. Hib-IT-a contained thiomersal 
but no sucrose excipient (see Fig 5 .2). 100 \.II of the tetravalent (DTP-HBV) vaccine was 












prepared for analysis. Samples were hydrolysed and treated as described in section 
5.3.3. Pentavalent samples were spiked with 2.64 ~g of sorbitol solution before filtration 
and the amount of saccharide quantified by HPAEC-PAD as previously described in 
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Fig 5.5: HPAEC-PAD chromatograms for tetra- and 
pentavalent combination vaccines. The green anow indicates 
sorbno! and the blue arrow riMo!. 
The chromatogram of the hydrolysed tetravalent DTP-HBV vaccine shows that under the 
conditions used, no peaks eluted at the retention times of either ribitol or sorbitol (Fig 
5.5), therefore this method could be applied to the analysis of the DTpMHBV-Hib vaccine 
without interference from the DTP-HBV components. The internal standard sorbitol 
eluted near 16 min and ribitol near 17.5 min so the method was selective for these 
analytes. The different retention times permitted integration of the sorbitol and ribitol 
peaks and thus determination of the corrected ribitol concentration. 
The free saccharide assay was then applied to the pentavalent vaccine to evaluate its 
potency (total saccharide content) and integrity (% free saccharide) . This study was 
performed using Hit>-TT ~A, formulated with sucrose. 500 ~I samples of the pentavalent 












supplier) were prepared for total and free saccharide analysis. Separation of free from 
bound saccharide was achieved by DOC/Hel and UF (detailed procedure provided in 
section 4.3.2). The recovery of the free saccharide assay was tested by spiking some 
samples with 25 and 50 % of a PRP intermediate (PRP-ADH). Samples were treated as 
described in section 5.3.3 and 3.3 1-19 of sorbitol was added to each sample after 
hydrolysis. The HPAEC-PAD chromatograms for DOC/Hel and UF samples were very 
similar and so only chromatograms for UF are displayed in Fig 5.6 . 
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Fig 5.6: HPAEC-PAD chromatograms of total and free saccharide (left 
panel) wfth 25 and 50 % PRP-ADH spikes (right panel) for the pentavalent 
DTP-HBV-Hib vaccine. Sorbitol and riMoi peaks are indicated by the 
green and blue arrows respectively. 
-
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The internal standard sorbitol eluted frst at approximately 14.7 min and the ribitol near 
16 min, after which the chromatogram was dominated by large peaks derived from 












Table 5.3: Total and free saccharide results obtained using HPAEC-PAD for DTP-HBV-
Hit>-IT-A with spike recovery 
Test conjugate PRP ConciSE (~g/ml)' % Free % recovery 
Total 13.0.8 - - - - -
DOC UF DOC UF DOC UF 
Free 2.0±0.5 1.8.0.3 15 14 - -
Free + 25 % spike 6.2.0.3 6.1.0.2 48 47 84 86 
Free + 50 % spike 11tO.3 11.0.2 85 85 90 92 
·U_ In .ppenalX t; 
The concentration of total saccharide was found to be 13 ~glml ; this is lower than the 
expected value of 20 ~g/ml determined from the concentration provided by the supplier. 
The concentration of free saccharide determined using the DOC/Hel method was 
2.0±O.7 ~g/m' which corresponded to 15 % of the total saccharide present. Similar 
results were obtained when UF was used for free saccharide separation (i.e. 1.8 ~ml 
and 14 %). The pentavalent vaccine contains less than 20 % free saccharide, but will 
need to be assessed for its immunogenicity in the target age group before licensure 16. 
The recovery of the free saccharide assay was tested with two spike samples; 
pentavalent + 5 ~g of PRP-ADH (25 % spike) and pentavalent + 10 ~g of PRP-ADH 
(50 % spike). When the DOCIHCI method was used. the free saccharide value 
increased to 48 and 85 % for the 25 and 50 % spike samples respectively. Similar 
values were obtained using UF which saw an increase to 47 and 85 % for the 25 and 50 
% spike samples respectively. PRP recovery in the above samples was ~ 84 % which 
was lower than that obtained for the monovalent vaccine and is an indication that the 
presence of other antigens affects free saccharide recovery. In the pentavalent vaccine, 
there may be an increased possibility of entrapment of free saccharide as the protein 
antigens are precipitated with DOC/I-ICI. The interaction of free saccharide with other 
antigens present in the formulation is also a possibility. The tetravalent components 
may interfere with the UF separation because some of the pores in the UF membrane 
became blocked and therefore longer spin times were required. 
5.5 Analysis of Hib in adjuvanted vaccines 
Formulations of conjugate vaccines vary, but many are adsorbed onto or dispersed into 
adjuvants, which serve as excellent vehicles for delivery. Aluminium-based adjuvants 












recommends that antigen adsorption should be demonstrated to be within the range of 
values found for vaccine lots shown to be clinically effective IS, Adjuvants and buffer 
systems are formulated to ensure conjugate structural integrity for the specified shelf life 
of the vaccine. Analysis of the final formulation for the evolution of free saccharide 
provides a good way to determine structural wholeness or integrttl8 , To accomplish this 
however requires elution of the antigen jf adsorbed to the adjuvant. A survey of the 
literature revealed different strategies for desorption of the antigen from aluminium-
containing adjuvants. For example, dissolution of aluminium-containing adjuvants to 
release adsorbed antigens has been reportecf8' 27. 29, In addition, anions such as 
phosphate have been effective in causing elution of antigens from aluminium-containing 
adjuvants. In the case of ALH adjuvant, elution is caused by adsorption of phosphate 
anion by the adjuvant which lowers its isoelectric point (IP). High phosphate 
concentrations cause the surface charge of ALH to change from positive to negative. 
Consequently, electrostatic repulsive forces between the negatively charged adjuvant 
and the negatively charged antigen resulted in elution. Adsorption of additional 
phosphate anions by ALP adjuvant also reduces its IP and increases its negative 
surface charge thus resulting in increased electrostatic repulsion with a negatively 
charged antigen30• 
Following confirmation that PRP was adsorbed to ALH adjuvant. the current study 
investigated the dissolution of adjuvant in NaOH and sodium citrate27 and the 
displacement of bound antigen by the phosphate anion when pH and ionic strength are 
increased29• 3O• Antigen elution in the presence of Pheroid™ was also investigated. In 
these experiments saccharide quantification was made by use of the ribose assay. 
5.5.1 Adsorption study 
Adsorption refers to interactions at surfaces without formation of covalent bonds. In the 
context of vaccine production, adsorption refers to the attraction between antigens 
dissolved in the medium and the adjuvant. The zero charge point of aluminium 
hydroxide (AlH) has been reported as 11 .4 and for aluminium phosphate (ALP) as 5.029. 
At neutral pH, electrostatic attraction would result in the efficient binding of PRP to ALH 
whereas electrostatic repulsion would lead to poor binding of PRP to ALP. As a result, 












Adjuvanted Hib vaccines (mono- and pentavalent) available to this study were obtained 
already formulated by the manufacturer. Therefore, a series of experiments to 
determine how long it takes the antigen to adsorb at different pH, concentration or salt 
concentration have already been performed by the manufacturer. However I to show that 
TT and PRP are adsorbed to the ALH adjuvant, 1 mglml solutions of each were 
prepared separately and stirred gently ovemight in 1 mglml ALH. MilliQ water was used 
as diluent. Samples were then centrifuged at 10 000 rpm for 10 min and 00280 nm 
readings of the supernatant was determined followed by the colorimetric assay for 
ribose. The results confirmed that both TT and PRP were adsorbed to the adjuvant 
(data not shown). In subsequent studies incubation of PRP with the adjuvant was 
performed overnight. 
These results are in agreement with studies that have shown that TT adsorbs to ALH31. 
Interaction between the adjuvant and antigen is electrostatic regardless of whether the 
antigen is a polysaccharide or protein. Ligand exchange and hydrophobic interactions 
(especially with proteins) occur over time making it increasingly difficult for full recovery 
of antigen. The following three sections investigate various conditions that would favour 
adjuvant dissolution or desorption of the attached antigen prior to quantification of PRP. 
5.5.2 Methods investigated for the separation of adjuvant from conjugate vaccines 
5.5.2.1 Adjuvant dissolution with sodium hydroxide and sodium citrate 
In the current study, two conditions published in the literature for adjuvant dissolution 
were investigatedv . 29. The effect of a 10 % sodium citrate solution on the dissolution of 
ALH was tested at pH 10 by dissolving 0.1 g sodium citrate in 1 ml aluminium hydroxide 
(1 mg/ml)21. The mixture was incubated overnight at 40 °C. Under these conditions, the 
adjuvant did not dissolve. Increasing the amount of citrate to 15 then 20 % did not 
dissolve the adjuvant either. 
The solubility of aluminium phosphate (ALP) adjuvant (0.6 mglml) was tested using 
NaOH solutions of varying concentrations (40-600 mM)29. A 10 M stock solution of 
NaOH was prepared by diluting 2.B ml conc. NaOH to a final volume of 5 ml with milliQ 
water. This solution was further diluted to 2 M and used to prepare 500 ~I samples of 
ALP containing 40, BO, 120, and 200 mM NaOH. The more concentrated 10 M NaOH 
stock solution was used to prepare 500 ~I samples of ALP containing 500 and 600 mM 












only when NaOH concentration was ~ SOD mM. This method would not be suitable for 
routine analysis of Hib because the harsh alkaline conditions would induce hydrolysis of 
the PRP, resulting in an erroneously high free saccharide concentration. 
5.5.2.2 Antigen recovery with addition of phosphate anion 
In order to determine if the adsorption of PRP to aluminium adjuvants and Pheroid™ is 
due to electrostatic interactions which are interrupted by increasing phosphate 
concentration, a modification of the method developed by Jendrek and co-wokers was 
applied first to samples of PRP mixed with the adjuvants and then to both non-
adjuvanted and adjuvanted Hib conjugates32. The free saccharide assay was 
subsequently used to analyse a Hib conjugate formulated with aluminium-containing 
adjuvants. 
A 200 mM phosphate buffer at pH 7.5 was prepared by dissolving 3.57 g of anhydrous 
monosodium phosphate (lasechem) and 7.71 g of trisodium phosphate dodecahydrate 
(Lasechem) in 250 ml milli-Q water (Buffer 1). Stock solutions of PRP and ALH 
adjuvant with concentrations of 7.92 mglml and 30 mg/ml respectively were used. Two 
separate mixtures containing 40 and 100 jJ9/ml PRP in 1 mglml ALH adjuvant were 
prepared. The mixtures were stirred gently overnight to aid adsorption of PRP onto the 
adjuvant. 0.5 rnl of each mixture was diluted to 20 and 50 jJg/ml respectively using the 
phosphate buffer and a 0.9 % saline solution to obtain 1 ml samples containing 10, 20, 
30, 40, 50 and 100 mM phosphorus (n = 2). The control sample was diluted with saline 
alone and contained no phosphorus. These samples were vortexed, incubated at room 
temperature for 1 hour and then centrifuged at 10 000 rpm for 10 min to precipitate the 
adjuvant, leaving the desorbed PRP in the supernatant. The supernatant was then 
analysed for its ribose content as described in section 5.3.2. A conversion factor of 2.31 
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Fig 5.7: PRP recovery from ALH at two different concentrations. 
PRP is a highly charged polyanion which is expected to bind to ALH by electrostatic 
interactions. At low PRP concentration (20 IJglml), all the PRP was adsorbed to ALH 
and virtually no desorption of PRP occurred with addition of the phosphate anion 
(Fig 5.7). This may be because 01 the low concentration of PRP. As a result, PRP binds 
to some but not all of the sites on ALH so that the phosphate anion can bind to the 
remaining sites without having to displace PRp33, The 00 values obtained at 20 IJglml 
PRP were low and therefore only the graph obtained at 50 lJg/ml was used for further 
interpretation of the data. 
In section 5.5.1, 1 mglml PRP was completely adsorbed by 1 mg/ml ALH when water 
was used as the diluent. However it has been reported by Jendrek and co-workers that 
an increase in ionic strength reduces electrostatic forc:es32• This might explain why the 
control sample (prepared in saline and not water and therefore possessing a higher ionic 
strength) contained 10 % unadsorbed PRP. At 50 ~glml PRP, the maximum percentage 
of PRP recovered was 70 % and this occurred at 30 mM phosphate anion concentration. 
Thereafter, increasing phosphate concentration did not result in further release of PRP 
(Fig 5.7). The fact that the presence of phosphate led to the desorption of at least 60 % 
of bound PRP suggests that the binding of PRP to ALH is primarily electrostatic in 
nature. 
In conclusion, addition of phosphate anion at neutral pH caused 60 % of the adsorbed 
PRP to be released into the supernatant. The ultimate objective would be to obtain 
greater than 90 % recovery of the adsorbed PRP from ALH. Other factors that affect the 












buffer (ionic strength or type of ions). In an attempt to improve PRP recovery, the effect 
of increasing adjuvant pH (from 6.5 to 7.0) on release of the adsorbed antigen was 
investigated. 
5.5.2.3 Effect of modifying pH from 6.5 to 7.0 on PRP recovery with addition of 
phosphate anion 
The pH afthe ALH and ALP adjuvant stock solutions was adjusted from 6.5 to 7.0. Two 
separate mixtures containing 200 .,.gJrnl PRP in 1 mg/ml ALH and 0.6 mg/ml ALP were 
prepared and allowed to stir gently overnight. 0.5 ml of each was diluted using the 
phosphate buffer and the 0.9 % saline solution to obtain 1 ml samples containing 
100 1J9/ml PRP in 50 and 100 mM phosphate buffer (Buffer 1). The control sample was 
diluted with saline alone and contained no phosphorus. Samples were vortexed, 
incubated at room temperature for 1 hour and then centrifuged at 4 000 rpm for 20 min. 
Supernatants were transferred to fresh eppendorf tubes and the pellets resuspended in 
0.5 ml saline (control) and 0.5 ml 50 and 100 mM phosphate buffer (Buffer 1) then 
centrifuged at 10 000 rpm for 10 min. This wash step was included to maximise 
recovery of PRP. Supernatant and washings were pooled (± 1 ml) and the saccharide 
content quantified using the ribose assay (described in section 5.3.2). The percentage 
of PRP recovered in each sample is presented in Fig 5.8. 
PRP recovery in ALP va. AlH 
100 





0 20 " 60 60 '00 Pnosplwte concentr.UOn (mM) 
Fig 5.8: PRP recovery from both ALH and ALP by increasing 
phosphate ion concentration (pH 7.0). 
Although PRP was poorly adsorbed to ALP (zero phosphate concentration showed 80 % 
recovery), at 100 mM phosphate concentration an increased electrostatic repulsion 












adjuvant is positively charged, addition of the negatively charged PRP resulted in 
immediate binding. 100 mM phosphate concentration was not sufficient to desorb all 
adsorbed antigen from ALH as only 40 % PRP was recovered. Compared to Fig 5.7, it 
is evident from Fig 5.8 that adjusting the pH and including a wash step was not effective 
in improving PRP recovery from ALH. 
In adsorption experiments conducted with purified diphtheria toxoid or tetanus toxoid as 
used in vaccines, Matheis and co-workers demonstrated complete adsorption of these 
toxoids onto ALH31. In the case of ALP, only partial adsorption was observed. 
Desorption of the antigens (diphtheria toxoid or tetanus toxoid) was easier from ALP 
adsorbed vaccines in comparison to ALH adsorbed vaccines. Although these 
investigators used negatively charged proteins31, the present study has confirmed that 
when the antigen is a negatively charged saccharide (in this instance PRP), it is more 












5.5.2.4 Using Pheroid'fM as adjuvant 
Pheroid™ is a patented fatty-acid based formulation which has shown potential for use 
as an adjuvant. Zeta potential studies revealed that Pheroid™ fonns a micro-emulsion 
with negatively charged particles3<4 . Previous studies on emulsions have demonstrated 
that electrolytes such as NaCI can be used to decrease the elastic behaviour of the 
interfacial film, resulting in interfacial film breakdown and the release of entrapped 
antigens35• Thus, the present study was undertaken to investigate PRP recovery after 
overnight incubation with Pheroid™ and diluted using a 1 x PBS buffer prepared by 
dissolving 8 9 NaGI, 0.2 9 KGI, 1.44 9 Na2HP04 and 0.24 9 KH2P04 in a litre of MilliQ 
water and adjusting the pH to 7.4 (Buffer 2). 
In previous studies conducted using Pheroid™ as adjuvant, the vaccines were 
formulated with either 1.85 or 1 00 % Pheroid™ (v/v) therefore these two concentrations 
were used~ . 200 IJglml PRP in 1.85 and 100 % Pheroid™ were stirred gently overnight. 
Both samples were then diluted to 100 IJglml PRP with Buffer 2. Centrifugation of the 
mixture at 13 400 rpm allowed separation of a relatively thin layer of oil on top of the 
aqueous phase. The centrifugation step was repeated for PRP in 100 % Pheroid™ in 
order to recover as much of the aqueous layer as possible. The amount of PRP present 
in this aqueous phase was analysed using the ribose assay (as outlined in section 
5.3.2). The results obtained are displaved in Table 5.4 . 100 % recovery was obtained at 
1.85 % Pheroid™ concentration. Under the conditions used, only 75 % recovery was 
possible at 1 00 % Pheroid™ concentration probably because complete separation of the 
oil and aqueous phase was not achieved. 
Table 5.4: PRP recovery from samples containing Pheroid™ 
Sample Rlbos. Cone (I'IIIml) PRP Cone (I'IIIml) % Recovery 
PRP in 1.85 % Pheroid 43.8 102 102 
PRP in 100 % Pheroid 31 .1 72 72 
From the above resuhs it is evident that Buffer 2 is a suitable elution buffer which can 
inhibit PRP adsorption to aluminium phosphate adjuvant and Pheroid™. Initial 
experiments also revealed that following centrifugation of the adjuvant. the free 
saccharide assay with ribose quantification can be used to determine the amount of free 












5.5.2.5 Pre-treatment of Hib-TT -0 adsorbed to aluminium~ontaining adjuvants 
Hit>.TT-O conjugate was provided by the manufacturer with a stock concentration of 
0.9 mglml and high free saccharide content. The effect of Buffer 2 on desorption of Hib-
IT-D from ALP (Hlb-IT-D/ALP) adjuvant was investigated. The pH of ALP was 
adjusted from 6.5 to 7.0 before sample preparation. A sample containing 200 !-I9/ml Hib-
TT-D and 0.6 mglml ALP in Buffer 2 was stirred gently overnight. 0.5 ml aliquots were 
diluted with Buffer 1 to yield 1 ml samples containing 100 IJglml Hib-TT-D in 50 and 
100 mM additional phosphorus (duplicate). The control sample was diluted with 0.5 ml 
saline and contained no phosphate ions Samples were vortexed, incubated at room 
temperature for 1 hour and then cenbifuged at 4 000 rpm for 20 min. Supernatants were 
transferred to fresh eppendorf tubes and the pellets resuspended in 0.5 ml saline 
(control) and 0.5 ml 50 and 100 mM phosphate buffer then cenbifuged at 10 000 rpm for 
10 min. Samples were evaluated for their PRP content using the ribose assay (see 
section 5.3.2 for detailed procedure). 
Similar amounts of PRP were recovered from the control and from samples to which 50 
and 100 mM add~ional phosphate had been added (95±1 .3, 95±1.4 and 97±1.0 % 
respectively) . The results from this study suggest that in the presence of Buffer 2 alone, 
the antigen is unadsorbed and the amount of PRP recovered was >90%. Addition of 
phosphate buffer (10 mM) has been used to extrad the Hib conjugate in vaccines 
formulated with aluminium phosphate adjuvant17. In that study the conjugate consisted 
of PRP oligosaccharides attached to a non-toxic variant of the diphtheria toxin (Cross-
Reading Material, CRM1a7) . Thus, the addition of phosphate anions was successful in 
extracting the conjugate into the supernatant in ALP-adjuvanted Hib-CRM and Hib-IT 
vaccines. 
5.5.2.6 Determination of free saccharide in Hib-IT~D formulated with aluminium-
containing adjuvants 
Hib-IT -0 conjugate provided by the manufacturer with a stock concentration of 
0.9 mg/ml and high free saccharide content was used to prepare two sets of samples. 
The first set consisted of separate mixtures of 100 [Jglml Hib-IT-D and 1 mg/ml ALH in 
Buffer 2 (Hlb-IT-D/ALH) and 100 ~glml Hib-IT-D and 0.6 mglml ALP in Buffer 2 (Hib-
TT -D/ALP). The second batch was prepared in the same way but saline was used 
instead of Buffer 2. The mixtures were stirred gently overnight to aid adsorption of the 












Buffer 1 to yield 1 ml samples containing 100 1-19/ml Hib-TI-D in 50 and 100 mM 
additional phosphate. The control samples were diluted with 0.5 ml saline. Samples 
were vortexed, incubated at room temperature for 1 hour and then centrifuged at 4 000 
rpm for 20 min. Supernatants were transferred to fresh Eppendorf tubes and the pellets 
resuspended in 0.5 ml saline (control) and 0.5 ml 50 and 100 mM phosphate buffer then 
centrifuged at 10 000 rpm for 10 min. The supernatants were pooled and ultrafiltered as 
described in section 4.3.2 then analysed using the ribose assay (see section 5.3.2 for 
detailed procedure). Fig 5.9 shows the results obtained. 
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Fig 5.9: Free saccharide detennination of Hib-TT-D vaccine 
adsorlJed to ALH and ALP. 
The adsorption of phosphate anions has been found to lower the isoelectric point of 
ALH30. Hence addition of PBS (Buffer 2) would increase the electrostatic repulsion 
between the adjuvant and PRP and UF would separate free PRP into the filtrate. The 
amount of free saccharide recovered from samples prepared in Buffer 2 was expected 
to be higher than those prepared in saline and this was indeed the case as shown in Fig 
5.9. When Hib-TT-D was prepared with ALH (Hlb-TT-D/ALH) in saline, the amount of 
free saccharide increased with increasing phosphate anion concentration until a 
maximum of 35 % indicating that the conjugate and some free saccharide is still 
adsorbed to the adjuvant. However, when Buffer 2 was used in place of saline, a 
maximum of 53 % free saccharide was obtained. Further evidence that Buffer 2 alone 
is sufficient for conjugate desorption can be seen in the fact that addition of extra 
phosphate did not improve free saccharide recovery because at 0 and 100 mM 












In the case of ALP which is negatively charged at neutral pH, PBS (Buffer 2) would 
increase the repulsive forces between the adjuvant and conjugate (Hib-IT-O/ALP)30. 
Previous experiments in saline (see Fig 5.8) had shown successful recovery of PRP 
from the adjuvant. therefore no dramatic variation in free saccharide was expected when 
saline and PBS was compared. This was indeed the case as shown in Fig 5.9. In 
saline, free saccharide concentration increased with increasing phosphate to reach a 
maximum of 35 %. In Buffer 2, addition of extra phosphate caused the amount of free 
saccharide to increase slightly to 38 %. 
This investigation has demonstrated that Buffer 2 alone can be used for elution of free 
saccharide without addition of extra phosphate. However, the amount of free saccharide 
recovered from ALH and ALP varied (53 and 38 % respectively). Therefore, to 
determine the correct concentration of free saccharide, this experiment was repeated 
using the DOCIHCI and UF methods of free saccharide separation and the more 
sensitive HPAEC-PAD method for saccharide quantification. 
5.5.3 Comparison of DOC/HCI and UF methods for the separation of free 
saccharide in Hib-TT-O formulated with alumlnlum-containing adjuvants 
The total and free saccharide assay was now applied to Hib-TT-D, Hlb-TT-D/ALH and 
Hlb-TT-D/ALP. The pH of both ALH and ALP was adjusted to 7.0 by dropwise addition 
of 0.1 M NaOH. 100 ~g/ml sampes of Hlb-TT-D/ALH and Hlb-TT-D/ALP were 
prepared in Buffer 2 and allowed to stir gently overnight. 100 ~g/ml samples of 
Hi!> TT -0 served as the control. Separation of free from bound saccharide was achieved 
by the OOCIHCI and UF (100 kOa membrane) methods. Samples were hydrolysed as 
described in section 5.3.3 and 16.4 ~g of sorbitol was added to each sample prior to 
filtration. Total and free saccharide quantification was conducted using the HPAEC-PAO 
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Rg 5.10: " free secch8ride cietenniflBtion for Hib conjugate aJone (Hib-IT-D), conjugate 
formul8ted in ALH (Hlb-TT-DIAUI) and conjugate formul8ted in ALP (Hlb-TT-DI ALP). 
The error b8fS represent the standard error. 
In the conjugate sample formulated without adjuvant, the DOCIHCI and UF methods 
indicated the presence of 22:t1 .6 and 27±O.4 % free saccharide respectively. It may be 
that the wash step included in the UF method resulted in better recovery of free 
saccharide or perhaps the 100 kDa membrane was permitting some conjugate to pass 
through. Additional experiments were later conducted (and presented in section 5.7) to 
determine firstly whether the 100 kOa membrane was permitting some conjugate to pass 
through and secondly what effect if any the type of buffer had on PRP recovery when the 
DOCIHCI method was used. 
When the DOC/Hel method was used, free saccharide was lower in Hib-TT -OJALH 
(7±1.4 %) compared to the control (22±1 .B %). Therefore, compared to the 
unadjuvanted control , the DOCJHCI method may underestimate the amount of free 
saccharide present. The decrease in free saccharide did not correspond to the free 
saccharide results obtained using UF (38±1 .4 %) and was therefore attributed to the 
method of free saccharide separation since the selection of a buffer and the ionic 
strength of the vaccine fonnulation can affect both the amount of antigen that is 
adsorbed as well as the strength of the adsorption force32. 
In Hib-TT-D/ALP, the DOCIHCI and UF methods yielded 7>2.2 and 37>2.B % free 
saccharide respectively. A decrease in the amount of free saccharide was also 












saccharide separation. Therefore, it may be worth investigating what effect different 
buffers would have on PRP recovery when the DOCIHCI method is used. 
Differences in the free saccharide data obtained using the DOCIHCI and UF methods 
were investigated and are presented in section 5.7. In the following section however, 
analysis of Hitr IT -0 was performed using the free saccharide assay with spike 
recovery. 
5.5.4 Total and free saccharide analysis (with spike recovery) of Hib-TT-D 
formulated with aluminium-<:ontalnlng adjuvants 
The pH of both ALH and ALP was adjusted to 7.0 by dropwise addition of 0.1 M NaOH. 
The O.g mglml stock solution of Hit>-TT-D was used to prepare 100 ~glml samptes of 
Hit>-TT-D/ALH and Hib-TT-D/ALP in PBS (Buffer 2) and allowed to stir gently 
ovemight. 100 jJglml samples of Hib-TT-D salVed as the control . 500 IJI aliquots were 
subsequently diluted to 1 ml and a final concentration 50 I-lglml with Buffer 2 (for 
samples containing adjuvant) or saline (for the Hib conjugate alone). Samples 
containing adjuvant were centrifuged at 4 000 rpm for 20 min prior to determination of 
free saccharide. Supernatants were collected in fresh Eppendorf tubes and the pellets 
washed by resuspending in 250 IJI of Buffer 2 and centrifuged at 10 000 rprn for 10 min. 
Supernatants were pooled and uttrafiltered as described in section 4.3.2. Some samples 
were spiked separately with 50 % (i.e. 25~) and 100 % (i.e. 50 ~g) of an activated PRP 
intenmediate (PRP-ADH) for two reasons. Firstly, to establish proof of concept by 
confirming the separation efficiency of UF in samples formulated with aluminium-
containing adjuvants. Secondly, to establish that the HPAEC-PAD method can 
accurately detect an increase in the amount of free saccharide and therefore be used to 
analyse the stability of conjugate vaccines formulated with aluminium-containing 
adjuvants. Samples were hydrolysed as described in section 5.3.3 and 16.4 IJg of 
sorbitol was added to each sample after hydrolysis. Total and free saccharide 
quantification was performed using the HPAEC-PAD method. A summary of the results 
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FIg 5.11: HPAEC~AD quantifICation of free saccharide with 50 and 100 % PRP-ADH 
spikes for Hib conjugata alone (HilrTT-O), conjugate formulated in ALH (Hi~TT-DIALH) 
and conjugate formulated in ALP (Hlb-TT-DIALP). Error bars represent the standard error. 
The concentration of total and free saccharide in the conjugate sample formulated 
without adjuvant (Hib-IT-D) was 56±O.4 and 22±1 .8 ~glml respectively. The results 
showed 96 and 92 % recovery in the low (50 %) and high (100 %) concentration spike 
samples respectively. Analysis of Hlb·IT -D/ALH yielded total and free saccharide 
concentrations of 43±1.4 and 20±1 .4 IJglml respectively. This time only 72 and 74 % of 
the spiked PRP was recovered from the low and high concentration spike samples 
respectively. Total and free saccharide content in Hlb-TI-O/ALP samples was 40±S.7 
and 14±2.2 ~glml respectively. 76 and 82 % of spiked PRP was recovered from the low 
and high concentration spike samples respectively. 
Free saccharide determination of aluminium-adjuvanted Hib vaccines has been reported 
for Hib-CRM17 and Hib-OMPC21, however not for Hib-IT conjugates. No published 
studies have described the use of UF for the analysis of free saccharide in Hib-IT 
vaccines formulated with ALH or ALP. This investigation specifically examined the 
separation of free saccharide in a Hib-IT conjugate vaccine formulated with ALH and 
ALP adjuvants. PBS was used for desorption and extraction of the antigen from ALH 













In summary, the amount of free saccharide determined in this study was in the range 
35-47 %. For Hib-TT-D, Hib-TT-DIALH and Hib-TT-DIALP samples, a corresponding 
increase in percentage free saccharide accompanied both the 50 and 100 % spike 
samples. PRP recovery was > 90 % in the conjugate samples fonnulated without 
adjuvant but < 90 % when ALH and ALP were used. This method shows potential for 
use in monitoring the stability of Hib-IT in the presence of aluminium-containing 
adjuvants during routine vaccine manufacturing. Therefore, this method was tested by 
performing a thermal stability study on Hib-TT in a pentavalent formulation containing 
adjuvant. 
5.6 Accelerated thermal stability study 
A key criterion for determining the quality and stability of conjugate vaccines is the 
measurement of free saccharide. This can be a challenge in combination vaccine 
formulations due to the presence of different components which may cause interference 
with detection of ribitol. In addition, the use of aluminium-containing adjuvants with 
combination vaccines necessitates the development of sample preparation methods to 
desorb the antigen of interest from the adjuvant prior to analysis. Previous experiments 
have established that using a high ionic strength phosphate buffer like PBS (Buffer 2), 
even at physiological pH of 7.4 could result in the phosphate anion electrostatically 
competing or exchanging ions with the aluminium hydroxide and aluminium phosphate 
adjuvant complexes in Hib vaccines thus releasing free saccharide. Preliminary 
experiments indicated that Buffer 2 was also a suitable elution buffer in samples 
formulated with PheroidTU. 
Analysis of Hib in the pentavalent vaccine (OTP-HBV-Hitr TT -A) formulated with 
adjuvant was investigated. Four combination vaccines were prepared: Penta (control 
vaccine formulated without adjuvant), PentalALH, PentalALP and PentalPherold™ 
(containing 1.85 % Pheroid™) were the pentavalent vaccine formulated with ALH, ALP 
and Pheroid™ respectively. The vaccines were supplied by a local vaccine 
manufacturer. Hitr IT -A contained sucrose excipient. The Hib component was 40 jJgJml 
(concentration provided by the manufacturer). The thermal stability of these vaccine 
formulations was monitored at 4, 25 and 40 DC for a period of 0, 2 and 5 weeks. AU 
samples were stored at 4 DC until testing. For analysis, 500 jJl aliquots were diluted to 
20 ~glml with 500 ~I of Buffer 2 (based on concentration provided by the manufacturer). 












determination of free saccharide. Supernatants were collected in fresh Eppendorf tubes 
and the pellets washed by resuspending in 250 1-11 Buffer 2 and centrifuging at 10000 
rpm for 10 min. Supernatants were pooled and ultrafiltered to obtain the free saccharide 
(as described in section 4.3.2). Following hydrolysis (see section 5.3.3 for detailed 
procedure), 16.4 1-19 of sorbitol was added to each sample prior to filtration and analysis. 
Saccharide quantification was pelformed using HPAEC-PAD. Total peak areas were 
used to determine ribitol and sorbitol content. The ribitol concentration was corrected 
using the internal standard sorbitol. 
The HPAEC-PAD chromatograms for Penta obtained at 25 'c showing total (A) and free 
at 2 (8) and 5 (C) weeks respectively are presented in the left panel of Fig 5.12. The 
right panel contains chromatograms obtained at 40 °C for total (D) and free at 2 (E) and 
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Fig 5.12: HPAEC-PAD chromatograms for Penta showing total and free 
saccharide after 2 and 5 w_s 8t 25·C (A-C) and 40 ' C (D-F). So/Mol and 
ribftol peaks are indicatoo by the green and blue arrows respectively. 
Hib analysis of the combination vaccine was complicated by the presence of a large 
amount of sucrose (added to the vaccine as a stabiliser) which was detected as glucose 
and frudose after approximately 17 min. A large peak for the Tris buffer was detected at 












sorbitol and ribitol peaks wh ich eluted between 14-16 min. The chromatograms were 
resized and the peaks for sorbitol and ribitol estimated. It is evident from Fig 5.12 that 
the vaccine was stable for 5 weeks at 25 DC because no ribitol was detected (only 
sorbitol was detected at approximately 15 min). Ribitol was detected in all samples 
stored at 40 °C for 2-5 weeks. Deterioration of the column during analysis led to poor 
resolution of the sorbitol and ribitol peaks. Amino acid residues that are not retained on 
the SPE cartridge used for sample clean up or on the guard column will irreversibly bind 
to the resins on the column thus reducing the separation efficiency of the column over 
time. The use of an AminoTrap column in future studies may help to eliminate this 
problem36• The presence of interfering matrix components such as sucrose also 
complicated the analysis. Partial overtap of peaks for sorbitol and ribitol meant that the 
peak areas were estimated, thus increasing the margin of error. 
The HPAEC-PAD chromatograms for PentaJALH obtained at 25 'c showing total (A) 
and free at 2 (8) and 5 (C) weeks respectively are presented in the left panel of Fig 5.13. 
The right panel contains chromatograms obtained at 40 °C for total (D) and free at 2 (E) 
and 5 (F) weeks respectively. 
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Fig 5.13: HPAEC-PAD chromatograms for PentalALH showing total and free 
saccharide affer 2 and 5 weeks at 25 oC lA-C) and 40 oC ID-F). Sorbitol and 












Peaks for sorbitol and ribitol were detected between 14-16 min. Free saccharide was 
detected in all PentalALH samples analysed. At both 25 and 40 °C, the amount of free 
saccharide generated increased over time. The amount of tree saccharide also 
increased with increasing temperature (25°C < 40 Ge). The peaks for sorbitol and ribitol 
were very small in comparison to that of the other vaccine components such as Tris 
(near 9 min), glucose and fructose (after 17 min) and hence analysis of the 
chromatograms was complex. In addition, peak overlap caused difficulties in accurately 
integrating the peak areas for sorbitol and ribitol. 
The HPAEC-PAD chromatograms for Penta/ALP obtained at 25 ' C showing total (A) 
and free at 2 (8) and 5 (C) weeks respectively are illustrated in the left panel of Fig 5.14. 
The right panel contains chromatograms obtained at 40 °C for total (D) and tree at 2 (E) 







• - -25 oc TOT 0 40 oC TOT 
SO!tiIoI Ribitol 
II - I I , . ____ ...l.....!.. 
.. .. .. -•• --- •• • . .. ... •• • .. .. .. ... , -- - ., - - .. 
2W2SoC UF E 2W40oC UF 
I I II .. 
. !.~ 




I I - I I .. 
Fig 5.14: HPAEC-PAD chromatograms for Penta/ALP showing tolal and 
free saccharide aner 2 and 5 weeks at 25°C (A-C) and 40 oC (f>.F) . Sorbffol 
and ribffol peaks are indicated by the green and blue arrows respectively. 
•• -
•• • • 
Peaks for sorbitol and ribitol eluted between 14-16 min. As with PentaiALH, Penta/ALP 
samples contained some ribitol after 2·5 weeks of storage at 25 and 40 °C but the 













The HPAEC-PAD chromatograms for PentaiPheroidTil obtained at 25 °C showing total 
(A) and free at 2 (8) and 5 (e) weeks respectively are illustrated in the left panel of 
Fig 5.15. The right panel contains chromatograms obtained at 40 °C for total (0) and 
free at 2 (E) and 5 (F) weeks respectively . 
. . 
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Fig 5.15: HPAEC-PAD chromatograms for PentalPherold'" showing totat and 
free saccharide after 2 and 5 weeks at 25 ·C (A-C) and 40 · C (OoF). Sorbftol 
and ribitol peaks are indicated by the green and blue snows respectively. 
In PentalPheroidTII formulations, peaks for sorbitol and ribitol were detected between 
14-16 min. Again, the chromatograms were dominated by peaks derived from sucrose. 
The amount of ribitol detected generally increased with increasing temperature. The 
vaccine appeared to be stable when stored at 25°C because no ribitol was detected 
over the 5 week period. However, ribitol was detected in samples stored at 40 DC for 2-5 
weeks. Therefore, it is likely that free saccharide was present at 25 DC but poor free 
saccharide extraction from the adjuvant by PBS, especially at low concentrations 
resulted in it not being detected. Hence, future studies will investigate alternative 













A summary of the quantitative results obtained are presented in Table 5.5. 
Table 5.5: % free saccharide (± standard error) obtained for the pentavalent DTP-HBV-
Hib-A vaccine fonnulations stored at 4, 25 and 40°C for 0-5 weeks. 
Penta 
Week 4 ' C 25 °C 40°C 
0 NO' NO NO 
2 NO NO 77±1 .4 
5 NO NO 82.1 .1 
PentlALH 
Week 4 'c 25 °C 40°C 
0 35%1.4 35.1 .4 35.1.4 
2 42.1.3 49%2.1 75:t:1 .8 
5 50%2.0 58%2.2 9S±1 .8 
Penta/ALP 
Week 4 'c 25 °C 40°C 
0 NO NO NO 
2 NO 35.1.5 98.1 .9 
5 NO 52±1 .0 99±1 .5 
PentaiPherold' '" 
Week 4 ' C 25 °C 40 °C 
0 NO NO NO 
2 NO NO 90.1 .6 
5 NO NO 99%2.0 . 
The control non-adjuvanted Penta sample contained no detectable free saccharide in 
the filtrate at the start of the investigation, indicating a stable formulation. Similar results 
were obtained for Penta/ALP and PentalPheroldTV• PentalALH had the highest initial 
free saccharide value (35 %). Because 4 °C represented the nonnal storage 
temperature of the vaccine, it was expected to remain stable at this temperature with 
very low levels of free saccharide14, This was indeed the case for aU samples analysed, 
with the exception of PentaiALH. 
The Hib conjugate has been reported by Cuervo and co-workers to retain its stability at 
25 and 37 °C for 5 weeks and therefore a large increase in % free saccharide was not 
expected14 , Their study used a monovalent Hib-TT conjugate formulated without 
sucrose. The present study investigated the stability of Hib-TT in a pentavalent vaccine 
formulated with sucrose excipient. The results indicated that in the absence of adjuvant, 
the vaccine was stable at 25 °C because no free saccharide was detected, At 40 °C, the 












stability of Hib. However, the Hib conjugate was expected to be more stable than 
Mn A-TI because PsA is more susceptible to decomposition from exposure to 
suboptimum temperatures due to the lability of the phosphodiester bond31 , This was not 
the case. At 40 °C the % free saccharide in the Penta control increased by 77 % and 
82 % after 2 and 5 weeks respectively (while the Mn A-TT conjugate had shown an 
increase from 14 % to 86 % after storage for 5 weeks at 40 °e). Consequently. the large 
increases in % free saccharide were attributed to interference from the large amount of 
sucrose present in the fannulation, which made accurate integration of the sorbitol and 
ribitol peaks difficult (standard error values were > 1 and were generally higher than in all 
previous experiments) . 
The PentalALH formulation had the highest initial free saccharide value of 35 %. At aU 
temperatures, the % free saccharide increased over time. Only in PentaJALH samples 
did the percentage of free saccharide reach 50 % at 4 °C providing evidence that the 
adjuvant catalyses depolymerisation of PRP. Similar large increases in % free 
saccharide was observed at 25 (58 %) and 40 ·C (95 %). Evidence of catalytic 
depolymerisation of PRP in the presence of AlH has been reported2 1, 26, 38. The 
mechanism of this reaction is thought to be that the multivalent aluminium cation acts as 
a lewis acid catalyst, coordinating to the phosphorus atom in the PRP chain and making 
it more electrophilic. The nucleophilic OH group on C2 of ribose donates its lone pair of 
electrons to the phosphorus, causing cleavage of the phosphorus-oxygen bond in the 
chain and the production of 2,3-cyclophosphate21 • 
No free saccharide was detected in PentaJAlP samples stored at 4 °C for 5 weeks. The 
amount of free saccharide increased to 52 % after storage for 5 weeks at 25 °C. The 
vaccine was least stable at 40 °C. After only 2 weeks at 40 °C, the amount of free 
saccharide was 98 % of its original value and after 5 weeks had reached 99 %. Thus, 
exposure of the vaccine to temperatures above 4 °C facilitated its degradation. The % 
free saccharide detected after storage at 40 °C for 5 weeks was greater for PentaJAlP 
than for Penta/ALH and was attributed not to the fact that the Penta/ALP was a less 













The current study also included a pentavalent vaccine formulated with Pheroid™ 
(PentaJPheroJdTlil) . Under the conditions used, at 4 and 25 °C no free saccharide was 
detected over the 5 week period. This may be either because Pheroid™ had a 
stabilising effect on the vaccine or because of poor extraction of free saccharide from the 
adjuvant prior to separation. At 40 °C however, the % tree saccharide detected was 
90 % and 99 % after 2 and 5 weeks respectively. Therefore, it is unlikely that no 
degradation occurred at 25 °C. A more probable explanation is that use of PBS resulted 
in poor free saccharide extraction from the adjuvant. Column degradation over time 
added to the problem and led to peak integration errors resulting from the partial over1ap 
of peaks for sorbitol and ribitol. A different strategy for free saccharide extraction in 
Pheroid™-adjuvanted vaccines will be investigated in future studies. 
Most combination vaccines are formulated with aluminium-containing adjuvants. It is 
vital that such vaccines remain stable to maintain their immunogenicity. The WHO 
recommends that each batch of conjugate should be tested for free, unconjugated 
saccharide in order to ensure that the amount present is within previously set limits 
based on lots shown to be clinically safe and efficacious lB. In the present study, the 
control vaccine (i .e. Penta) which contained no adjuvant was stable at 4 and 25 °C for 5 
weeks. The Penta/ALP formulation was stable at 4 °C for 5 weeks. The amount of free 
saccharide reached 35 % after exposure to 25 °C for 2 weeks. In the control pentavalent 
vaccine and aluminium phosphate-adjuvanted vaccine, the finding that the free 
saccharide assay could detect increasing amounts of free saccharide generated showed 
the potential of this method for these formulations. Rapid degradation of PentalALH 
was observed after storage for 5 weeks at 4 °C (50 %). This observation agrees with 
published reports that ALH catalyses the depolymerisation of PRP and is a major 
hindrance to the Hib conjugate vaccine's stability. Use of Buffer 2 was not very effective 
in extracting low concentrations of free saccharide in the PentaJPheroid™ formulation. 
Therefore, future studies will investigate alternative methods of free saccharide 
extraction from Pheroid™-adjuvanted vaccines. Based on this study therefore, ALP 
would be preferable to ALH for use in the pentavalent liquid vaccine because it can 
potentiate the immune response without hindering vaccine stability. Hence, the vaccine 
will have a longer shelf-life. 
Accelerated degradation of Hib conjugate vaccines has been used to check whether the 












in the short-term stability of the vaccine at elevated temperatures .. 2, "3, That was the 
primary objective of the present study and as demonstrated in Table 5.5 this objective 
was accomplished because increases in free saccharide which correlated with a 
decrease in vaccine integrity could be monitored using the free saccharide assay 
developed in this study. 
The effect of degradation on the biological activity of the vaccine can be monitored using 
animal immunogenicity assays. With Hib vaccines in particular, immunogenicity studies 
in animals do not correlate well with protective immunity in the target population. 
However, such studies are necessary because physicochemical methods alone cannot 
be assumed to predict the biological activity of Hib conjugate vaccines without extensive 
validation against immunological data. In a study by Bolgiano and co-workers, two 
Hib-CRM191 vaccines (one contained no adjuvant and the other was fonnulated with 
aluminium phosphate adjuvant) were subjected to adverse storage conditions and used 
to establish correlates between physicochemical characteristics and immunogenicity-«. 
Vaccines were stored at 4 (control) , 37 and 55 °C and oligosaccharide depolymerisation 
was significantly higher in samples stored at 55°C compared to the control. Following 
subcutaneous injection of the samples into CBA mice and New Zealand White rabbits, 
the amount of IgG raised against CRM191 was significantly lower for samples incubated 
at 37 or 55 °C compared with the control due to confonnational changes in the protein 
induced at elevated temperatures. Moreover, there was a parallel reduction in the 
amount of IgG raised against PRP by the vaccines stored at 55°C and this was 
consistent with the observed depolymerisation of the oligosaccharide chains. 
Importantly, carrier protein confonnational changes resulting from storage under adverse 
conditions did not affect the immunogenicity to PRP in laboratory animals unless 
associated with loss of bound saccharide presumably because the carrier protein retains 
continuous T -helper ceH epitopes which are unaffected by confonnational changes. The 
TT conjugates used in this thesis would be expected to have higher thennal stability than 
the above CRM191 conjugate because previously published stability studies have 
demonstrated that the fanner retained their immunogenicity following incubation at 
elevated temperatures22 . 
Hib vaccines can have a shelf-life of up to 3 years-«. The stability of the conjugate 
vaccine during this period is also dependent on whether the fonnulation is in the 












formulations of conjugate vaccines have been shown to be resistant to storage at 
elevated temperatures or to freeze-thawing22, The stability of Iyophilised final fill 
vaccines has been reported to extend past their licensed expiry dates by up to 6 years, 
with no variations in the endotoxin content, total saccharide and percentage free 
saccharide content44• 
5.7 Investigating methods by which the free saccharide assay may be improved 
5.7.1 Vaccine fannutatlon without sucrose 
The presence of sucrose in the pentavalent formulations used for the thennal stability 
study greatly interfered with the accurate determination of ribitol in these samples. To 
investigate whether this problem was vaccine specific, the free saccharide assay was 
determined for two aluminium phosphate-adjuvanted pentavalent formulations 
PentaUALP and PentaH/ALP, fonnulated wHhout sucrose. PentaUALP was 
formulated with Hib-TT-E while PentaH/ALP contained Hib-TT-F. The vaccines were 
supplied by a local vaccine manufacturer. The % free saccharide for Hib-TT-E and Hib-
TT-F prior to formulation was determined as 0 % (low % free saccharide) and 16.5 % 
(high % free saccharide) respectively by the manufacturer using the DOC/Hel method. 
The Hib component was 40 I-Iglml (concentration provided by the manufacturer). 
Samples containing adjuvant were pre-treated with Buffer 2 at pH 7 prior to separation 
of free saccharide. Free saccharide separation was performed using the UF method 
described in section 4.3.2. Following hydrolysis (detailed procedure in section 5.3.3), a 
fixed amount of the intemal standard sorbitol (4.4 1-19) was added to each sample prior to 
filtration. Saccharide quantification was performed using HPAEC-PAD. Ribitol amounts 
were calculated from peak areas and then corrected using the internal standard sorbitol. 
The HPAEC-PAD chromatograms for total (A) and free saccharide for PentaUALP (8) 
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Fig 5.16: HPAEC-PAD chromatograms for total (A) and free 
saccharide for PentaUALP (8) and PentaHiALP (C). SorMoi and 
ribftol peaks are indicated by the green and blue anows respectively. 
The chromatograms are much cleaner than those obtained for the pentavalent vaccine 
formulated with sucrose excipient. Column performance remained a major chaUenge 
with the HPAEC-PAD method. Over time, sites on the column can became blocked by 
contaminants. This led to reduced retention times and peak overlap. The ionic strength 
of NaOH was lowered to compensate for this. Sorbitol and ribitol eluted at 17.5 and 
18.5 min respectively. The peak for the Tris buffer was detected near 9 min but did not 
interfere with the analysis of Hib. Use of sorbitol as an internal standard permitted 
correction of the ribitol concentration. The total saccharide peak (A) corresponds to 
39.2±2 ~g/ml saccharide. Free saccharide analysis for PentaUALP (8) and 
PentaHIALP (C) yielded 2.2 and 22.9 % free saccharide respectively. The % free 
saccharide values obtained for PentaUALP and PentaH/ALP in the present study was 












DOCIHCI method and ribose assay) in the monovalent vaccine and indicated good free 
saccharide recovery in the two pentavalent formulations. However, the fact that the UF 
method gave slightly higher free saccharide values than the DOC/HCI method may be 
an indication that free saccharide is underestimated by the DOC/Hel method. These 
results also confirmed that without interference from sucrose, the free saccharide assay 
can be used to measure low levels of free saccharide and detect differences in the 
amount of free saccharide present in combination vaccines containing adjuvant. This 
investigation also highlighted that some challenges associated with the physicochemical 
analysis of conjugate vaccines are formulation specific. 
5. 7.2lnv8stigation of fucose as an alternative Internal standard 
Overiapping of the sorbitol and ribitol peaks made it necessary to investigate the use of 
an alternative internal standard. The hexose deoxy sugar fucose was selected because 
it has successfully been used as an internal standard for the quantitative determination 
of saccharides by high performance liquid chromatograph/o ... , . 
For this study a local vaccine manufacturer supplied a monovalent Hib-IT -G (20 ~glml) 
and a pentavalent vaccine (Penta) formulated with aluminium phosphate adjuvant (initial 
concentration of 0.95 ~glml provided by the supplier was diluted to 20 ~g/ml) . Extraction 
of free PRP in the adjuvanted sample was performed using Buffer 2 followed by 
centrifugation for 10 min at 5 000 rpm and removal of the supernatant layer for analysis. 
Free saccharide was separated using the UF method described in section 4.3.2. All 
samples were spiked with 25 ~g of the internal standard fucose after the hydrolysis and 
neutralisation steps and HPAEC-PAD was used for saccharide quantification. Ribitol 
peak areas were corrected from the averaged peak areas of the internal standard 
fucose. The HPAEC-PAD chromatograms for total and free saccharide for Hib-IT-G 
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Fig 5.17: HPAEG-PAD chromatograms for total and free saccharide for 
Hib-TT-G (Left panel) and p."ra (Right panel). Fucose and ribffol paaks 
are indicated by the red and blue arrows respecUvely. 
- .. 
In the Hib-TI-G chromatograms for total and free (left panel), fucose and ribitol eluted 
separately at approximately 14 and 16 minutes respectively. Therefore, the two peaks 
could be integrated separately. The amount of total saccharide was 19.5 ~glml and the 
percentage of free saccharide was 7.8 %. For the adjuvanted pentavalent sample (right 
panel), fucose and ribitol eluted at approximately 14 and 15 min respectively and could 
therefore be integrated separately. Analysis of the pentavalent sample yielded 
17.1 ~glm' PRP and 15.2 % free saccharide. In section 5.7, column deterioration was a 
problem and contributed to the incomplete resolution of the sorbitol and ribitol peaks. 
The results from this preliminary study were promising because separation of fucose and 
ribitol was achieved on the same column but spike recovery experiments in both the 
monovalent and pentavalent formulations would be required to confirm the use of fucose 
as an internal standard. 
5.7.3 Investigating two buffers for DOC/HCt analysis 
In adjuvanted vaccines, both the amount of adsorbed antigen and the strength of the 
adsorption force can be affected by the type of buffer used as diluent". The DOCIHCI 
method has consistently yielded lower free saccharide values compared to the UF 
method. This experiment was performed to determine whether the amount of free 
saccharide recovered would vary as a function of ionic strength. 
Hitr TT -G provided by the manufacturer was used to prepare separate samples diluted 












To determine the separation efficiency, some samples were spiked separately with 28 
~g of an activated PRP intermediate (PRP-AOH). The DOCIHCI method described in 
section 4.3.2 was used for separation of free saccharide in the samples and saccharide 
quantification was performed using the ribose assay described in section 5.3.2. The 
amount of free saccharide obtained for the different samples are presented in Table 5.6. 
Table 5.6: % free saccharide results using DOCIHCI and ribose assay for Hib-TI-G with 
spike recovery 
Conjugate %frH .J'a recovery 
Hib--TT-G (dil in Milia H2O) <1 -
Hib-TT-G (dil in O.15M Saline) 11 .7 -
Hib-TT-G (dil in PBS) 17 -
Hib-TT-G + 28 % spike (dil in Milia H2O) 0 47 
Hib-TT-G + 28 % spike (dil in O.1 5M Saline) 18.3 99.6 
Hib-TT-G + 28 % spike (dil in PBS) 18.2 96.9 
The amount of free saccharide in the vaccine ranged from <1 % to 17 % depending on 
whether MilliQ water, 0.15 M saline or PBS (Buffer 2) was used as diluent. This 
suggests that the type of buffer used as diluent affects the recovery of free saccharide, 
an observation that has been noted by other researchers. For example, carrageenans 
are sulphated polysaccharides and t-carrageenan can form an electrostatic complex with 
bovine serum albumin (BSA) in aqueous solution at low ionic strength and pH S 7. This 
interaction becomes stronger at pH 6 but is dissociated in 100 mM NaC145• Association 
of free saccharide with the conjugate can be interrupted by increasing the ionic strength 
of the buffer. This was achieved in the present study with 0.15 M saline or Buffer 2 
(99.6 and 96.9 % recovery respectively) . Thus in future stUdies. either 0.15 M saline or 
Buffer 2 should be used as diluents to enhance PRP recovery when the DOCIHCI 
method is used for free saccharide separation. 
5.7.4 Investigating the use of membranes wtth 30, 50 and 100 kOa molecular 
weight cut-off for ultrafl~ration (UF) 
The UF method physically separates free saccharide (which is small enough to pass 
through pores in the membrane) from the conjugate (which is too large to cross the 
membrane and is retained on it) . If the pores in the UF membrane are too small . they 












However, if the pores are large enough to allow conjugated saccharide to pass through, 
then erroneously elevated free saccharide values would be obtained. In previous 
experiments, a membrane with a 100 kOa cut-off was chosen based on the size of the 
conjugate. The molecular weight of IT alone is 150 kOa therefore both IT and the 
conjugate were expected to be retained on the membrane with a 100 kDa molecular 
weight cut-off. However, data obtained in sections 5.5.4 and 5.5.5 suggested that the 
present UF protocol may overestimate the amount of free saccharide. The use of a UF 
membrane with a 30 kDa molecular weight cut-otf has been reported17. Thus, the 
present study was undertaken to investigate PRP and TT recovery after passage 
through UF membranes with 30, 50 and 100 kDa molecular weight cut-off. 
Samples containing 100 I-Ig/ml of Hib-TI-G in 0.15 M saline were prepared and spiked 
separately with either 40 ~g activated PRP (PRP-AH) or 50 ~g n . Free saccharide was 
separated from bound using UF (30, 50 and 100 kDa cut-off). HPAEC-PAD was used 
for quantification of free saccharide and the protein content determined using the SeA 
assay (procedure described in section 2.2.5). A summary of the results is presented in 
Table 5.7. 
Table 5.7: Results for ultrafiltration experiments with spike recovery 
Sample PRP 
ITi::
ke %- %PRP %ITln 
("",ml) PRP recovery filtrate 
Hib-IT -G (no UF) 100 - - - -
Hib-TT-G + n (30 kDa) 100 50 NO· NO· 1.64 
HiI>-IT -G (30 kOa) 100 - 0 - NO· 
Hib-TT -G + PRP-AH (30 kOa) 140 - 0 0 0.97 
Hib-IT-G + IT (50 kOa) 100 50 NO· NO· 4.51 
Hib-IT-G (50 kOa) 100 - 11 .9 - NO· 
Hib-IT -G + PRP-AH (50 kOa) 140 - 50.S 98 NO· 
Hib-n -G + TT (100 kOa) 100 50 NO· NO· 13.0 
Hib-IT-G (100 kOa) 107 - 13.4 - NO· 
Hib-TT-G + PRP-AH (100 kOa) 140 - 48.7 97 NO· 
• . 
No free saccharide was detected in the filtrate when the membrane with a 30 kOa 
molecular weight cut-off was used, even after spiking the sample with 40 I-Ig PRP. This 
suggests that free saccharide was retained by the membrane. The fact that <2 % 












contain amino acid chains and not TT. This could be confirmed using sodium docecyl 
sulphate (SDS)-polyacrylamide electrophoresis (PAGE) to analyse the filtrate. 
PRP recovery was high for spiked samples when the 50 and 100 kDa membranes were 
used (98 and 97 % respectively). Moreover, the amount of free saccharide detected 
using the 50 and 100 kDa membranes was comparable (11 .9 and 13.4 % respectively) 
and although the small amount of protein detected in the filtrate when both membranes 
were used is probably a fragment of IT. the 50 kDa membrane is preferable because it 
permitted less protein through. The SeA assay indicates the presence of protein in the 
filtrate. Further investigation would be required to confirm whether this is an artefact due 
to the presence of a reducing agent in the filtrate or actually due to protein such as a 
fragment of TT (using SDS-PAGE for example). 
The data obtained showed that the 50 kOa membrane can be employed for this Hib-TT 
vaccine. Ultrafiltration using the 50 kOa membrane gave low protein «5 %). good spike 
recovery and comparable free saccharide to the 100 kOa membrane. Ultrafiltration has 
the added advantage of sample concentration not possible with OOCIHCI. However, the 
choice of membrane will be vaccine specific. 
5.7.5 Method validation and statistical analysis 
Analytical method validation is a process of performing several tests designed to verify 
that an analytical test system is suitable for its intended purpose and is capable of 
providing useful and reliable analytical data (Fig 5.18).a. A validation study involves 
testing multiple attributes of a method (including accuracy, precision, specificity, limit of 
detection, limit of quantification, linearity and range, ruggedness and robustness) to 
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Fig 5.18: Method validation processes4' 
Vaccine samples provided by a local vaccine manufacturer for the present study were 
still in the developmental stage and contained highly variable amounts of free saccharide 
and in some cases only a limited volume of sample was available for performing the 
analyses. Thus, the free saccharide assay was not validated completely however a 
number of key performance parameters have been established which will aid the 
validation process"7. For example, the limit of detection was determined to be 1 ~glml. 
In addition, the HPAEC-PAD method can be used for PRP quantification even in 
combination vaccines where other antigens are present. Moreover the intemal 
standards sorbitol (or possibly fucose) can be used to account for changes in ribitol 
concentration during the analysis. Spike recovery experiments were used to 
demonstrate the robustness of the free saccharide assay, another key parameter 
required for validation of the methcxfH . With these parameters in place, future studies 
will focus on completing validation of the free saccharide assay. Furthermore, statistical 














The objective of this study was to develop the total and free saccharide assay for 
analysing the integrity and stability of conjugate vaccines. The assay was developed (in 
chapter 4) using Mn A conjugate vaccines as a model compound and then applied to 
different Hib formulations. 
Free saccharide and conjugate were separated by selective precipitation of conjugate 
using DOC/Hel or UF (100 kDa membrane and later a 30 kDa membrane). When 
0.09 % NaCI was used as diluent, the DOC/Hel method underestimated the amount of 
free saccharide especially in pentavalent vaccines formulated with adjuvant. Further 
investigation revealed that free saccharide recovery could be improved by using a buffer 
with a higher ionic strength such as 0.15 M saline or PBS (Buffer 2) . 
The traditional colorimetric assays for phosphorus and ribose were investigated for 
quantification of saccharide. The presence of sucrose and thiomersal were found to 
interfere with saccharide quantificatiClt'l when the phosphate assay was used. As a 
result, application of this assay was limited to vaccines formulated without sucrose and 
thiomersal and which did not contain phosphate buffer. Hib analysis using the ribose 
assay worked well for concentrated samples, but dilute samples yielded low 00 values 
which were less reliable because they contained a higher margin of error. 
Colorimetric methods cannot be applied to analyse Hib in combination vaccines due to 
interference from the OTP component. Therefore, a method based on acid hydrolysis of 
Hib to ribitol, separation on a CarboPac MA 1 column and quantification by HPAEC-PAO 
was developed and applied to various Hib formulations. Addition of sorbitol as the 
internal standard to each sample after hydrolysis enabled determination of the corrected 
ribitol concentration. Since sorbitol was present at a constant amount, it was used to 
account for changes in sample concentration during preparation for chromatography and 
to compensate for changes in the chromatographic system such as detector sensitivity. 
Good recovery from spiked samples proved that this method could detect varying 
concentrations of Hib saccharide in non-adjuvanted mono- and pentavalent vaccines. 
Fucose was later investigated as an alternative internal standard to sorbitol . The free 
saccharide assay could possibly be further improved by using a second internal 












Monovalent vaccine samples formulated with ALH, ALP and Pheroid™ adjuvants were 
analysed using the free saccharide assay to evaluate their stability and integrity. Elution 
of antigens from all three adjuvants was possible using PBS (Buffer 2) at pH 7.5. Free 
saccharide desorption with Buffer 2 was much easier in formulations containing ALP but 
was not as efficient in ALH-containing formulations. In adjuvanted vaccines, use of the 
DOCIHCI method underestimated the amount of free saccharide present and UF (100 
kOa molecular weight cut-off) may overestimate it. Further investigation revealed the 
presence of a small amount of protein in the filtrate (of the unadjuvanted samples 
tested) . Future studies using 80S-PAGE would be required to determine whether the 
protein is indeed TT or a fragment thereof. In addition, interference studies should also 
be conducted to ensure that vaccine excipients (such as sucrose) do not interfere with 
the BGA assay (and yield a false positive result) . Thus. a comparison of the BGA and 
Bradford assay results on the filtrate are recommended for future studies. 
An accelerated thermal stability study was conducted on pentavalent vaccines 
formulated with ALH, ALP or Pheroid™ (I.e PentalALH, Penta/ALP and 
PentalPheroidTil respectively) and containing sucrose excipient in order to determine 
the quality of the vaccines during storage at 4, 25 and 40 °C. Due to severe interference 
from the large amount of sucrose in these formulations, conclusions from this study were 
based on the general trends observed. The control vaccine (Penta) and Penta/ALP 
were generally stable at low temperatures (4 and 25 °C). PentalALH was least stable at 
all temperatures and the results suggested that ALH catalyses hydrolysis of the 
phosphodiester bond in the PRP chain . Unlike the monovalent vaccine, use of PBS 
(Buffer 2) was unsuitable for free saccharide extraction in the PentalPherold™ 
formulation. In all samples, storage of vaccines at 40 °C resulted in the generation of 
large amounts of free saccharide after 5 weeks. In the control pentavalent vaccine and 
aluminium phosphate-adjuvanted vaccine, the finding that the free saccharide assay 
could detect increasing amounts of free saccharide generated showed the potential of 
this method for these formulations. 
Interference from sucrose was found to be formulation specific because when the free 
saccharide assay was conducted on a pentavalent vaccine formulated with aluminium 
phosphate but without sucrose excipient, good results could be achieved by HPAEC-
PAD. The free saccharide assay was subsequently applied to two aluminium 












without sucrose. The monovalent Hib--TT vaccines used to prepare PentaUALP and 
PentaH/ALP contained 0 % and 16.5 % free saccharide respectively (as determined by 
the manufacturer using the DOC/Hel method). Free saccharide was extracted from the 
adjuvant using Buffer 2, separated by UF and quantified by use of the HPAEC-PAD 
method. Good free saccharide recovery was obtained from the pentavalent formulations 
because the % free saccharide values obtained (2.2 % and 22.9 % for PentaUALP and 
PentaH/ALP respectively) were similar to those in the monovalent vaccines. This 
confirmed that in the absence of interference from sua-ose, the free saccharide assay 
can successfully be used to measure low levels of free saccharide. Hence, success of 
the free saccharide assay was found to be formulation specific. Since these were the 
last batches of samples to be analysed, severe column degradation had occurred with 
loss of separation efficiency. The free saccharide assay could be improved by using 
fucose as an intemal standard instead of ribitol since the fucose peak did not overtap 
with that of ribitol. In addition, the use of a high ionic strength buffer such as 0.15 M 
saline or PBS (Buffer 2) enabled improved free saccharide recovery during the 
OOCIHCI assay by reducing electrostatic interactions. For this vaccine ultrafiltration with 
a 50 kOa membrane gave low protein concentration in the filtrate «5 %), good free 
saccharide recovery and comparable free saccharide to the 100 kOa membrane. 
A complete validation of the free saccharide assay is planned for future studies using 
ICH (Intemational Conference on Harmonisation) guidelines. Key parameters which will 
be investigated include accuracy, precision, limit of quantification, linearity and range, 
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SUMMARY, DISCUSION, CONCLUSION AND FUTURE OUTLOOK 
Routine administration of Hib conjugate vaccine to infants provides protection against 
invasive disease caused by Haemophi/us influenzae type b 1 • A local vaccine 
manufacturer is in the process of developing a combined tetravalent DTP-HBV as well 
as a liquid pentavalent DTP-HBV-Hib vaccine. The development and application of 
appropriate physicochemical methods for conducting quality control of these complex 
products were required and provided motivation for this study. 
Most combination vaccines are formulated with aluminium-containing adjuvants which 
serve to enhance the immune response to the antigen2, 3, However, aluminium 
hydroxide has been found to catalyse the hydrolysis of PRP when added to Hib 
conjugate vaccines4• Although this can be circumvented by the use of aluminium 
phosphate, there is a need for new adjuvants that elicit broader immune responses. A 
patented fatty acid-based formulation containing nitrous oxide results in a micre-
emulsion (Pheroid™) which has shown potential for use as an adjuvant for viral vaccines 
and may also be used for bacterial vaccines. Physicochemical analysis of this promising 
adjuvant by NMR spectroscopy and Coulter Counter was undertaken (Chapter 3). NMR 
spectroscopy provided a structural fingerprint for Pheroid™ formulations and indicated 
the relative proportions of the major components but the method was invasive because it 
required removal of the aqueous phase. Nevertheless, the NMR spectroscopy 
presented in this thesis can be used routinely to monitor the quality of Pheroid™ raw 
materials and to evaluate the final formulation to ensure batch-te-batch consistency. 
Evaluation of the particle size distribution in Pheroid™ was performed using a Coulter 
Counter. The average size distribution in the two formulations studied was similar and 
ranged between &.12 J,lm. Antigen encapsulation in Pheroid™ would enable protection 
from degradation, targeted delivery and controlled release, thus enhancing its immune 
response. Indeed, the engineering of nanoparticles for use in nasal (to induce mucosal 
immunity) and transcutaneous vaccines (to target immature dendritic cells found in high 
density in the epidermis and dermis of the skin) is a cutting-edge area of research in 
which immunogenicity is enhanced by targeted delivery of antigens which facilitates 
lymphatic uptakes. 
A non-invasive NMR method which enables analysis of the intact emulsion by using 












emulsion should be investigated because it has the potential of replacing the Coulter 
Counter methocf. Acoustic and electroacoustic spectroscopies are two new techniques 
that can be used to investigate the particle size distribution and calculate the zeta 
potential of emulsion particles7 , 8. These new non-invasive techniques will also be 
applied to the study of Pheroid™ in future studies. It has been suggested that adjuvant 
action results from a depot effect by prolonging the duration of the interaction between 
antigen and cells, and thus is related to the antigen-releasing properties of emulsion 
adjuvants9 • Future physicochemical studies on Pheroid™ (e.g. conductivity, viscosity, 
surface charge) should aim to clarify the physicochemical basis or molecular reasons for 
its adjwant activity. Such studies usually include analysis of cell death by the emulsion 
adjuvant in vitro because cell apoptosis is an important factor for induction of 
immunogenicity by emulsion aduvants10 . This is followed by an assessment of antibody 
response in animal models after subcutaneous (and possibly intranal) immunisation with 
the antigen plus adjuvant using enzyme linked immunosorbent assay (ELISA). 
The use of modem physicochemical methods for the assessment of glycoconjugate 
vaccines is necessary because traditional assays using live animals do not correlate well 
with immunogenicity in humans. The primary focus of this thesis was the application of 
appropriate physicochemical procedures for evaluation of the locally manufactured Hib 
vaccine alone and when in combination with DTP-HBV-Hib. In the absence of a suitable 
Hib conjugate, model compounds such as HSA, PsA and Mn A-TT were used to 
investigate methods of free saccharide separation namely SPE, DOCIHCI and UF 
(Chapter 4). The SPE cartridge was selected to retain the conjugated saccharide while 
the free saccharide passed through as eluent. At physiological pH, the binding capacity 
was low and so this method was not investigated further. The DOCIHCI method 
underestimated the amount of free saccharide. This problem was initially thought to be 
circumvented by use of the UF method because the ultrafiltration membrane could be 
washed to ensure maximum recovery of free saccharide. Although the free saccharide-
containing filtrate was diluted due to washing of the filter, it could be concentrated using 
a speed-vac system consisting of a centrifuge, refrigerated vapour trap and vacuum 
pump prior to hydrolysis and chromatography. Saccharide quantification was performed 
using a colorimetric assay for phosphorus as well as the more sophisticated HPAEC-
PAD method for the monomer (mannosamine-~phosphate from acid hydrolysis). The 
HPAEC-PAD method permitted quantification of free saccharide at low levels and 












In the absence of appropriate vaccine intennediates, validation of the free saccharide 
assay was not possible. However, an accelerated stability study was conducted to 
evaluate both the stability of the vaccine and the performance of the tree saccharide 
assay. Mn A-IT conjugate samples were stored at 25 and 40 °C for 5 weeks. 
Quantification of the amount of free saccharide in these samples by the phosphate and 
HPAEC-PAD methods after separation using the DOCIHCI and UF methods showed 
little increase in the % free saccharide for the conjugate stored at 25 °C and a 
sUbstantial increase in free saccharide following storage at 40 °C for 5 weeks. As part of 
the accelerated stability study, changes in the molecular size distribution of the 
conjugate induced by exposure to elevated temperatures was monitored by HPSEC·UV 
on a Waters Uttrahydrogel 2000A column. The results showed that Mn A-IT remained 
stable at 25 °C, however when kept at 40 °C, the chromatographic profile changed 
dramatically after 3 weeks and supported the free saccharide assay results determined 
by HPAEC-PAD and use of DOC/HCI and UFo The HPSEC-UV melhod was lim~ed in 
that it provided no quantitative indication of the effect of elevated temperatures on the 
amount of free saccharide generated. Inclusion of a refractive index detector in future 
studies would enable detection of the free saccharide generated. The results of the 
study agreed with previously published reports which demonstrated the thermal stability 
of Mn A conjugates at 4 °C but degradation ensued following incubation at 37 °C or 
higherll.12. 
Induction of an immune response by conjugate vaccines occurs when pathogen-
associated molecular patterns (PAMPs) contained in the vaccine antigens are 
recognised by pattern recognition receptors (PRRs) such as toll-like receptors on 
dendritic cells and monocytes. Binding of an antigen to its receptor triggers activation of 
dendritic cells and monocytes, which modifies the expression of receptors on their 
surfaces and induces their migration along lymphatic vessels to the draining lymph 
nodes or spleen where activation of T and B lymphocytes takes place. Thermal 
degradation of vaccines results in the destruction or alteration of the PAMP regions and 
therefore little or no binding to PRRs. Thus, dendritic cells remain immature and upon 
contact with naive T ceUs, the T cells do not differentiate into effectors but into regulatory 
CD4+ T cells which maintain immune tolerance 13. ' 4. 
It was concluded from this investigation that free saccharide separation by UF and 












is specific for M6P quantification and has a higher sensitivity than the phosphate assay. 
However, further investigation of the UF method was necessary to ensure that the 
conjugate was not passing through the membrane and yielding erroneously high free 
saccharide values. 
The free saccharide assay was subsequently applied to investigate the potency of the 
Hib component in monovalent and pentavalent vaccines. Separation of free saccharide 
from bound was achieved by the DOC/Hel and UF methods followed by quantification 
using the phosphate and ribose colorimetric assays and HPAEC-PAD analysis of the 
ribitol component (released by acid hydrolysis) (Chapter 5). Use of the phosphate assay 
was limited because the presence of sucrose (added as a stabiliser) and thiomersal 
(added as a preservative) interfered with saccharide quantification. As a result, 
application of this assay was to vaccines formulated without sucrose and thiomersal and 
which did not contain phosphate buffer. Application of the ribose assay to Hib analysis 
in concentrated samples was poSSible, but dilute samples yielded low 00 values which 
were less reliable because they contained a higher margin of error. The HPAEC-PAO 
method proved to be sensitive and specific and with the use of an internal standard, 
potentially applicable to the analYSis of Hib in both monovalent and combination 
vaccines. Glucose-6-phosphate and glucose-1-phosphate have been used by other 
researchers as internal standards but for the quantification of Hib saccharide after base 
hydrolysis. Sorbitol (and later fucose) was found to be a suitable internal standard 
because it was stable and measurable under the conditions used but eluted at a different 
retention time from ribitol. It could therefore be used to account for changes in sample 
concentration during preparation for chromatography and to compensate for changes in 
the chromatographic system such as detector sensitivity. The Hib vaccine available for 
most of this study was formulated with sucrose (85 000 jJg sucrose: 20 jJg). The 
presence of such a large amount of sucrose severely interfered with ribitol detection and 
column degradation may have been facilitated by residual amino acids in the samples 
after hydrolysis. Column deterioration in turn caused the peaks for ribitol and sorbitol to 
overlap slightly which made accurate integration of small peaks difficult. This problem 
could be circumvented by using sucrose-free samples and fucose as an internal 
standard. 
A review of the literature revealed two common methods by which adsorbed antigens 












ALP in either 10 % sodium citrate or NaOH respectivell . The former was found to be 
ineffective in dissolving ALH. The latter was effective at NaOH concentrations C!: 500 mM 
but would not be suitable for routine analysis of Hib because the harsh alkaline 
conditions would induce hydrolysis of the PRP, resulting in an erroneously high free 
saccharide concentration. A second method for elution of antigen was the use of the 
phosphate aoion '5, In theory, the phosphate anion specifically adsorbs to ALH and 
lowers its isoeledric point (IP) causing the surlace charge of ALH to change from 
positive to negative. Consequently, electrostatic repulsive forces between the negatively 
charged adjuvant and the negatively charged antigen results in elution. Adsorption of 
additional phosphate anions by ALP adjuvant also reduces its IP and increases its 
negative surface charge thus resulting in increased electrostatic repulsion with a 
negatively charged antigen. Free saccharide desorption with PBS (Buffer 2) was much 
easier in formulations containing ALP but was not as efficient in ALH containing 
formulations. Preliminary results also suggested that PBS could potentially be used for 
saccharide recovery in Pheroid™-adjuvanted samples and the mechanism by which this 
takes place merits further investigation in future stUdies. 
The present study investigated the applicability of the free saccharide assay to the 
analysis of Hib in four pentavalent formulations containing sucrose excipient the 
pentavalent formulated without adjuvant (Penta) and with ALH , ALP and Pheroid™. The 
samples were stored at 4, 25 and 40°C for 5 weeks. Accurate quantification of ribitol in 
these formulations was complicated by interference from sucrose. Free saccharide 
extraction by PBS (Buffer 2) was effective in formulations containing ALP and difficult 
when ALH or Pheroid™ was used. Therefore, general conclusions were derived, based 
on the results obtained in the control (Penta) and Penta/ALP formulations. Both Penta 
and Penta/ALP appeared to be stable at 4 °c for 5 weeks. The Penta control appeared 
more stable (no free saccharide detected over 5 weeks) than Penta/ALP (35 % and 
52 % free saccharide detected at 2 and 5 weeks respectively) when the vaccines were 
stored at 25 °C. After storage for 2 and 5 weeks at 40 °C, both Penta and Penta/ALP 
formulations showed a large increase in % free saccharide. The immunogenicity of Hib 
conjugate Vaccines which have been subjected to adverse conditions depends upon the 
depolymerisation of the attached saccharide and the nature of the carrier protein. IT 
conjugates have been reported to have a higher thermal stability than conjugates 
prepared using CRM191t6. Published studies have demonstrated that carrier protein 












the immunogenicity to PRP in laboratory animals unless associated with loss of bound 
saccharide presumably because the carrier protein retains continuous T-helper cell 
epitopes which are unaffected by conformational changes. Real time stability studies 
have demonstrated the stability of Iyophilised vaccines to extend past their licensed 
expiry dates by up to 6 years while liquid formulations are less stable '8, However, the 
advantage of a liquid formulation is that the logistical requirements and the number of 
clinical manipulations required prior to obtaining a preparation suitable for administration 
are significantly reduced. Real time stability studies on the bulk and final fill formulations 
of the locally manufactured DTP-HBV-Hib is likely to confirm that the formulation is 
stable (and immunogenic) at 4 °C for at least two years. 
A number of experiments were conducted to investigate different ways in which the free 
saccharide assay could be improved. In the first experiment the free saccharide assay 
was applied to two aluminium phosphate-adjuvanted pentavalent vaccines PentaUALP 
and PentaHlALP, formulated wffhout sucrose. The monovalent Hib-TT vaccines used to 
prepare PentaUALP and PentaH/ALP contained 0 % and 16.5 % free saccharide 
respectively (as determined by the manufacturer using the DOCIHCI method). Free 
saccharide was extracted from the adjuvant using phosphate buffer, separated by UF 
and quantified by use of the HPAEC-PAD method. Good free saccharide recovery was 
obtained from the pentavalent formulations because the % free saccharide values 
obtained (2.2 and 22.9 % for PentaUALP and PentaH/ALP respectively) were similar to 
those in the monovalent vaccines. This confirmed that in the absence of interference 
from sucrose, the free saccharide assay can successfully be used to measure low levels 
of free saccharide. Hence, success of the free saccharide assay was found to be 
formulation specific. 
The search for a better internal standard to sorbitol was necessitated by the overlapping 
of the sorbitol and ribitol peaks. Fucose had successfully been used as an internal 
standard for the quantitative determination of saccharides by high performance liquid 
chromatography and was therefore investigated as an alternative internal standard to 
sorbitol17• lB. The HPAEC-PAD chromatograms showed complete separation of the 
fucose and ribitol peaks. Therefore, they could be integrated separately. Spike recovery 













An important observation was that free saccharide recovery using the DOCIHCI method 
is affected by the type of buffer used as diluent. Electrostatic interaction of free 
saccharide with the conjugate CQuid be interrupted by increasing the ionic strength of the 
diluent. The use of either PBS (Buffer 2) or O.1SM saline yielded good free saccharide 
recovery when the DOCIHCI method was used. 
Ultrafiltration using a membrane with a 30 kDa molecular weight cut-off has been used 
for the separation of free saccharide in conjugate vaccines. Selection of a membrane 
with a 100 kOa molecular weight cut-off for the present study was based on the size of 
the conjugate (thought to be >100 kDa because TT alone is 150 kDa). In addition, the 
choice of this molecular weight cut-off was supported by the fact that the vaccine 
manufacturing process includes diafiltration using a 100 kDa membrane for conjugate 
purification. Analysis of the filtrate from three different membranes (30, 50 and 10 kDa) , 
using the BeA assay, showed the presence of a small amount of protein - probably a 
fragment of TT. However, further investigation by 80S-PAGE for example would be 
required to confirm this. Filtrate from the membrane with a molecular weight cut-off of 
30 kDa contained no free saccharide even when the samples were spiked with free 
saccharide. This suggests that the membrane pore size was too small and so free 
saccharide was retained on the membrane. The 50 kOa membrane is recommended for 
future studies because not only did it give a low concentration of protein in the filtrate 
«5 %) but also good free saccharide spike recovery as well as comparable free 
saccharide to the 100 kOa membrane. 
The HPAEC-PAD method could replace colorimetric assays for the analysis of Hib 
vaccines but a complete validation of the free saccharide assay using ICH «International 
Conference on Harmonisation») guidelines would be required in future studies. This 
includes accuracy, precision, specificity, limit of detection, limit of quantification, linearity 
and range, ruggedness and robustness. 
Consideration of all of the afore-mentioned results shows that this thesis has provided 
background for the development of some very important methods for determining the 
free saccharide content of unadjuvanted and adjuvanted conjugate vaccines. Further 
studies could investigate the use of two internal standards to compensate for ribitol lost 
during separation, filtration and hydrolysis. Both the UF and DOCIl-lCI methods are 












combination Hib vaccines. ALP is recommended over ALH for use in Hib vaccines for 
two reasons. Firstly, it does not catalyse depolymerisation of the Hib polysaccharide: 
and secondly, electrostatic repulsion with the negatively charged PRP moiety facilitates 
free saccharide recovery in the presence of the phosphate anion. Future studies could 
also investigate suitable buffers and conditions for the recovery of PRP from PheroidTl,l. 
In addition, data obtained from physicochemical analyses will be validated against 
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